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Introduction 1
Ovarian cancer represents a great clinical challenge. First, early detection of the disease remains 
problematic as there are no good screening tests and there is a lack of a clearly defined precursor lesion. 
A further concern is the response to current therapy. Despite improvement in cytoreductive surgery 
and the recent introduction of platinum- and taxol-based (intraperitoneal) chemotherapy, gains in 
survival rates over the last three decades are rather modest.[1] Although 65-80% of the patients 
respond to first-line chemotherapy, most patients will relapse with drug-resistant disease.[2] 
Consequently, the 5-year survival rate of patients with advanced stage disease is only 5-30%.[3] 
For this reason, it is necessary to obtain insight in mechanisms of cellular drug resistance of ovarian cancer. 
However, studying ovarian cancer pathology is complicated, as the disease does not appear as a single 
entity. Instead, ovarian cancer comprises a heterogeneous group of histological subtypes each with 
its own expression profiles of genes, proteins and metabolites.[4-7] These difficulties have limited 
the introduction of successful biomarkers that can predict clinical response and guide treatment.
Biology and pathology of ovarian cancer
There are more than 25 major types of ovarian neoplasms. This broad range of histological features 
displayed by ovarian tumors reflects the diverse anatomical structure of the ovary itself. Approximately 
90% of the ovarian tumors are histologically classified as surface epithelial neoplasms. The malignant 
potential of these ovarian epithelial tumors is categorized on the basis of the extent of epithelial 
proliferation, nuclear atypia and stroma invasion as benign, borderline or malignant.[8]
During embryonic life, the celomic cavity is lined by a mesothelium, parts of which become specialized 
to form the serosal epithelium covering the gonadal ridge. The same mesothelial lining gives rise to 
the müllerian ducts, from which arise the fallopian tubes, uterus and endocervix. Epithelial ovarian 
cancer (EOC) exhibits a variety of müllerian-type differentiations. This histological subclassification 
of EOC is based entirely on tumor cell morphology and is categorized according to the World Health 
Organization (WHO) histological classification system.[4] The four most common subtypes of EOC, 
referred to as serous, mucinous, endometrioid and clear cell tumors, bear strong resemblance with 
the normal cells lining the fallopian tube, endocervix and endometrium, respectively (Figure 1).[9,10] 
This has recently been confirmed at the molecular level, as the genes that were expressed in different 
EOC subtypes also were concordantly expressed in the normal tissue that they resemble histologically^! 1] 
Less frequently diagnosed are transitional (Brenner), squamous cell, mixed type and undifferentiated 
EOC.[8] In addition to the type of differentiation, EOC can be subclassified based on the degree 
of differentiation (tumor grade). During the last decades, several grading systems have been used 
in different institutions. The most commonly used have been proposed by the International 
Federation of Gynecology and Obstetrics (FIGO) [12] and WHO [13]. At present, a conceptual change
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occurs as in the approach of EOC, the heterogeneity of the disease is taken into account. Accordingly, 
pathologists believe that a histospecific grading system is more appropriate than a universal grading 
system to reflect the diversity of the disease.[14,15] However, there is as yet no universally accepted 
grading system for EOC.
Figure 1. Morphological features of epithelial ovarian cancers. (a) Hematoxylin-eosin-stained section of normal human ovary 
surrounded by monolayered epithelium (arrow) and containing an inclusion cyst (i.c.). (b) Sections of ovarian carcinomas: 
serous, with papillary features; endometrioid, with glandular features; and mucinous, with cribriform features. (c) Sections 
of normal fallopian tube, endometrium en endocervix.(source: Naora et al. 2007 [10])
Ovarian neoplasms are characterized by their cystic appearance. Serous carcinomas may range from 
microscopic to about 20 cm in diameter. They are typically multilocular and cystic, with soft, friable 
papillae containing serous, turbid or bloody fluid.[8] Mucinous carcinomas are generally larger than 
serous carcinomas, with a diameter sometimes up to 50 cm. They are mostly cystic and multilocular, 
display mucoid surfaces and are filled with thick tenacious gelatinous material that is usually pale yellow 
but may be turbid or brown. Endometrioid carcinomas range from 12 to 20 cm, are frequently cystic 
and typically contain friable soft masses and bloody cyst fluid.[8]
A short history on ovarian cyst fluid
In the days before the first abdominal surgical extirpation was performed, massive cystic enlargement 
of the ovary must have been one of the most disabling diseases among women. Due to the lack of a 
proper treatment, the abdomen often increased to a size of a full-term pregnancy which could result
12
in severe respiratory and gastro-intestinal problems caused by mechanical pressure from the ovarian 
tumor. In addition, symptoms of hypoalbuminemia were strikingly common those days, attributed to 
the accumulation of protein in the large amount of ovarian cyst fluid.[16]
1
In the first half of the 19th century, only pioneering surgeons performed abdominal surgery.[17,18] 
Therefore, the common treatment that was offered to a patient with an ovarian tumor comprised 
palliation by "tapping" pervaginam.[18] Due to a quick refill of the cyst with fluid, in most of the cases 
these tapping procedures often had to be performed on a regular base. Of the numerous reports on 
repetitive tapping, a case of a women who underwent 253 tappings in 8 years, with a total production 
of more than 1,000 liters of cyst fluid, is perhaps one of the most remarkable.[19] As a result, 
pathologists became aware and subsequently fascinated by the large differences in aspect(s) of the 
cyst fluid between ovarian tumors. As availability of tissue specimens was mostly limited to autopsies, 
for many years cyst fluid had been the most important source for pathologic examination. 
This is evidenced by the extensive pathological description of the characteristics of the fluid in most of 
the reported cases.[16-18]
By performing chemical analyses, pathologists discovered that transparent cyst fluid consisted almost 
completely of water, with a few constituents. Red cyst fluid was found to contain large numbers of 
erythrocytes, whereas thick cyst fluid, nowadays referred to as mucinous fluid, was reported to contain 
a large amount of protein(s) and slimy compounds. Green colored cyst fluid was thought to be related 
to human bile and it was found to contain mostly anorganic compounds. The fatty aspect of some 
cyst fluid was attributed to the existence of crystals and/or cholesterol.[18,19] More importantly, 
until the days that abdominal surgery was introduced, ovarian cyst fluid was also analyzed from 
a prognostic point of view. In his work on ovarian dropsy published in 1862, Brown stated that "an 
increase of density in the dropsical fluid, whether that increase manifests itself by a mucilaginous 
consistence, a more plentiful production of flaky, or gruel, honey, or brainlike matter, betokens a 
more depraved or morbid condition of the cysts, and indeed of the general health, and consequently 
a condition less amenable to cure"[18]
The introduction of the abdominal ovariectomy during the late 19th century gradually led to a greater 
emphasis on pathological inspection of tissue specimens removed at operation.[20] Slowly it became 
clear that preoperative punction of ovarian cyst fluid was dangerous in case of ovarian cancer because 
it could cause iatrogenic spread of malignant cells in the abdomen.[21] Therefore, ovarian cyst fluid 
was no longer regarded to be of clinical value. After pathological inspection of the ovarian tumor, 
the pathologist of the 21th century generally discards the cyst fluid and uses the ovarian tissue for 
histopathological diagnosis. Thus, although ovarian cyst fluid had been a main focus of interest until 
the 20th century, it more or less has lost its clinical importance thereafter.
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Predictive and prognostic biomarkers for ovarian cancer
Over the past several decades, considerable investment has been made in the screening and early 
detection of EOC. In the 1980s, cancer antigen 125 (CA 125) was introduced for diagnosis of EOC.[22] 
Later on, dozens of proteins or protein fragments have been suggested as new candidates for 
the detection of EOC. However, none of these proposed biomarkers had enough sensitivity and 
specificity to be of clinical value.[23,24] Currently, a shift in biomarker research takes place 
and the main focus is on tests that may predict response to therapy (predictive biomarkers) 
and/or patient survival (prognostic biomarkers). With the introduction of many preclinical therapeutic 
agents, appropriate markers can be used to determine which tumor(s) will respond to which 
treatment(s) in order to predict the likelihood of drug resistance and the efficacy of the therapeutics. 
A severe limitation for translational research however, is the extreme histological diversity of EOC. 
It has become clear that, due to their diverse cellular differentiation, the histological subtypes 
of EOC respond differently to current chemotherapeutics, [25-27] and each of them seems to have its 
own characteristic biomarker profile.[27-30] Therefore, during the search for predictive and prognostic 
biomarkers, the complex histological presentation of various subtypes has to be seriously taken into 
account. In an attempt to improve biomarker studies or find tumor-derived biomarkers, different 
sources of biospecimen have been used, all with their own advantages and disadvantages (Table 1).
Table 1. Advantages and disadvantages of different biological sources for EOC research
Material Advantages Disadvantages
Blood Easy to obtain
Multiple longitudinal assessments possible
Components are not always tumor-derived 
Tumor-derived components not always present
Tissue Components of the tumor directly assessed Surgery required
Heterogeneity of cells
Single biopsy not always representative
Cyst fluid Tumor-derived components 
Serum-based assessments
Tumor spill when preoperatively obtained
Surgery required
Not present in all ovarian tumors
Biomarker studies using blood
Most studies that investigated potential predictive and prognostic biomarkers for patients with EOC 
have used blood as starting material.[24,31,32] The reason is clear as blood is directly available and 
most assessments in serum or plasma are inexpensive. Of all biomarkers that have been investigated 
during the years, serum CA 125 has most frequently been documented. It has been shown that the kinetics
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of serum CA 125 levels during chemotherapy has prognostic significance, but the predictive role 
of the preoperative serum CA 125 concentration for response to chemotherapy still remains 
questionable.[24,33] In addition, not any of the other investigated preoperative serum biomarkers has 
proven its clinical value for prediction of prognosis of the disease.[24,31,32] The difficulty of developing 
an appropriate prognostic test in serum might be caused by the many subtypes of EOC resulting in 
distinct histologybased biomarkers patterns present in blood.[28] Also, the concentration of circulating 
compounds in blood may be influenced by physiological processes. In addition, the mechanisms and 
conditions responsible for the release of tumor-derived components into the circulation are poorly 
understood.
Tissue biomarker studies
Although investigated less frequently than serum, ovarian cancer tissue has also been studied to 
identify predictive and/or prognostic biomarkers.[24,34-42] Most of the research has been performed 
using immunohisto- and immunocytochemical techniques, by which the degree of staining can be 
compared between different EOC tissues. These methods are limited by interobserver variation in 
identifying stained cells and different subjective scoring systems. The introduction of techniques 
measuring biomarkers in tissue extracts (e.g. cytosol), or in DNA and RNA, has basically solved this 
problem as such assessments can be done quantitatively. Nevertheless, tissue biomarker research in 
general is severely limited by the extreme heterogeneity of EOC tissue, resulting in tumor areas with 
diverse cellular differentiation within the same tissue specimen.[43-45] As a consequence, the expression 
of tumor-derived compounds differs significantly within the ovarian cancer tissue specimen, which 
increases the risk of sampling bias.[37,46-53] Table 2 lists the studies that compared expression of 
biomarkers between different sections of the same tumor. These studies have demonstrated that 
ovarian intratumoral heterogeneity is present in almost half of the cases (range: 18-53%).[54-58] 
A single biopsy might thus not be representative for the whole ovarian tumor, whereas the analysis 
of multiple regions of the same ovarian tumor would be extremely time-consuming and impractical 
for clinical purposes.
Table 2. Studies that compared biomarker variation within the same EOC tissue using multiple tissue sections of the tumor
Author No.* Biomarker






Quinn et al.[54] 10 ER and PR 2-3 IHC 44%
Zangwill et al.[55] 19 DNA ploidy 3-12 FCM 47%
Takahashi et al.[58] 41 DNA ploidy 3-10 FCM 49%
Zborovskaya et al.[56] 25 LOH 3-8 IHC 18-53%
Tuefferd et al.[57] 320 HER2 2 IHC/FISH 46%
*Number o f ovarian carcinomas in the study; ER =  estrogen receptor; PR =  progesterone receptor; HER2 =  Human Epidermal growth factor 
Receptor 2; LOH =  Loss o f  heterozygosity; IH C =  immunohis-tochemistry; FCM =  flow cytometry; FISH =  fluorescent in situ hybridization
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Cyst fluid biomarker studies
Although not as frequently investigated as blood and tissue, ovarian cancer cyst fluid has been studied 
as a source for biomarkers. It has been demonstrated that the concentration of analytes in ovarian 
cyst fluid often reflects the biological processes taking place within the ovarian epithelial cyst wall. 
[51-53,59-63] Using immunohisto- and immunocytochemical staining, a significant association between 
expression of several tumor-associated antigens in tissue sections and cyst fluid cells was found. 
[47,51-53,59-63] Additional evidence for the direct release of tissue-derived compounds into the ovarian 
cyst fluid is provided by the fact that absolute levels of tumor-associated antigens in ovarian cyst fluid 
were found to be significantly higher than in serum of the same patients.[64-73] Because of its adjacent 
relation to the tumor surface, ovarian cyst fluid might therefore offer an interesting source for biomarker 
studies.
Thus far, biomarker research using ovarian cyst fluid typically had an explorative design and has been 
focused on the differences in the concentration of various biomarker candidates between cyst fluid of 
benign and malignant ovarian tumors.[64] As preoperative aspiration of ovarian cyst fluid might cause 
iatrogenic metastasis of tumor cells, the analysis of biomarkers in ovarian cyst fluid may not be used for 
the preoperative diagnosis of EOC.[21,68] Aspiration of the ovarian cyst after removal of the tumor at 
surgery is permitted and the fluid can be subsequently used for the analysis of predictive and prognostic 
biomarkers contributing to the understanding of the biology of ovarian tumors. Surprisingly, despite 
the shift in focus of biomarker research as described earlier, to the best of our knowledge no studies 




Tumors are known to induce the release of many proteins which might be used as biomarkers for 
detection and progression of cancer. The first recognized test for a specific type of cancer was reported 
in 1965, when the carcinoembryonic antigen (CEA) level was found to be elevated in serum of patients 
with colon cancer.[74] By the end of the 1970s, potential tumor-associated serum tests had been 
developed for a variety of cancers.[75] In 1981, Bast et al. discovered that a large membrane bound 
glycoprotein, cancer antigen (CA) 125, was present on tumor cells of the majority of patients with EOC. 
[22] An immunoassay for the quantification of CA 125 in serum was developed using the monoclonal 
antibody OC 125.[76] After initial interest in this molecule for its potential use as a serologic biomarker 
for early EOC diagnosis, studies revealed that the sensitivity and specificity of this marker were insufficient 
for use in populationbased screening.[77] A plethora of studies have subsequently been performed
16
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to investigate the role of serum CA 125 as a predictive and/or prognostic marker for EOC. The monitoring 
of serum CA 125 levels during early chemotherapy has now proven its relevance and is currently used 
in clinical practice.[78] However, the clinical value of preoperative serum CA 125 levels in prediction 
of disease outcome or response to chemotherapy for EOC patients remains controversial. Although 
the majority of studies could not demonstrate a prognostic significance, [38,79-84] some studies found 
that preoperative serum CA 125 correlated significantly with survival.[85,86]
CA 125 levels in ovarian cyst fluid of EOC patients have found to be 100 to 1,000 fold higher than in 
serum, [68] suggesting a direct release of CA 125 from the tumor tissue into the ovarian cyst fluid. 
No attempts have been made so far to investigate whether CA 125 in ovarian cyst fluid might serve as 
a prognostic biomarker for EOC.
Proteases
A major step in cancer growth and dissemination involves the degradation of the extracellular matrix 
(ECM). This process is mediated by multiple degradative actions of proteolytic enzymes or proteases.[87] 
Proteolysis is a physiological mechanism the cell employs in order to regulate the function of its proteins. 
Tumor cells have the capacity to directly alter the surrounding ECM by quantitatively influencing 
the production of proteolytic enzymes.[88,89] Different proteases use different strategies to hydrolyze 
proteins and on this basis they can be grouped into four major classes: the aspartyl and cysteine 
proteases (lysosomal cysteine proteases), which are mainly involved in intracellular proteolysis, and 
the metallo and serine proteases, which are responsible for extracellular proteolysis.[87,88]
Activation of the proteolytic cascade participating in ECM degradation, in general, is induced by 
the lysosomal cysteine proteases.[88] Lysosomal cysteine proteases or cathepsins, comprise a large 
family of enzymes divided into subgroups (B, H, L, S, C, K, O, F, V, X and W) on the basis of their catalytic 
mechanisms.[90] Under physiological circumstances, cathepsins are localized in lysosomes but during 
cancer development and progression, they are often translocated to the cell surface or even secreted 
into surrounding fluids.[91] Cathepsins are distributed ubiquitously in most cancer tissues and studies 
have shown a correlation between cancer development and differential expression and localization of 
cathepsins.[91-93] Due to their increased levels in extracellular fluid, cathepsins have been implicated 
as biomarkers for the prognosis of cancer.[91] For this purpose, cathepsin B and H have most frequently 
been investigated and serum levels have been associated with a shorter survival of patients with 
colorectal, lung, breast and head and neck cancer.[91] Similar results were found when cathepsins were 
explored in urine, [94,95] and cerebrospinal [96] and pleural fluid [97] of cancer patients. Until now, 
the prognostic value of cathepsins in ovarian cyst fluid for EOC has not been established.
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Enzymes involved in the metabolism of drugs
Multiple enzymes are present in cells to protect molecules such as nucleic acids, proteins, and lipids 
against drugs and oxidative stress. The process of detoxification by these enzymes usually involves two 
distinct stages, commonly referred to as phase I and phase II reactions. Phase I reactions, exemplified 
by the P-450 isoenzyme family, provide the target molecule with hydroxyl- or amino-groups. Phase II 
reactions, mainly executed by the glutathione S-transferase (GST) family, involve the addition of 
hydrophilic moieties to the target molecule, creating a more watersoluble conjugate, which may be 
less toxic and more readily excretable.[98] Therefore, phase II reactions are generally cytoprotective. 
The human GST superfamily comprises cytosolic isoenzymes, which have been assigned to at least 
four generic classes: Alpha (A), Mu (M), Pi (P) and Theta (T).[99] The Pi class GSTs (GSTP1-1) are believed 
to interact with platinum-based compounds and are frequently found to be overexpressed in a variety 
of neoplastic tissues, including EOC.[99,100] It has been shown that high GSTP1-1 activity results in 
an increased metabolism of platinum-based compounds, which subsequently results in a diminished 
cytotoxic effect on tumor cells.[98,100,101] Studies have shown that overexpression of GSTP1-1 in ovarian 
cancer tissue corresponded with a reduced response to chemotherapy of EOC patients.[39,102-105] 
These results are promising for the potential implication of GSTP1-1 as a biomarker for chemoresistant EOC. 
Therefore, there is a need for studies that investigate the feasibility of GSTP1-1 as a biomarker in biological 
fluids of patients with EOC.
Identification of new prognostic biomarkers
Genomics and proteomics
Until recently, the discovery of individual cancer biomarkers advanced rather slowly. Each candidate 
biomarker must be identified among an enormous amount of proteins and metabolites. In addition, 
clinical validation by means of very costly large multicenter randomized prospective trials is 
subsequently mandatory.
The last decade, genomic technologies such as microarrays have made it possible to study several 
thousands of genes simultaneously to obtain a global gene expression profile of tissue samples. To date, 
a variety of studies have employed gene expression profiling to classify ovarian carcinomas into clinically 
relevant subtypes, while more recent papers entirely focused on the development of gene expression 
profiles that correlate with chemoresistance or survival of EOC patients.[44,106-112] However, genomic 
research is limited by the fact that DNA alterations or RNA expression profiles are not always representative 
for the expression of the protein they encode. About 60% of the human genome is expressed while only 
40% is translated into protein.[113]
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The progress in proteomic approaches to identify novel biomarkers has relied on large scale protein 
expression profiling analysis by mass spectrometry. After the first attempts were made to use spectra 
of overexpressed proteins for discrimination between malignant and benign ovarian tumors, [114-116] 
more recently, a few studies have focused on the overexpression of proteins in chemoresistant ovarian 
cancer cell lines.[117-122] Again, large scale proteomic research has been limited to tissue and blood of 
patients with EOC.
Metabolomics
Metabolomics involves the study of the metabolome, the total repertoire of small molecules present 
in tissues, isolated cells and body fluids. It is a rapidly expanding field of scientific research which has 
become, after genomics and proteomics, the latest "omic" science. Metabolites are the end product of 
gene and protein activity. They are small, low-molecular weight compounds that predominantly serve 
as substrates and products in various metabolic pathways.[123] The number of different metabolites in 
humans is unknown; estimates range from 3,000 to 20,000, compared with approximately 23,000 genes 
and 60,000 proteins.[124] Individual metabolites have already been used as disease markers for years, 
such as glucose in diabetes mellitus or creatinine clearance in renal failure. By the introduction of proton 
nuclear magnetic resonance OH-NMR) spectroscopy, it became possible to provide a full spectrum of 
proton-containing compounds in a given fluid sample. So far, a view studies have been published using 
'H-NMR spectroscopy to explore differences in metabolic profiles between fluid samples of patients 
with malignant and benign ovarian tumors.[7,125,126] Further research is necessary to identify whether 
or not metabolomics will serve as a complementary or even an alternative tool to traditional approaches 
to define biomarkers for prediction of disease outcome in EOC.
19
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Outline of this thesis
Despite improvements in aggressive debulking surgery and the initial good response of patients to 
platinum- and paclitaxel-based chemotherapeutics, there has been little improvement in the survival 
rates of EOC patients over the last three decades. Unfortunately, there are no reliable biomarkers for 
predicting clinical response and guiding treatment regimens. Blood en tissue of EOC patients have been 
traditionally used as starting material for biomarker research. In contrast, compounds in ovarian cyst 
fluid have never been investigated for their prognostic and/or predictive value. Ovarian cyst fluid has 
several advantages over blood and tissue. The aim of this thesis is to investigate the prognostic 
and predictive value of a number of potential biomarkers in ovarian carcinoma cyst fluid. To achieve 
this objective, at first, the prognostic value of three classical (groups of) biomarkers is studied. 
Hereafter, novel biomarkers are revealed by metabolomic profiling and subsequently studied for their 
prognostic significance. In chapter 1, the selection of the studied biomarkers is described in detail. 
Although cyst fluid can be obtained easily from ovarian tumors after primary surgery, not all EOCs 
contain cyst fluid. Therefore, availability is the main problem when using cyst fluid biomarkers for clinical 
purposes. In chapter 2 the exact prevalence of cysts in EOC is studied as well as tumor characteristic that 
may be related to the presence of cysts.
CA 125 is the only biomarker for EOC that is used in daily clinical practice worldwide. Serum CA 125 
is valuable for monitoring during chemotherapy. However, the role of pre-operative serum CA 125 as 
a prognostic marker remains questionable. In chapter 3 the prognostic value of CA 125 in ovarian cyst 
fluid is studied for patients with EOC.
Another group of potential prognostic biomarkers might be the proteases. With their capacity to 
degrade tumor basement membrane components and other structural proteins, they have been 
frequently associated with tumor progression and metastasis. For several types of cancer, extracellular 
presence of proteases and their endogenous inhibitors turned out to be of prognostic value. In chapter 4, 
cathepsin B, L and cystatin C are explored in the cyst fluid of ovarian tumors. Hereafter, in chapter 5, 
the prognostic value of cyst fluid cathepsin B, H, L, and X and their endogenous inhibitor cystatin C is 
studied for patients with EOC.
Detoxification enzymes are involved in the metabolism of drugs and by-products of oxidative stress. 
Overexpression of GSTP1-1, a member of the phase II detoxification enzymes, in cancer tissue has found 
to be related to a reduced response to platinum-based chemotherapy in cancer patients. In chapter 6, 
the predictive role of GSTP1-1 in ovarian cyst fluid as a biomarker for resistance to platinum-based 
chemotherapy is investigated.
By the introduction of 'H-NMR spectroscopy, it became possible to provide a full spectrum of proton- 
containing compounds in a given fluid sample. In chapter 7, ’H-NMR spectroscopy is used to reveal 
ovarian cancer biomarkers by comparing ovarian cyst fluid profiles between different histopathological
20
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subgroups. N-acetylaspartic acid (NAA) and drug binding protein Alpha 1-acid glycoprotein (AGP) were 
subsequently identified and validated by quantitative techniques. NAA is the second most abundant 
free amino acid in the human brain but synthesis has never been found in human tissues outside 
the cerebrospinal system.[127] In chapter 8, the relation between cyst fluid NAA and different ovarian 
tumor subtypes is further investigated. The second biomarker, AGP, is an acute phase protein with drug 
binding properties. During pathological conditions, the synthesis of AGP increases due to an acute 
phase response.[128] A high serum concentration of AGP has found to be an indicator for poor survival 
in patients with cancer. However, little is known about the direct relation between treatment failure 
and binding of AGP to chemotherapeutics. In chapter 9, the prognostic and predictive value of AGP is 
determined for EOC patients treated with chemotherapy. In addition, the binding affinity is established 
between AGP and paclitaxel/cisplatin.
Finally, in chapter 10, the results of this thesis are discussed in general.
21
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PREVALENCE OF CYSTS IN EPITHELIAL OVARIAN CANCER
Abstract
Ovarian carcinomas mostly appear as large cystic masses. However, the exact prevalence of cystic 
epithelial ovarian cancer (EOC) has never been documented as well as the tumor factors that are 
related to the presence of cysts. Proving prevalence of cysts in EOC is of essential for research focused 
on predictive and prognostic biomarkers in ovarian cyst fluid. From 233 patients with primary EOC who 
underwent surgery, pathological data were collected from pathology reports. Univariate and multivariate 
logistic regression were used to analyze the relationship between the presence of cysts and other tumor 
characteristics. Cysts in EOC were present in 83.7% of the patients and were mostly (61%) multilocular. 
The most common histological subtypes (serous, mucinous, endometrioid, clear cell) contained cysts in 
more than 85% of the cases. In univariate regression analysis, early FIGO stage, low tumor grade and a large 
tumor size were significantly associated with the presence of cysts (OR (95% CI) = 5.312 (1.81-15.57), 
6.906 (2.31-20.66) and 1.169 (1.08-1.27), respectively). In multivariate regression analysis, apart from 
tumor size, only tumor grade was independently associated with the presence of cysts (adjusted OR 
(95% CI) = 4.234 (1.36-13.22)). The large majority of all EOCs contained cysts. Histological subtype, 
FIGO stage, tumor necrosis, and age were not associated with the presence of cystic EOC. This means 
that cystic EOCs represent a subgroup of larger and more well-differentiated tumors. The evident 
relationship between the presence of cysts and differentiation grade is interesting from a clinical point 
of view as grading is especially important for the prognosis and treatment of patients with stage I EOC.
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Introduction
Epithelial ovarian cancer (EOC) accounts for almost 90% of all malignant ovarian tumors and is the most 
lethal gynecological malignancy worldwide. Its high mortality rate is mainly caused by the inability 
to detect the disease in an early stage, due to the absence of specific clinical symptoms and availability 
of proper screening techniques.[1]
These days, there is a gaining interest for biomarkers that are able to predict survival and response to 
treatment of patients with EOC at time of diagnosis, and gynecologic oncologists have emphasized 
the need for these biomarkers to select patients for individually based treatment.[2] During the last 
decade, many researchers have attempted to identify clinically relevant biomarkers in EOC tissue. 
However, results of such studies are difficult to compare due to sampling errors, inappropriate 
pathological evaluation of ovarian tumors, the use of different histological techniques, and most 
importantly, the intratumoral tissue heterogeneity.[3] To avoid these difficulties, researchers have 
become increasingly interested in the analysis of the biochemical composition of ovarian cyst fluid 
to find relevant biomarkers.
Ovarian tumors, benign as well as malignant, often present as cystic masses which contain variable 
amounts of fluid.[4] These cysts generally are encapsulated within the tumor tissue. Cyst fluid therefore 
contains compounds released by the tumor tissue thus reflecting the biological processes of 
the surrounding tumor cells.[5] Also, in contrast to ovarian cancer tissue, compounds in cyst fluid 
are homogeneously distributed and analyses are quantitative and often uncomplicated.[6] 
Since preoperative punction of cyst fluid might cause tumor spill, ovarian cyst fluid has to be obtained 
after surgical removal of the tumor and cyst fluid biomarkers can only be clinically used as predictors 
of survival and/or response to treatment. For example, glutathione S-transferase pi (GSTP1-1) levels in 
post-operatively obtained ovarian cyst fluid have recently been shown to be of independent prognostic 
value for patients with EOC.[7] However, the exact prevalence of cystic epithelial ovarian cancer (EOC) 
has never been documented as well as the tumor factors that are related to the presence of cysts. 
Proving prevalence of cysts in EOC is a serious prerequisite for research focused on various predictive 
and prognostic biomarkers in ovarian cyst fluid.
In the present study, prevalence of cysts was investigated in a large series of EOCs and pathological 
tumor characteristics were related to the presence of cysts.
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Materials and Methods
Patients and pathological reports
The present study was performed with pathological data of 233 patients diagnosed with primary EOC 
who had surgery between January 1985 and August 2008 at the Radboud University Nijmegen Medical 
Centre (RUNMC), and Bernhoven Hospital (BH), locations Oss and Veghel, the Netherlands. In the national 
pathological database, the pathological anatomical national automatized archive (PALGA), a data search 
was performed with the terms: "ovary" and "malignancy" which resulted in 475 pathology reports of 
patients who had surgery at RUNMC or BH. From these reports, 58 were excluded because it concerned 
biopsies or revisions, 114 were excluded because patients had a benign or atypical proliferative (borderline) 
ovarian tumor, [8-10] and 29 were excluded because of preoperative chemotherapy. In addition, 
37 pathological reports were not conclusive on stage and 1 was not conclusive on aspect of the tumor 
(solid or cystic). Of the remaining reports, 3 tumors were of non-epithelial origin and were excluded 
as well. Complete pathological reports of 233 patients with primary EOC could be included.
Histopathological characteristics
For the purpose of this study, pathological reports were retrospectively obtained and reviewed for 
macroscopic and microscopic features.
Macroscopic features that were scored were: bilaterality or unilaterality of the ovarian tumor, largest 
diameter of the tumor (cm), the presence of cysts and the number of cysts. According to the Dutch 
guidelines for Pathologists, after macroscopic incision of the tumor, EOC has to be defined as unilocular, 
multilocular, or purely solid. Whenever a tumor was mentioned to macroscopically contain both cystic 
and solid parts, for this study purposes the tumor was scored as cystic.
Microscopic features that were achieved were: presence of necrosis, histological subtype, and tumor 
grade. Histological tumor type was scored according to the World Health Organization histological 
classification of ovarian tumors.[9] Adenocarcinomas "not otherwise specified" (NOS) were epithelial 
tumors of which the pathological report was not conclusive on histology. Tumor grade was scored as 
reported by the initial pathologists. For grading, the pathologists formerly relied on cytological atypia 
and architecture. In present years, grading has often been performed according to Silverberg.[11] 
In patients with bilateral ovarian cancer, pathological features of both ovaries were scored, and eventually, 
only features of the most unfavorable tumor, based on surface involvement and tumor grade, were 
included for analysis. Stage of disease was determined according to the criteria of the International 




Statistical analysis was performed to investigate which factors were related to the presence of cysts in 
EOC. Association between clinicopathologic features and the presence of a cystic tumor were tested 
using the Chi-square test. Differences of medians of continuous variables between the groups were 
analyzed using a non-parametric test (Mann-Whitney). Univariate and multivariate logarithmic regression 
analyses were performed to determine which clinicopathological factors were significantly related to 
the presence of cysts in EOC. Because the small number of patients with FIGO stage II (n = 20, 8.6%) 
and IV (n = 18, 7.7%) and tumor grade 1 (n = 30, 12.9%) (Table 1), for the purpose of univariate and 
multivariate analyses FIGO stage and tumor grade were grouped. FIGO stage was grouped into early 
stage (I-IIa) and advanced stage (IIb-IV). Early stage FIGO stage (I-IIa) comprised 75 patients with stage I 
and 4 patients with stage IIa. Advanced FIGO stage (IIb-IV) comprised 16 patients with stage IIb and IIc, 
120 patients with stage III and 18 patients with stage IV. Tumor grade was grouped into grade 1 and 2 
versus grade 3. The group with grade 1 and 2 tumors comprised 89 patients and the group with grade 
3 comprised 106 patients. Tumor grade was scored as 1 and 2 versus grade 3 (instead of the more 
common classification of grade 1 versus grade 2 and 3) because of statistical reasons as none of the 30 
tumors with grade 1 was solid. For histological subtypes, reports of patients with transitional tumors 
and undifferentiated tumors were excluded from uni- and multivariate regression analyses due to low 
sample sizes (Table 1). Adenocarcinomas NOS were excluded from uni- and multivariate regression 
analyses because it was unclear which histological subtype was represented. Variables found to be 
significantly related to the presence of a cystic tumor by univariate logistic regression were entered into 
a multivariate logistic regression model with forward selection procedures to identify the variables that 
were independently associated with the presence of a cystic tumor. Reports with missing data were 
excluded from the multivariate analysis. In all tests a p-value <0.05 was considered to be statistically 
significant. Statistical analyses were performed using SPSS software version 16.0 (Chicago, Illinois, USA).
Results
Patient and tumor characteristics
The study population included 233 patients with primary EOC of whom complete pathological reports 
were reviewed. Median age at diagnosis was 58 years (range: 17-88 years). The median diameter of 
the cystic tumors was 12 cm (range: 4-44 cm) whereas solid tumors had a median diameter of 6.8 cm 
(range: 2.5-18 cm) (p <0.001, Mann-Whitney test). Of the 4 most common histopathological subtypes, 
serous tumors had a median diameter of 9 cm (range: 2-30 cm), and mucinous, endometrioid and clear cell 
tumors had a median diameter of 20 cm (range: 4.5-44), 13 cm (range: 6.5-22 cm) and 12 cm (range: 6-23 cm), 
respectively. Table 1 represents the remaining clinicopathological characteristics of the study population.
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Table 1 Clinicopathological characteristics of 233 patients with primary EOC
total cystic tumors solid tumors
Clinicopathological characteristics n  (% ) n  (% ) n  (% )
FIGO stage I 75 (32.2) 72 (36.9) 3 (7.9)
II 20 (8.6) 18 (9.2) 2 (5.3)
III 120 (51.5) 89 (45.7) 31(81.5)
IV 18 (7.7) 16 (8.2) 2 (5.3)
Tumor grade 1 30 (12.9) 30 (15.4) 0
2 59 (25.3) 55 (28.2) 4 (10.5)
3 106 (45.5) 80 (41.0) 26 (68.4)
unknown 38 (16.3) 30 (15.4) 8 (21.1)
Histological subtype serous 97 (41.6) 83 (42.6) 14 (36.8)
mucinous 28 (12.0) 26 (13.3) 2 (5.3)
endometrioid 36 (15.5) 31 (15.9) 5 (13.1)
clear cell 14 (6.0) 12 (6.2) 2 (5.3)
transitional cell 1 (0.4) 1 (0.5) 0
mixed 19 (8.2) 15 (7.7) 4 (10.5)
undifferentiated 5 (2.1) 3 (1.5) 2 (5.3)
NOS 33 (14.2) 24 (12.3) 9 (23.7)
Laterality bilateral 114 (48.9) 91 (46.7) 23 (60.5)
unilateral 119 (51.1) 104 (53.3) 15 (39.5)
Presence of necrosis yes 120 (51.5) 101 (51.8) 19 (50.0)
no 113 (48.5) 94 (48.2) 19 (50.0)
Total 233 (100) 195 (83.7) 38 (16.3)
Prevalence of cystic EOC
For all clinicopathological variables scored, prevalences of cystic and solid tumors are listed in Table 1. 
The majority of the patients (n = 195; 83.7%) presented with EOC that contained one or more cysts. 
Prevalence of these cysts was more than 88% in patients with FIGO stage I, II and IV (96%, 90%, and 89%, 
respectively). Only EOC stage III had a lower prevalence of cysts (74%). All well-differentiated tumors 
in this study appeared to be cystic, which was also true for almost all moderately differentiated 
tumors (93.2%). In contrast, 87.7% of the solid tumors were poorly differentiated. Of the three most 
common histological subtypes (serous, mucinous and endometrioid), more than 85% of the tumors 
appeared to contain one or more cysts (86%, 93%, and 86%, respectively). Also, clear cell tumors were 
found to be cystic in more than 85% of the cases. Only mixed type and undifferentiated adenocarcinomas 
showed lower percentages of cysts (78.9% and 60% respectively). The majority of cystic EOC was 
multilocular (n = 119; 61%), 45 (23.1%) were unilocular and in 31 (15.9%) only the presence of a cystic 
component was reported without being conclusive of the number of cysts.
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Logistic regression analysis
Variables significantly associated with the presence of cysts in EOC were: largest tumor diameter, 
tumor grade and FIGO stage (all p < 0.001, Table 2). Age, histological subtype, laterality and necrosis 
were not associated with the prevalence of cystic EOC (p = 0.354, p = 0.754, p = 0.118, and p = 0.840, 
respectively, Table 2). No differences were found in presence of cysts when tumors were compared 
between the prior grading guidelines (n = 149) and the current system according to Silverberg (n = 84) 
(p = 0.912; solid: 16.1% versus 16.7%; cystic: 83.9% versus 83.3%, respectively). Variables significantly 
associated with the presence of cysts in EOC (largest tumor diameter, tumor grade and FIGO stage) 
were entered into logistic regression analysis. After univariate logistic regression, tumor size (OR = 1.169, 
95% CI = 1.08-1.27, p < 0.001), tumor grade 1 or 2 (OR = 6.906; 95% CI = 2.31-20.66, p = 0.001), and FIGO 
stage I-IIa (OR = 5.312, 95% CI = 1.81-15.57, p = 0.002) were significantly associated with the presence 
of cysts (Table 2). The analysis was concluded by performing a multivariate logistic regression on the factors 
that showed a significant relation with cystic EOC prevalence.
According to this analysis, size of the tumor and tumor grade were independently associated with 
the presence of cysts in EOC (multivariate regression, Table 2). FIGO stage was not independently 
associated with the presence of cysts in EOC by multivariate analysis. Tumor grade 1 and 2 appeared 
to be most strongly related to the presence of cystic EOC (adjusted OR = 4.234, p = 0.013), followed by 
tumor size (adjusted OR = 1.192, p = 0.002).
Discussion
It has been generally accepted that most EOCs contain one or more cysts. However, the exact prevalence 
of cystic EOC has never been documented. Also, it has not been clarified which clinicopathological 
factors are related to the presence of cysts in EOC. These epidemiologic data are important to determine 
in which way ovarian cyst fluid is clinically available as a source of prognostic and predictive biomarkers.
The present study has demonstrated that 83.7% of the ovarian adenocarcinomas macroscopically 
contained a cystic component, which was mostly multilocular (61%). Moreover, the four most common 
histological EOC subtypes (serous, mucinous, endometrioid and clear cell), were cystic in more than 85% 
of the cases. Tumor grade and tumor size were independently related to the presence of cystic EOC. 
This means that cystic EOCs represent a subgroup of larger and more well-differentiated tumors. 
Histological subtype, FIGO stage, tumor necrosis, and age were not independently associated with 
the presence of cystic EOC.
We found that tumor grade and tumor size were independently associated with the presence of cysts 
in EOC. The significantly larger tumor size found in cystic EOC can almost certainly be explained by
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Table 2. Prevalence of ovarian cystic EOC for clinicopathological characteristics using univariate 
and multivariate logistic regression analysis
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the large volume of cyst fluid that is usually present in these tumors.[4] Interestingly, histological 
subtype was not an independent variable in multivariate analysis for the presence of cysts even though 
mucinous tumors are known to have the largest diameter of all histological subtypes due to sometimes 
enormous amounts of cyst fluid.[4] Although FIGO stage was significantly associated with cystic EOC in 
univariate analysis, no independent relationship was found in multivariate analysis. Therefore, we conclude 
that cystic EOCs are larger and less poorly differentiated than solid EOCs. As not any of the solid tumors 
in our study was well-differentiated, statistical analysis had to be performed with grade 1 and 2 versus 
grade 3 instead ofthe common classification of grade 1 versus grade 2 and 3 (low-grade versus high-grade). 
This means that if low-grade (grade 1) and high-grade (2 and 3) tumors would have been compared, 
a stronger relationship between grade and presence of cysts in EOC had most likely been found. 
From a clinical point of view grading is especially important for the prognosis and treatment of patients 
with stage I EOC. It has been shown that patients with stage Ia-Ib and grade 1 tumors face a good 
prognosis and do not need chemotherapeutic treatment after surgery.[13] Kang et al. recently 
demonstrated that patients with stage Ia-Ib grade 3 tumors, patients with Ic tumors and patients with 
clear cell tumors, were of high risk compared to the other patients with stage I EOC.[14] In addition, 
in another study, the 5-year survival of patients with stage Ia and grade 1 or 2 was found to be more 
than 90%.[15] These data emphasize the clinical significance of the unification of grade 1 and 2 versus 
grade 3. The evident relationship between the presence of cysts and differentiation grade in the present 
study is also interesting in terms of the popular theory that claims that EOC arises by two different 
pathways of carcinogenesis.[16] The type I EOCs, which are classified as low-grade tumors, are thought 
to arise from benign or borderline ovarian tumors and develop slowly. These benign and borderline 
tumors are well known for their cystic nature.[4] In contrast, the type II EOCs, which are classified as 
high-grade tumors, are thought to arise de novo and progress far more rapidly.[16]
Epidemiologic data from our study population regarding age, FIGO stage, tumor grade and 
histopathological subtypes are consistent with the distribution found in previous literature.[4,17,18] 
However, compared to most other epidemiological overviews, the present study contained somewhat 
less serous type carcinomas. This is probably due to the fact that we included a subtype of adenocarcinoma 
NOS (not otherwise specified) in our study. This group of unspecified carcinomas probably consisted 
for a large part of serous carcinomas, because the remaining histological subtypes correspond well to 
previous found rates.[4,17,19] Moreover, our findings regarding histological subtypes are comparable 
to the series of Vernooij et al. [18] who also added a group of adenocarcinoma NOS to their classification 
of histopathological subtypes which resulted in 38% serous EOCs.
The present study might have been biased by the retrospective analysis of the pathology reports, 
because not always all pathological features were mentioned (differentiation grade and histology) 
and inter-observer variation might have occurred. In addition, two different grading systems were used 
during the time-interval of this study. The system used in the past was based on cytological atypia and 
architectural pattern. Recently, however, the grading system of Silverberg [11] has been introduced. 
Using this system, besides atypia and architectural pattern, mitotic activity has to be scored as well.
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However, no differences in presence of cysts in EOC were found when results were compared between 
the prior grading system and the new grading system according to Silverberg.
To the best of our knowledge, we report the first structured study in which the prevalence of cysts in 
EOC was investigated. Besides the fact that these data have never been documented and might be of 
interest for pathological and epidemiological statistics, the present study also determined the factors 
related to the presence of cystic EOC.
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Abstract
Most ovarian tumors contain ovarian cyst fluid (oCF) which can be easily obtained during surgery. 
This is the first study that explored if CA 125 in oCF could be of prognostic value for patients with 
epithelial ovarian cancer (EOC). Of 54 patients with primary EOC, oCF and preoperative serum were 
collected and clinicopathological data were retrospectively obtained. CA 125 was measured with the 
commercially available CA 125 assay. CA 125 in oCF (n = 54, median: 55,500 U/ml, range: 590-10,200,000 
U/ml) was always higher than in the corresponding serum (n = 51, median: 179 U/ml, range: 13-11,000 
U/ml) (p <0.001) and values were moderately correlated (R = 0.337, p = 0.016). CA 125 in oCF was 
associated with histology (p <0.001) and tumor grade (p = 0.038). High levels of oCF CA 125 (> median) 
were significantly associated with a poor disease free survival (DFS) (log-rank p = 0.002, and p = 0.005 
univariate Cox-regression). Other factors associated with a poor DFS in univariate analysis were advanced 
FIGO stage, suboptimal debulking (both p <0.001), high tumor grade (p = 0.025), serous histology 
(p = 0.003) and high serum (>median) CA 125 (p = 0.009). In multivariate analysis, only FIGO stage was 
of independent predictive value. These findings indicate that, although high levels of oCF CA 125 were 
significantly associated with a poor survival of EOC patients, CA 125 in oCF was not of independent 
predictive value and might therefore not be useful as a prognostic biomarker for EOC.
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Introduction
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological malignancies in 
developed countries. Due to the absence of specific signs and symptoms in an early stage of disease, 
the majority of patients are diagnosed when the tumor has already metastasized to the upper abdomen 
with a subsequent 5-year overall survival of less than 20%.[1,2]
Prognostic biomarkers are gaining attention as they are able to predict survival and response to treatment 
of patients with EOC at time of diagnosis, and many gynecologic oncologists have emphasized the need 
for these markers to select patients for individually-based treatment.[3,4] Cancer Antigen (CA) 125 is the 
best known biomarker for EOC and the only biomarker that is used in daily practice worldwide. It was 
discovered by Bast et al. [5] in 1981 and has been used ever since. Clinically, post-treatment serum CA 125 
has proven its value and is used for the follow-up of EOC patients.[4,6,7] However, the role of preoperative 
serum CA 125 as a prognostic marker for survival remains questionable. The majority of studies could not 
demonstrate a prognostic significance, [8-12] while other studies found that preoperative serum CA 125 
correlated significantly with survival in univariate analysis, [3,13-16] although the prognostic effect was 
lost in multivariate analysis in most of these studies.[3,13,15]
EOC typically presents as a large cystic mass which contains variable amounts of fluid.[17] Ovarian cyst 
fluid (oCF) is encapsulated in the ovarian tumor and therefore, it represents a micro-environment which 
contains compounds directly released by the tumor tissue. Since preoperative punction of oCF might 
cause tumor spill, it is advised to obtain oCF only during or after surgery. Therefore, the clinical value of 
biomarkers in oCF is limited to prediction of survival and/or response to treatment of patients with EOC. 
A number of studies have compared oCF CA 125 levels between patients with benign and malignant 
ovarian tumors.[18-21] However, to our knowledge, no studies have been published investigating 
the prognostic value of oCF CA 125 for patients with EOC.
We performed the first study that explored the prognostic value of oCF CA 125 for the prediction 
of survival of patients with EOC. We also investigated the relation between oCF CA 125 levels and 
important clinicopathological parameters of patients with EOC.
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Material and Methods
Patients
In the period between January 2000 and January 2008, oCF was collected from patients who underwent 
primary surgery for an ovarian tumor at the Radboud University Nijmegen Medical Centre (RUNMC) 
and stored at our cyst fluid biobank. During or after primary debulking or diagnostic surgery, oCF was 
collected when a cystic ovarian tumor was diagnosed as malignant by frozen section examination. 
Cyst fluid collection was performed during primary debulking or diagnostic surgery, never during 
interval debulking surgery. From 68 patients, oCF was obtained. Four patients were excluded because 
final paraffin examination revealed that the origin of the primary tumor was not ovarian derived. 
Another 10 patients were excluded because the ovarian malignancy was non-epithelial. Included in 
this study were patients with histologically proven primary EOC (n = 54 patients). Informed consent was 
obtained from all participants.
Sample collection
Cyst fluid samples of the ovarian tumors were collected by aseptic fine-needle aspiration at the Department 
of Pathology, immediately after surgical removal of the tumor. Preoperative serum samples of patients 
with EOC (n = 51) were taken within one week prior to surgery. From 3 patients, preoperative serum 
could not be obtained. After cooled transport to our laboratory, the oCF and blood samples were 
centrifuged at 3000 x g for 10 min and the supernatant was aliquoted and stored at -35 °C until use.
CA 125 measurements
CA 125 measurements in oCF and serum were performed with the commercially available CA 125 assay 
(AxSYM, Abbott Laboratories, Chicago, Illinois, USA) with a minimum detectable concentration of 2 U/ml. 
This assay is based on Microparticle Enzyme Immunoassay technology and uses the murine monoclonal 
antibody OC 125 as catching antibody. Determination of CA 125 was carried out without prior knowledge 
of the patients' clinical outcome.
Clinicopathological characteristics
Complete pathological reports of all EOC patients were reviewed for correct histopathological diagnosis 
(primary ovarian carcinoma, histological tumor subtype and tumor grade) by one pathologist (JB), 
specialized in gynecological oncology. Surgery and FIGO staging was always performed by a gynecologist 
specialized in oncology from the RUMCN. From the medical records, the following clinicopathological
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characteristics were retrospectively retrieved: age at diagnosis, International Federation of Gynecology 
and Obstetrics (FIGO) stage, residual tumor after surgery, tumor recurrence, and date of death. 
For some patients, information about one or more clinicopathological parameters could not be retrieved 
(Table 1). Staging was performed according to the criteria of the FIGO.[22] Patients were divided into 
two groups: patients with early stage (FIGO stage Ia-IIa) and patients with advanced stage (FIGO stage 
IIb-IV) EOC.[23] Histopathological tumor type and grade were classified according to the World Health 
Organization criteria.[24] Existence of residual tumor after surgery was divided into two groups by 
the criteria for optimal cytoreduction [25]; patients who had no residual disease or a residual lesion 
less than 1 cm, and patients with a suboptimal debulking of one or more centimeters residual tumor. 
Recurrence of disease was defined as a measurable lesion during follow-up evaluated by computed 
tomography, magnetic resonance imaging and/or ultrasonography.
Statistical analyses
Statistical analyses were carried out using SPSS 16.0.2 software (SPSS Benelux BV, Gorinchem, 
the Netherlands). Correlations between oCF CA 125 and serum CA 125 values were analyzed by 
Spearman's rank correlation testing. Normality of value distributions was assessed using Kolmogorov- 
Smirnov testing, and obtained by normal-log (Ln) transformation of both serum and oCF CA125 levels. 
Differences in levels of CA125 in serum or oCF samples from EOC patients categorized by clinicopathological 
characteristics, as grouping variables, were assessed with parametric Student's t-tests or ANOVA with 
post-hoc Tukeys HSD tests where appropriate. The median of CA125 values (for both serum and oCF CA 
125) was used as the cut off value for dichotomizing oCF and serum CA 125. Disease-free survival (DFS) 
time was used as follow-up endpoint and was defined as the time interval from the date of surgery to 
the date of recurrence or death, and censored at last follow-up. Survival curves were generated using 
the method of Kaplan and Meyer. Equality of survival distributions was tested using log-rank testing. 
The hazard ratio's (HR) with the corresponding 95% confidence interval (CI) are presented. Multivariate 
Cox regression analysis was performed to find the clinicopathological parameters that independently 
contribute to a decreased time to recurrence. P-values of < 0.05 were regarded as statistically significant.
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Results
Study population
The patient's age at diagnosis ranged from 32 to 89 years, with a median age of 56 years. Numbers of 
patients in various clinicopathological subgroups are listed in Table 1.
Table 1. Association of CA125 (U/ml) in oCF and serum and clinicopathologically defined patient categories
CA125 in oCF (U/ml) CA125 in serum (U/ml)
Category n  (% ) median (IQR) P* median (IQR) P *
*p-value o f  student's t-test or ANOVA of Ln normalized values; a and b denote categories that differ significantly in post-hoc Tukey's 
HSD analysis; IQR =  interquartile range
Serous carcinomas were found in 24 patients (44%), 14 patients had mucinous carcinomas (26%), 
and 8 patients had endometrioid type carcinomas (15%). Of the remaining 8 patients in the category 
"other", 2 patients had clear cell carcinomas (4%), 1 patient had an undifferentiated adenocarcinoma (2%) 
and 5 patients had ovarian adenocarcinomas not otherwise specified (NOS) (9%). Of the 19 patients with 
early FIGO stage, 11 had Ia, 1 had Ib and 7 patients had FIGO Ic. Of the 34 patients with advanced FIGO 
stage, 2 had IIb, 2 had IIc, 3 had IIIa, 8 had IIIb, 13 had IIIc, and 6 patients had FIGO stage IV. For 1 patient, 
FIGO stage could not be obtained. Of the total number of 54 patients, 31 (58%) were treated with
6 courses of adjuvant platinum-based chemotherapy after primary surgery, 5 (9%) patients received
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neo-adjuvant chemotherapy before interval surgery, and 18 (33%) patients did not receive chemotherapy 
at all. Median follow-up time was 42 months (range: 10-120 months). None of the patients was lost 
to follow-up. DFS ranged from 1 to 120 months, with a median of 16 months. Within the follow-up period, 
25 patients (46%) showed recurrent disease and 17 patients died (32%).
CA 125 levels in oCF and preoperative serum
3
Values for CA125 in oCF (n = 54) of patients with EOC ranged from 590 up to 10,200,000 (median 55,500) 
U/ml. Preoperative serum CA125 values could be obtained from 51 patients, and ranged from 13 to
11,000 (median 179) U/ml. CA125 in oCF was always higher than in serum (p <0.001, Student's t-test, 
Figure 1A). Serum and oCF CA 125 within single patients were moderately correlated (R = 0.337, 
p = 0.016, Spearman's correlation test, Figure 1B).
A B
1,000 , 000,000
Cyst fluid Serum 10 100 1'000 10,000 100,000
CA 125 (U/ml) in preoperative serum
Figure 1. (A) Serum and OCF levels of CA 125 in patients with EOC. CA 125 in oCF is always higher than in serum (p <0.001, student's t-test). 
(B) CA 125 levels between oCF and serum only moderately correlate (p= 0.016, R = 0.337, Spearman's correlation test).
Differences between histopathological patient categories
Table 1 lists the association of CA 125 in oCF and CA 125 in preoperative serum with different 
clinicopathological patient characteristics. CA125 in oCF was significantly lower in patients with 
mucinous tumors compared to patients with other histological subtypes (p <0.001), and was 
significantly lower in patients with well differentiated tumors compared to patients with poorly 
differentiated tumors (p = 0.038). Serum CA125 was also lower in patients with mucinous tumors 
(p = 0.014) compared to patients with serous tumors and correlated with tumor grade (p = 0.007) as 
well. In addition, serum CA 125 was significantly higher in patients with advanced FIGO stage (p <0.001) 
compared to patients with early FIGO stage.
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Table 2. Univariate Cox regression analysis of clinicopathological parameters and oCF CA 125 as prognostic factors for DFS 
in patients with EOC
Variable
DFS
HR (95%  CI) p-value
Age 0.493
< 56 years (Reference)
> 56 years 1.30 (0.61-2.79)
Histology <0.001
serous 10.96 (2.28-52.67) 0.003
mucinous (Reference)
endometrioid 1.30 (0.12-14.72) 0.834








< 1 cm (Reference)
> 1 cm 5.82 (2.44-13.93)
CA125 serum 0.009
< median (Reference)
> median 3.11 (1.29-7.51)
CA125 oCF 0.005
< median (Reference)
> median 3.40 (1.45-7.97)
Survival analysis
Figure 2 shows the Kaplan-Meier DFS curves of the patients with oCF CA 125 values above the median 
of 55,500 U/ml and below 55,500 U/ml (Figure 2). High levels of oCF CA125 were significantly associated 
with a poor DFS (p = 0.002, log-rank test). Table 2 shows the hazard ratio with 95% CI, using the univariate 
proportional hazard model. For the variables "FIGO stage", "Tumor grade", and "Serum CA 125" one, 
four and three cases were missing, respectively. Advanced FIGO stage, serous histology, high tumor 
grade, a suboptimal debulking, high preoperative serum CA 125 and high oCF CA 125 levels were 
significant predictors of a poor DFS. However, using the multivariate proportional hazard model with 
selection procedure, FIGO stage was the only independent predictor that had impact on DFS (HR = 87.1; 
95% CI: 1.11-6845; p = 0.045). As a result, the other factors did not contribute additionally to FIGO stage 
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Figure 2. Kaplan-Meyer estimates of DFS of patients with EOC (n = 54). Low oCF CA 125 values (n = 27; < median) and high 
oCF CA 125 values (n = 27; > median) are represented by the solid and broken line, respectively. Vertical bars indicate patients 
with censored data.
Discussion
This is the first study that explored if CA 125 in oCF could be of prognostic value for patients with EOC. 
Ovarian cyst fluid is in close contact with the ovarian tumor epithelium and can be easily obtained by 
fine-needle aspiration after removal of the ovarian tumor at primary surgery. CA 125 measurement in 
oCF is possible with the standard CA 125 assay and therefore, seems to be applicable in clinical practice. 
In the present study high levels of oCF CA 125 were significantly associated with a poor prognosis of 
EOC patients. In addition, CA 125 in oCF did not show any relationship with FIGO stage and/or debulking 
status, which have shown to be the most important prognostic factors for EOC.[3] These findings did 
suggest an independent prognostic role for oCF CA 125. However, multivariate survival analysis showed 
that FIGO stage was the only independent predictor of the time to recurrence. Therefore, we concluded 
that CA 125 in oCF was not of additional value as a predictive marker for patients with EOC.
Prognostic markers are of major importance for the clinical management of patients with EOC. 
Therefore, identification of the group of patients with a poor disease outcome should occur as early
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as possible. Currently, serum CA 125 is used during chemotherapeutic treatment to monitor response. 
It has also proven its value to predict recurrence and disease progression after primary therapy.[4,6,7] 
However, the role of preoperative serum CA 125 as a prognostic tumor marker remains unclear as most 
studies could not show a significantly independent predictive effect.[3,4,9,11-14,26] We found that 
preoperative serum CA 125 was a significant predictor of DFS in univariate analysis. However, it correlated 
strongly with FIGO stage, which also has been demonstrated in previous studies.[3,9,14,27] Therefore, 
similar to oCF CA 125, preoperative serum CA 125 in the present study was not of additional prognostic 
value either.
Only two reports have evaluated the prognostic value of CA 125 expression in ovarian tissue. De la Cuesta 
et al. [28] found that patients with a high expression of the analyte had a significantly poorer prognosis 
compared to patients with no expression. More recently, Hogdall et al. [8] reported for a large series of 
ovarian tissue samples that increased tissue expression of CA 125, as determined by immunohistochemistry, 
was related to poor prognosis, but only in the group of patients with advanced stage EOC. In the present 
study, we also found that patients with high levels of CA 125 in oCF had a significantly poorer prognosis 
and also that these oCF CA 125 levels were not related to FIGO stage. Therefore, we believe that oCF CA 
125 might give a representative reflection of the tumor tissue biology.
The present study demonstrated that oCF levels varied between different histopathological subtypes. 
More specifically, mucinous tumors contained significantly lower amounts of oCF CA 125 than all other 
subtypes. It has been shown previously that the proportion of CA 125- producing cells differs between 
EOCs due to its well-known variety of histopathological subtypes, [8,20,29] of which mucinous tumors 
produce less CA 125.[8] In their series of 584 ovarian cancer tissue samples, Hogdall et al. found CA 125 
expression in 12%, 40%, 65% and 85% of mucinous, clear cell, endometrioid and serous samples, 
respectively.®
The mechanism of CA 125 release from epithelial cells of the ovary into oCF or serum has been poorly 
understood. Jacobs et al. [30] reported that elevation of preoperative serum CA 125 is not always related 
to the production of the CA 125 analyte in ovarian tissue. In FIGO stage I EOC, when the tumor is still 
confined to the ovaries, the phenomenon of high tissue CA 125 levels in association with normal serum 
CA 125 levels has been demonstrated.[30] A similar observation was found in patients with benign 
ovarian tumors, where high CA 125 levels in oCF were accompanied by low serum CA 125 levels.[20] 
This might suggest that CA 125 is released into the serum only in case of extensive infiltrative growth 
and wide spread malignancy, probably because of loss of permeability of the basement membrane and 
the substantial contribution of metastatic lesions to the CA 125 production.[20] Therefore, preoperative 
serum CA 125 seems to be a biomarker for disease progression, which might explain its high correlation 
with FIGO stage of disease. On the other hand, CA 125 in oCF seems to result from a more continuous 
production brought about by the malignant ovarian epithelium. In the present study, oCF CA 125 was 
only correlated with histology and grade, which are pathological characteristics of the tumor tissue itself
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This study was performed to explore the predictive possibilities of analysis of CA 125 in cyst fluid of patients 
with EOC. We realize that our retrospective study comprised a relatively small and heterogeneous cohort 
of patients with EOC. Although we found that high levels of CA 125 were significantly associated with 
a poor DFS in univariate analysis, a prospective study with more uniform samples and increased power 
is required to replicate our findings. On base of the results of the present explorative study, we suppose 
that analyzing CA 125 in oCF has no additional value in prediction of recurrence for patients with EOC.
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CATHEPSINS B, L AN D  CYSTATIN C IN CYST FLUID OF OVARIAN TUM ORS
Abstract
In cancer, an extracellular and membrane bound localization of cathepsins contributes to the invasion 
of tumor cells at the basement membrane. This is the first study that explored levels of cathepsins B 
(CatB), L (CatL) and their inhibitor cystatin C (CysC) in the ovarian cyst fluid (oCF) of ovarian tumors 
(n = 110). Ovarian cyst fluid contained considerable amounts of CatB, CatL and CysC. Remarkable 
differences in CatB and CatL and cystatin C oCF levels were found between different histopathological 
tumor subtypes. Levels of CatB and CysC were significantly higher in oCF of malignant serous tumors 
compared to those found in benign serous tumors (p = 0.010 and p = 0.001, respectively), whereas 
levels of CatL were significantly higher in oCF of malignant mucinous tumors compared to those found 
in benign mucinous tumors (p = 0.035). CatB and CysC showed a strong correlation in the group of 
patients with malignant serous tumors (p <0.001; R = 0.921) suggesting that the increase in CatB 
might be balanced by a corresponding increase in CysC. Further studies are warranted to investigate 
cathepsins as possible prognostic biomarkers for the aggressiveness of ovarian cancer.
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Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy worldwide. Because of 
the absence of early symptoms, approximately 70% of the patients is diagnosed with International 
Federation of Gynecologists and Obstetricians (FIGO) stage III or IV, when tumor cells already have 
metastasized to the upper abdomen.[1] Compared to other types of cancer, insight in the carcinogenesis 
and progression of ovarian cancer is limited by the lack of a well-defined precursor lesion and by the lack 
of data from early stage cancers.[2]
In neoplastic transformation, the epithelial surface first becomes multicell layered. Tumor cells then 
degrade the basement membrane and invade the stroma or become detached from the primary 
tumors and metastasize.[3-6] It is now widely believed that the degradation of the basement membrane 
is catalyzed by proteolytic enzymes.[7-9] Among these enzymes are the lysosomal cysteine proteinases 
or cathepsins, which have an important physiological function in regulation of intracellular protein 
metabolism. The human family of cathepsins has 11 members (cathepsin B, C, F, H, K, L, O, S, V, W  and X), 
which share a conserved active site that is formed by cysteine, histidine and asparagine residues. 
In cancer tissue, an increased expression of cathepsins has been described and an extracellular and 
membrane bound localization of particularly cathepsin B (CatB) and cathepsin L (CatL) has been 
demonstrated, which might contribute to the invasion of tumor cells at the basement membranes. 
[8,10,11]
Numerous reports have now been published investigating cancer tissue expression of cathepsins. 
[9,12,13] Although quantitation of cathepsins in extracellular fluid has several advantages compared 
to measurement in tissue, reports investigating extracellular cathepsin levels are rather limited.[10] 
Higher levels of CatB and CatL were reported in sera of patients with several types of cancer, [14-20] 
including ovarian cancer, [21,22] compared to serum levels in healthy subjects or patients with benign 
lesions. The possibility of measuring cathepsins in blood increases its clinical value as a biomarker but 
reported levels in the serum are significantly lower than levels in tumor cells of cancer patients.[10] 
Lah et al. [23] have shown that CatB was present in ascites of patients with ovarian carcinoma. Moreover, 
they showed that extracellularly released CatB was inhibited most strongly by cystatin C (CysC), which is 
an extracellular cysteine proteinase inhibitor.[23] Recent studies on tissue of breast and ovarian cancer, 
and melanoma showed that an imbalance of CatB/CysC was correlated with a more aggressive tumor 
behavior.[15,24,25]
Most ovarian tumors exhibit, sometimes multiple, cysts which can be large. The ovarian cyst fluid (oCF) is 
in close contact with the tumor tissue. To our knowledge, no studies have been performed to investigate 
the levels of cathepsins or their endogenous inhibitors in this oCF. In the present study, we explored 
CatB, CatL as well as CysC levels in oCF of patients with benign, borderline and malignant ovarian tumors.
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Material and methods
Patients and cyst fluid collection
From our biobank containing oCF samples of patients with ovarian tumors who underwent primary 
surgery at the Radboud University Nijmegen Medical Center in the period between 1988 and 1998, 
all 110 oCF samples were retrieved for analysis. Samples in this biobank, were collected by aseptic fine 
needle aspiration at the Department of Pathology immediately after surgical removal of the tumor. 
After cooled transport to the laboratory, the oCF samples were centrifuged at 3000 x g for 10 minutes 
and the supernatant was stored at -35 °C in small portions until use. Histopathological diagnosis was 
performed by a pathologist specialized in gynecology and revealed 74 benign, 26 malignant and 
10 borderline epithelial ovarian tumors. Informed consent was obtained from all participants.
ELISA procedures
For the quantitative analysis of CatB and CatL and CysC in oCF, commercially available specific 
ELISAs (sandwich ELISAs, Krka d.d., Novo mesto, Slovenia) were used, as developed by Kos et al.[15] 
The components were purified and characterized, and the tests were optimized and performed as 
described.[26] To define the optimal dilution, oCF samples were serially diluted to the levels encompassing 
the range of the assays. The linearity of the response was evaluated by comparing the measured values 
with the calibration curves. The recovery was tested by the addition of different amounts of the antigen 
to the samples with known antigen concentration and varied from 88 to 108%, comparing expected 
versus observed concentrations. The intra-assay coefficient of variance varied from 7.6 to 12.7 %. 
CF samples were diluted 1:4 for CatB and CatL and 1:100 for CysC prior to being applied to the wells of 
microtiter plate. A microplate reader (SLT Rainbow, Salzburg, Austria) was used to measure absorbance. 
Determination of the levels of cathepsins and CysC was carried out without prior knowledge of 
the histological or clinical outcome.
Parameters for aggressiveness of the tumor
From the pathological and medical reports of the patients with EOC, the following parameters were 
retrieved: histopathologic subtype and histopathologic grade, age at diagnosis and FIGO stage of disease. 
Histopathologic subtype and tumor grade were classified according to the World Health Organization 
criteria.[27] Staging was performed using the FIGO criteria.[28] In case of uncertainty about the primary 
location of the tumor, extensive immunohistochemical staining was performed. Only patients with 
confirmed primary EOC were included.
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Statistical analyses
Values are shown as median with range (ng/ml). Normality of distributions was analyzed by Kolmogorov- 
Smirnov testing. Data regarding CatB, CatL and CysC could be normalized by Ln transformation. 
Differences between two groups were tested by Student's t-test, and for more than 2 groups by ANOVA 
and subsequent post hoc Tukey's HSD tests. Correlations were assessed by Pearson correlation tests of 
the Ln transformed values. A priori significance was set at a two-sided p <0.05. All statistical analyses 
were performed using SPSS version 16.0.01 (SPSS Inc. Chicago IL, USA).
Results
Patients
The mean age at diagnosis was 40 years (SD ± 14) for the patients with benign ovarian tumors (n = 74), 
42 years (SD ± 14) for the patients with borderline ovarian tumors (n = 10) and 57 years (SD ± 11) 
for the patients with EOC (n = 26). The mean age of patients with ovarian cancer was significantly higher 
than the mean age of patients with benign (p <0.001, Student's t-test) and borderline tumors (p = 0.009, 
Student's t-test). No differences in mean age were found between patients with benign and borderline 
tumors (p = 0.898, Student's t-test).
Histopathological subtype
Table 1 shows the median (range) concentrations of CatB, CatL and CysC in ovarian oCF of patients with 
malignant, borderline and benign ovarian tumors, grouped by histological subtype. Within the benign 
group, oCF levels of CatL were significantly different between serous cystadenomas and mucinous 
cystadenomas (p = 0.003) and between endometriosis cysts and mucinous cystadenomas (p <0.001). 
Although generally not significantly different from the other benign histological subtypes, the median 
concentrations of CatB and CatL in cystic endometriosis were remarkably high, and comparable 
to those found in oCF of malignant tumors. CysC concentrations were in the same range for all 
benign subclasses. Within the group of borderline and malignant tumors, oCF levels of CatB, CatL and 
CysC did not differ significantly between histopathological subtypes.
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Table 1. Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in cyst fluid of ovarian tumors (n = 110) grouped by 
histopathological subtype
Histology n (%) Cathepsin B Cathepsin L Cystatin C
Benign
serous cystadenoma 29 (39%) 12 (1-269) 31 (9-121)A 572 (131-1,781)
mucinous cystadenoma 21 (28%) 16 (1-227) 11 (1-95)A B 578 (39-9,984)
dermoid cyst 5 (7%) 11 (1-108) 10 (2-97) 618 (117-876)
cystic endometriosis 16 (22%) 71 (1-177) 69 (8-233)B 338 (92-1,931)
corpus luteum cyst 3 (4%) 18 (6-98) 15 (15-133) 644 (520-1,805)
Borderline
serous borderline tumor 2 (20%) 14 (8-21) 28 (18-38) 1,449 (1125-1,772)
mucinous borderline tumor 6 (60%) 31 (2-118) 75 (8-166) 697 (474-3,897)
mixed type borderline tumor* 1 (10%) 227 92 340
unknown 1 (10%)
Malignant
serous carcinoma 10 (38%) 65 (3-269) 61 (8-163) 1,443 (448-5,972)
mucinous carcinoma 8 (31%) 33 (5-269) 31 (13-187) 959 (399-9,984)
endometrioid carcinoma 6 (23%) 85 (1-269) 71 (14-181) 1,200 (64-2,907)
mixed type carcinoma* 1 (4%) 95 67 1,232
undifferentiated carcinoma* 1 (4%) 110 75 109
*  single concentration is listed. Statistical significance according to ANOVA (p =  0.001) with Tukey's H SD  Post-hoc test of values normalized 
after Ln transformation;A p =  0.003 for mucinous cystadenomas compared to serous cystadenomas;B p <0.001 for mucinous cystadenomas 
compared to cystic endometriosis
Table 2 and Figure 1 show median (range) oCF levels of CatB, CatL and CysC in benign (cystadenoma), 
borderline and malignant (cystadenocarcinoma) ovarian tumors according to the histopathological 
subtype. In serous tumors (n = 41), oCF levels of CatB were significantly higher for patients with malignant 
tumors compared to patients with benign tumors (p = 0.010), whereas CatL levels did not differ 
significantly within this histological subgroup. In contrast, in mucinous tumors (n = 35), oCF levels of 
CatL were significantly higher for patients with malignant tumors compared to patients with benign 
tumors (p = 0.035), whereas CatB levels did not differ within this histological subgroup. Ovarian cyst 
fluid levels of CysC only differed between patients with malignant and benign tumors in the subgroup 
of serous tumors (p = 0.001).
Parameters of aggressiveness of the tumor
Table 3 shows clinicopathological parameters of tumor aggressiveness and median (range) concentrations 
of CatB, CatL and CysC of the 26 patients with EOC. Since no differences in oCF levels of CatB, Cat L 
and CysC were found between serous, mucinous and endometrioid cystadenocarcinomas (Table 1), 
data of patients with EOC were merged. When patients were grouped according to FIGO stage of disease, 
tumor grading and presence of ascites, no significant differences in oCF levels of CatB, CatL and/or CysC 
were found.
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Correlation between cathepsins and cystatin C
Figure 2 shows the scatter plots of the correlation between cathepsins and CysC for patients with 
serous (Figure 2A and 2B; n = 41) and mucinous (Figure 2C; n = 35) tumors. For serous tumors, 
oCF levels of CysC and CatB were significantly correlated (p <0.001, R = 0.652, Figure 2A). The correlation 
between oCF levels of CysC and CatB was highest for the malignant group (p <0.001, R = 0.921). 
For mucinous tumors, oCF levels of CysC and CatB did not show any relationship (p = 0.923, Figure 
not shown). Correlations between oCF levels of CysC and CatL were significant for both serous and 
mucinous tumors (p = 0.001, R = 0.491, Figure 2B and p = 0.003, R = 0.481, Figure 2C, respectively). 
For mucinous tumors, the correlation between oCF levels of CysC and CatL was highest for the benign 
group (p <0.001, R = 0.665)
Discussion
In this study, we examined oCF levels of CatB, CatL, and their extracellular inhibitor CysC. In benign tumors, 
remarkable differences in oCF levels of CatB and CatL were found between different histopathological 
subtypes. For serous tumors, levels of CatB and CysC were significantly higher in the oCF of patients with 
EOC compared to oCF levels of patients with benign ovarian tumors. For mucinous tumors, levels of CatL 
were significantly higher in the oCF of patients with EOC compared to oCF levels of patients with benign 
ovarian tumors. Furthermore, correlations between cyst fluid levels of CatB and CysC and between CatL 
and CysC were found. Finally, we investigated the relationship between levels of CatB, CatL and CysC 
and parameters of tumor aggressiveness of EOC but could not find significant differences between 
the subgroups of patients.
We are the first to describe that oCF contains considerable amounts of CatB, CatL and CysC. In ascitic 
fluid of patients with ovarian cancer, Lah et al. [23] found CatB and a large pool of free CysC.
We showed that oCF levels of these enzymes were higher in ovarian cancer patients compared to 
patients with benign ovarian tumors. Serum studies in patients with other types of cancer have 
demonstrated similar results, as levels of CatB, CatL and CysC were found to be higher in serum of 
patients with cancer compared to serum levels of patients with benign tumors or healthy controls. 
[14-19,29-34] In serum of patients with ovarian cancer, Warwas et al. [22] found higher levels of CatB 
compared to levels in patients with benign ovarian tumors. On the other hand, Nishikawa et al. [24] 
could not observe a significant difference in serum CatB level between patients with benign ovarian 
tumors and EOC although they did find a significantly higher level of CysC in the serum of patients 
with ovarian cancer. Only one study has been published investigating CatL in the serum of patients 
with ovarian tumors.[21] The authors found that serum levels of CatL were elevated in 8/10 patients with 
ovarian cancer compared to 2/10 patients with benign ovarian tumors.
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Subtype n (% ) Cathepsin B p-value* Cathepsin L p-value* Cathepsin C p-value*
Serous 41 0.131 0.001
serous cystadenoma 29(71%) 1 2 (1-269)A 0.031 31 (9-121 ) 572 (131-1,780)“
serous borderline tumor 2 (5%) 14(8-21) 28(18-38) 1,449(1,125-1,772)
serous cystadenocarcinoma 10(24%) 65 (3-269)A 61 (8-163) 1,443 (448-5,972)“
Mucinous 35 0.017 0.136
mucinous cystadenoma 21 (60%) 16(1-227) 11 (1-95 )c 578 (39-9,984)
mucinous borderline tumor 6 (17%) 32(2-118) 0.315 75 (8-166) 697 (474-3,897)
mucinous cystadenocarcinoma 8 (23%) 33 (5-269) 31 ( 1 3-187)'1 959(399-9,984)
Statistica! significance according to ANOVA  *  and Student's t-testAÂC o f values normalized after Ln transformation/ p  =  0.010 for serous cystadenoma compared 
to serous carcinoma;8 p  =  0.001 for serous cystadenoma compared to serous carcinoma; cp  =  0.035 for mucinous cystadenoma compared to mucinous carcinoma
Subtype n (% ) Cathepsin B p-value* Cathepsin L p-value* Cathepsin C p-value*
FIGO stage 0.61 3 A 0.984 A 0.406 A
la-lla 13 (50% ) 48 (28-93) 40 (29-78) 1,040 (594-2,355)
>llb 12 (46%) 72 (16-109) 63 (18-125) 1,233 (1,055-1,500)
unknown 1 (4%)
Tumor grade 0.554“ 0.595 “ 0.535 “
1 6 (23%) 38 (10-269) 31 (14-187) 959 (465-9,984)
2 5 (19%) 71 (38-269) 62 (38-163) 1,076 (399-1,502)
3 13 (50%) 64 (3-11) 64 (8-181) 1,324 (448-2,908)
unknown 2 (8%)
Ascites 0.632 A 0.379 A 0.569 A
yes 11 (42%) 76 (5-269) 64(13-181) 1,330(1,048-2,908)
no 12 (46%) 970 (399-9,984)
unknown 3 (12%)
Statistical significance according toA Student's t test or 8ANOVA o f values normalized after Ln transformation
Table 
2. Median 
levels (range) of CatB, CatL 
Table 
3. Median 
levels (range) of cathepsin 































for aggressiveness of the 
tum
or
Figure 1. Boxplots of (A) CatB, (B) CatL, and (C) CysC (ng/ml) concentration (logarithmic scale) in ovarian cyst fluid for patients 
with malignant, borderline and benign ovarian tumors, clustered by histological subtype (serous and mucinous tumors).
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A
C
Figure 2. Scatter plots of Ln-transformed values of oCF (A) CysC with CatB and (B) CysC with CatL for patients with serous 
tumors (n = 41) and (C) CysC with CatL for patients with mucinous tumors (n = 35). Statistical significance (p <0.05) and 
correlation coefficient (R) according to Pearson's correlation test. * = malignant; A  = borderline; O = benign
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The mean age of patients with ovarian cancer is known to be significantly higher than the mean age of 
patients with benign ovarian tumors.[35] This was also found in our study group. This might confound 
our results, as there is definite evidence that renal function decreases with age, [36] which results in 
a reduced glomerular filtration rate in older people. CysC is known to be almost completely reabsorbed 
and catabolized in the proximal renal tubular cells.[37] This might explain the higher serum levels of 
CysC that were reported earlier in patients with EOC compared to serum levels of CysC in patients with 
benign ovarian tumors. However, we found no correlation in oCF between age and CysC level within 
the subgroups of patients. In addition, it is unclear whether CysC levels in oCF, in contrast to serum, 
are influenced by renal function. Finally, the group of patients with borderline tumors is of similar age as 
the patients with benign tumors, yet exhibited CatB and CatL and CysC levels similar to those of patients 
with EOC. The level of CysC might be changed also due to pathological renal failures, changing 
the glomerular filtration rate in cancer patients.[37] However, patients, included in this study, did not 
exhibit any impaired kidney function. Therefore, we believe that the results of CysC in this study have not 
been biased by age-related or pathological changes of kidney function.
Remarkably, CatB and CysC oCF levels were significantly higher in malignant serous tumors compared 
to benign serous tumors, whereas oCF levels of CatL were significantly higher in malignant mucinous 
tumors compared to benign mucinous tumors. This finding contributes to the theory that malignant 
serous and mucinous ovarian tumors are different diseases, with subtype-specific biomarker profiles. 
[38-40] In addition, a significant correlation between CatB and CysC was found for patients with serous 
tumors. Moreover, the correlation of CatB and CysC was extremely strong in the group of patients with 
malignant serous tumors (R = 0.921), which might indicate that an increase of oCF CatB in malignant 
tumors is balanced by a corresponding increase in oCF CysC level. This finding could be interesting as 
it was proposed in previous studies that a relative imbalance between CatB and CysC in patients with 
cancer might contribute to the invasion and metastasis of tumor cells.[10,24,41]
Although not significant, median oCF levels of CatB and CatL were up to seven times higher in cystic 
endometriosis compared to the other histopathological subtypes and levels were comparable to oCF 
levels of ovarian cancer patients with unfavorable tumor characteristics. Noteworthy is that CysC did 
not differ between cystic endometriosis and other benign subtypes, which might suggest a different 
balance between CatB and CysC in endometriosis cysts compared to the other histological subtypes. 
This might be explained by the continuous breakdown of components of blood and stromal tissue 
in endometriosis without a malignant invasion or metastasis. However, it is now well established that 
endometriosis does have neoplastic potential and it has been associated with the development of 
endometrioid and clear-cell ovarian carcinoma.[5,42]
Since ovarian cancer tissue is highly heterogeneous, multiple biopsies are necessary for a careful 
examination.[43,44] This means that quantitation of cathepsins and cystatins in biological fluids of 
ovarian cancer patients has several clinical advantages above measurements in ovarian cancer tissue. 
We found that levels of cathepsins and CysC in oCF were much higher than levels in serum of cancer
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patients as have been reported in literature. More specifically, up to 6 times more CatB was found in oCF 
than in the serum of patients with colorectal carcinoma [16] and melanoma [15], up to 10 times more 
CatL was found in oCF than in serum of patients with EOC, [21] and up to 8 times more CysC was found 
in oCF than in the serum of patients with EOC [24]. This might indicate that CatB, CatL as well as CysC 
are released from tumor cells into the oCF to a greater extent than the release of these compounds into 
the serum of cancer patients. In this way, oCF values may give a better reflection of local changes of 
the ovarian tumor than levels of cathepsins and its inhibitors in serum, which also might be affected by 
the systemic response on malignant disease and circadian variations.[45,46] From a clinical perspective, 
preoperative aspiration of oCF might cause iatrogenic metastasis of tumor cells, and oCF can only 
be used as a source of biomarkers for predicting prognosis and response to therapy. We therefore 
investigated the relationship between clinicopathological parameters that correspond with tumor 
aggressiveness and the levels of CatB, CatL and CysC in patients with EOC. However, when patients 
were grouped according to FIGO stage of disease, tumor grading and presence of ascites, no significant 
differences in oCF levels of CatB, CatL and/or CysC were found. This could be caused by the relatively 
small size of oCF samples from malignant tumors in the present study.
Ovarian cyst fluid levels of CatB, and its endogenous inhibitor CysC were significantly higher in serous 
EOC compared to benign serous ovarian tumors, whereas oCF levels of Cat L were significantly higher 
in mucinous EOC compared to benign mucinous ovarian tumors. The correlation between CatB and 
CysC was extremely strong for patients with serous EOC, which might indicate that an increase in CatB 
of these patients is balanced by a corresponding increase in CysC level. We feel that further studies with 
a larger series of samples from malignant tumors are needed to explore the possible prognostic value of 
cathepsins and cystatin in oCF.
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THE BALANCE BETW EEN  EXTRACELLULAR CATHEPSINS AN D  CYSTATIN C IS OF IM PORTANCE FOR OVARIAN CANCER
Abstract
A major step in cancer formation involves the degradation of the extracellular matrix, mediated by 
multiple degradative actions of (lysosomal) proteases. Extracellular release of lysosomal proteases 
(cathepsins) and their inhibitors has been associated with the development and progression of several 
types of cancer. We investigated whether cathepsins in ovarian cyst fluid (oCF) were associated with 
disease outcome in patients with epithelial ovarian cancer (EOC). The levels of cathepsin B (CatB), H (CatH), 
L (CatL), and X (CatX) and their most abundant extracellular inhibitor cystatin C (CysC) were determined 
in oCF of 50 EOC patients by quantitative ELISAs. The cathepsin levels and ratio's between cathepsins 
and CysC were related to clinicopathological parameters (Mann-Whitney and Kruskal-Wallis tests) and 
survival (Cox Regression analysis). Median (25th-75th percentile) levels of cathepsin B, H, L, X and CysC 
in oCF were 97 (42-203), 18 (12-32), 61 (37-108), 20 (13-47), and 657 (501-805) ng/ml, respectively. 
The ratio of CysC/CatB was significantly lower for patients with metastatic compared to localized EOC 
(p = 0.025). Ratio's of CysC/CatH and CysC/CatX differed significantly between histological subtypes 
(p = 0.012 and p = 0.035, respectively) and were significantly higher for high-grade tumors compared 
to low-grade tumors (p = 0.031 and p = 0.039, respectively). Neither cathepsins nor their ratio's were 
significant predictors of survival for EOC patients. Ratio's between CysC and cathepsins in oCF differed 
significantly between important clinicopathological subgroups. We believe that a complex cascade of 




Tumor recurrence is the limiting factor and the main cause of death in epithelial ovarian cancer (EOC).
[1] Due to its heterogeneity and lack of well-defined precursor lesions, development and progression 
of EOC are still poorly understood.[2] Insight in the carcinogenesis of EOC is of major importance for 
identification of biomarkers that predict early recurrence of disease for tailor-made treatment.
Tumor progression and metastasis are associated with proteolytic mechanisms to degrade the extracellular 
matrix (ECM) and other structural proteins.[3] Lysosomal cysteine proteases or cathepsins, comprise 
a large family of enzymes divided into subgroups (B, H, L, S, C, K, O, F, V, X and W ) on the basis of their 
catalytic mechanisms.[4] Physiologically, cathepsins are localized in lysosomes but during cancer 
development and progression, they are often translocated to the cell surface or even secreted into 
biological fluids.[5] In extracellular fluids, cystatin C (CysC) is the most abundant inhibitor to minimize 
uncontrolled tissue damage from escaping cathepsins.[6] Cathepsins most likely collectively influence 
ECM degradation, tumor invasion and angiogenesis through proteolytic cascades, in which individual 
proteinases have distinct roles.[7] For several types of cancer, proteases and their endogenous inhibitors 
have shown to be of prognostic value characterizing aggressiveness of the tumor and disease outcome.[3,5] 
However, for EOC, cathepsins have less often been investigated and research has been limited to 
establish the prognostic value of the expression of cathepsin B, D or L.[8-12]
Recently, we explored levels of cathepsin B, L and their inhibitor CysC in cyst fluid of epithelial ovarian 
tumors and found significantly higher levels for patients with EOC compared to patients with benign 
lesions.[13] Ovarian tumors typically present as large cystic masses, consisting of variable amounts of 
fluid which has proven to contain many compounds that reflect the biological processes taking place 
within the ovarian epithelial tumor wall.[14] Clinically, oCF cannot be used for differentiation between 
benign and malignant tumors as pre-operative punction of the ovarian tumor might cause metastatic 
tumor spread. Therefore, oCF can only be obtained during or after surgery and compounds in the fluid 
might serve as biomarkers for the prediction of disease outcome of patients with EOC.
The aim of the present study was to investigate whether the concentration of cathepsins B (CatB), 
H (CatH), L (CatL) X (CatX) and CysC was associated with important clinicopathological parameters 
and survival of EOC patients. Based on the recently proposed hypothesis that an imbalance between 
cysteine proteases and their cysteine protease inhibitor might lead to cancer invasion and progression, 
[5,15,16] we also investigated if the ratio between cathepsins and CysC was related to clinicopathological 
parameters and survival.
73
THE BALANCE BETW EEN  EXTRACELLULAR CATHEPSINS AN D  CYSTATIN C IS OF IM PORTANCE FOR OVARIAN CANCER
Material and Methods
Patients and oCF samples
In the period between January 2000 and January 2008, oCF was collected from patients who underwent 
surgery for an ovarian tumor at the Radboud University Nijmegen Medical Centre (RUNMC) and stored 
in our cyst fluid biobank. Ovarian CF was collected through aseptic fine needle aspiration during or 
after primary debulking or diagnostic surgery, never during interval debulking surgery. All patients were 
treated with radical cytoreductive surgery. From 68 patients, oCF could be obtained. Ten patients were 
excluded from this study because final paraffin examination revealed that the origin of the primary 
tumor was not ovarian derived. Another 8 patients were excluded because the ovarian malignancy was 
non-epithelial. Included were patients with histologically proven primary EOC (n = 50). Informed consent 
was obtained from all participants. After cooled transport to our laboratory, the oCF samples were 
centrifuged at 3000 x g for 10 minutes and the supernatant was aliquoted and stored at -35°C until use.
Enzyme-linked immunoassays (ELISAs)
Human cathepsins B, L, H, and X, and CysC were analyzed using ELISAs developed by the group of J. Kos, 
University of Ljubljana. The components were purified and characterized, and the tests were optimized 
as described earlier.[17] To define the optimal dilution, the samples were serially diluted to the levels 
encompassing the range of the assays. For cathepsins, samples in a 1:4 dilution were added to the wells 
of microtiter plate. For CysC, samples in a 1:100 dilution were used in the assay.
Cathepsin B. Sheep and rabbit polyclonal antibodies (IgG), purified from antisera by immunoaffinity 
chromatography on immobilized human CatB, were used as capture and detection antibodies, 
respectively, as described earlier.[18] The detection limit of the assay was 0.9 ng/ml.
Cathepsin H. Sheep polyclonal antibody was used as capture antibody and murine 2E3 monoclonal 
antibody for detection, as described earlier.[19] They both recognize free antigen and enzyme-inhibitor 
complexes. The detection limit was 2 ng/ml.
Cathepsin L. Sheep anti-CatL IgG purified on immobilized antigen was used as capture antibody and 
as detection horseradish peroxidase-conjugated antibody.[20] The detection limit was 1.7 ng/nl.
CathepsinX. In CatX ELISA 2F12 (recognizing mature CatX) and 3B10 (recognizing mature- and pro-form 
of CatX) monoclonal antibodies were used for capture and detection, respectively.[20] The detection 
limit was 2 ng/ml.
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Cystatin C. Rabbit affinity-purified polyclonal antibody was used for capture and murine 1A2 M-antibody, 
conjugated with horseradish peroxidase, was used for detection.[18] The detection limit of the assay 
was 0.6 ng/ml.
Polyclonal antibodies used for cathepsin B, H, L and CysC ELISA recognize precursor molecule and 
enzyme/inhibitor complexes, as well as the mature form of the enzyme. The linearity of the response in 
all ELISAs was evaluated by comparing the measured values with the calibration curves. The recoveries 
were tested by the addition of different amounts of the antigens to the serum with known antigen 
concentrations and varied from 85-104% for all assays, comparing expected versus observed 
concentrations. The intra-assay coefficient of variance (CV) varied from 5.6 to 11.6% the inter-assay CV 
varied between 8.5% and 14.5% for the assays. A microplate reader (SLT Rainbow, Salzburg, Austria) 
was used to measure absorbance. Determination of the levels of cathepsins and CysC was carried out 
without prior knowledge of the histological or clinical outcome.
Clinicopathological characteristics
Complete cyto- and histopathological reports of all EOC patients were reviewed for correct histopathological 
diagnosis (primary ovarian carcinoma, histological tumor subtype and grade and presence of malignant 
cells in ascites) by one pathologist, specialized in gynecological pathology. Histopathological tumor 
type and grade were classified according to the World Health Organization criteria.[21] Surgery and 
International Federation of gynecologist and Obstetrics (FIGO) staging [22] was always performed 
by a gynecologist specialized in oncology. From the medical records of the patients, the following 
clinicopathological characteristics were retrospectively retrieved: age at diagnosis, FIGO stage, residual 
tumor after surgery, time of tumor recurrence, and date of death. For some patients, information about 
one or more clinicopathological parameters could not be retrieved (Table 1). Recurrence of disease 
was defined as a measurable lesion during follow-up evaluated by computed tomography, magnetic 
resonance imaging and/or ultrasonography.
Statistical analyses
Statistical analyses were carried out using SPSS 16.0.2 software (SPSS Benelux BV, Gorinchem, 
the Netherlands). Values are shown as median with 25th-75th percentile (ng/ml). Normality of distributions 
was confirmed by Kolmogorov-Smirnov testing for all variables except CatX and CysC, which could 
be normalized by Ln transformation. Differences between two groups were tested by Student's t-test, 
and for more than 2 groups by ANOVA and subsequent posthoc Tukey's HSD tests. Ratio's between 
CysC and all cathepsins were tested non-parametrically using Mann-Whitney and Kruskal-Wallis tests. 
For statistical analysis, variables regarding clinicopathological characteristics were grouped in the following 
manner: FIGO stage: I versus II, III and IV, as the first category refers to tumors that are localized in
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Table 1. Patient and tumor characteristics
Characteristics n (% ) Median (range)




















good (1) 13 (26)
moderate (2) 15 (30)
poor (3) 18 (36)
unknown 4 (8)
Residual tumor after surgery
< 1 cm 41 (82)
> 1 cm 8 (16)
unknown 1 (2)
the ovaries and the second category refers to tumors that are metastasized; [22] histology: serous versus 
mucinous versus endometrioid, as the other subtypes consisted of less than 2 cases; differentiation 
grade: low-grade (well-differentiated) tumors versus high-grade (moderately and poorly differentiated) 
tumors; [23] age: median values; residual disease after surgery: lesions < 1cm versus lesions > 1 cm. 
For survival analyses, the median of the cathepsins and CysC concentration and their ratio was used as 
the cut off value for dichotomizing oCF levels. Disease-free survival (DFS) time was used as follow-up 
endpoint and was defined as the time interval from the date of surgery to the date of recurrence or 




Patient and tumor characteristics
Patient and tumor characteristics at time of surgery are listed in Table 1. All patients, except those with FIGO 
stage I, grade 1or 2 disease were given six cycles of platinum-based chemotherapy. Median follow-up 
time was 39 months (range: 9-160 months). DFS ranged from 1 to 117 months, with a median of 15 months. 
Within the follow-up period, 23 patients (46%) showed recurrent disease and 15 patients died (30%).
Cathepsins B, H, L, X and CysC levels in oCF
Median (25th-75th percentile) concentration of cathepsin B, H, L, X and CysC was: 97 (42-203), 18 (12-32), 
61 (37-108), 20 (13-47), and 657 (501-805) ng/ml, respectively. The median (25th-75th percentile) cathepsin 
and CysC concentration for different clinicopathological subgroups is listed in Table 2. CatB was 
significantly higher in patients older than compared to patients younger than 57 years of age (p = 0.049). 
The CysC concentration differed significantly between histological subtypes (p = 0.037). Although not 
significantly different, CatH concentration was slightly higher in mucinous (p = 0.055) and low-grade 
tumors (p = 0.059).
Ratio values between cystatin C and cathepsin B, H, L and X in oCF
Median (25th-75th percentile) ratio's between CysC and cathepsin B, H, L, and X were 7 (3-13), 
28 (17-56), 10 (7-21) , and 30 (13-54), respectively. Differences in ratio's between CysC and cathepsins for 
the clinicopathological subgroups are listed in Table 3. The ratio of CysC/CatB was significantly lower 
for patients with FIGO stage > II compared to FIGO stage I (p = 0.025, Figure 1 ). The ratio of both 
CysC/CatH and CysC/CatX differed significantly between histological subtypes (p = 0.012, Figure 2 and 
p = 0.035, Figure 3, respectively) and was significantly higher for high-grade tumors compared to 
low-grade tumors (p = 0.031 and p = 0.039, respectively).
Cathepsins and CysC and survival of EOC patients
Median levels were used to dichotomize cathepsins, CysC and their ratio's to study their prognostic 
significance. Table 4 shows the hazard ratio (HR) with 95% confidence interval (CI), using the univariate 
proportional hazard model. Histological subtype, FIGO stage, differentiation grade, residual tumor 
after surgery and preoperative CA 125 level were found to be significant predictors of DFS in univariate 
analysis. None of the individual cathepsins, CysC or their ratio's were significant predictors of DFS.
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Table 2. Relationship between median (25th-75th percentile) cathepsin B, H, L, 




Figure 1. The difference in ratio values of oCF CysC and CatB between patients with (n = 30) and without (n = 20) metastatic 
EOC (p = 0.025).
Figure 2. The difference in ratio values of oCF CysC and CatH between patients with serous (n = 23), mucinous (n = 14) 
and endometrioid (n = 6) type EOC (p = 0.012).
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Figure 3. The difference in ratio values of oCF CysC and CatX between patients with serous (n = 23), mucinous (n = 14) 
and endometrioid (n = 6) type EOC (p = 0.035).
Discussion
Recently, several studies reported that extracellular release of cathepsins and their inhibitors is predictive 
for prognosis of cancer patients.[5] In serum of cancer patients, a high concentration of CatB, CatH 
and CysC was correlated with a shorter survival [5]. Similar results were found when cathepsins were 
explored in urine, [24,25] and cerebrospinal [26] and pleural [27] fluid. Compared to tissue, biological 
fluid samples are easier to obtain, homogeneous and compounds can be measured quantitatively.
Compared to reported serum values in cancer patients, [8,28-30] we found a high concentration of 
cathepsin B, H, L and X in oCF of EOC patients, suggesting an extracellular release from the ovarian 
tumor into the oCF. Individual levels of cathepsins in oCF showed no significant correlation with any of 
the clinicopathological parameters. However, ratio's between cathepsins B, H, X and CysC were significantly 
associated with important parameters of tumor progression and metastasis although they were not 
predictive for recurrence of disease. Scorilas et al. did find that CatB expressing EOC tissue was 
significantly associated with early recurrence and shorter survival.[10] However, these authors scored 
intracellular immunohistochemical expression of CatB as either positive or negative, whereas we measured 
extracellular cathepsins quantitatively by ELISA. To our knowledge, no other studies have been reported 
investigating the prognostic value of cathepsins or CysC for patients with EOC.
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As cystatins have shown to be the most abundant and tight binding extracellularly inhibitors of all 
members of the cathepsin superfamily, [6] we suggest that an imbalance between the proteolytic 
cathepsins and their inhibitor might be essential for EOC progression and metastasis. This theory is 
supported by studies in which the ratio of CatB and CysC differed significantly between cancer patients 
and healthy controls.[16,18,26,31,32] We found that the ratio of CysC and CatB was significantly lower 
in oCF of advanced stage EOC patients compared to patients with localized disease. Since oCF CatB 
was found to be progressively increased with FIGO stage, high CatB concentration in metastasized EOC 
might be accompanied by less increased concentration of CysC. In agreement with our results, a high 
CatB concentration has been found in tissue and serum of advanced stage EOC patients as well.[10,33] 
In addition, for other types of tumors, a lower ratio between CysC and CatB has been found in serum and 
cerebrospinal fluid of patients with metastasized cancer compared to patients with early stage disease. 
[16,26] This lower ratio might be explained by a controlled decrease in cystatin concentration which 
results in an increase in activity of cathepsins.[7] It also has been suggested that a diminished binding 
affinity between CatB and CysC might be caused by changes in glycosylation, the presence of cathepsin 
activators or the binding of cathepsins with glycosaminoglycans [16]. We believe the CysC/CatB ratio 
might be of interest in order to obtain more insight into the complex carcinogenesis and progression of 
EOC. EOC does not appear as a single disease entity but comprises a heterogeneous group of tumors.[2] 
A further study with a larger series of samples is needed to investigate the association between CysC/ 
CatB and the metastatic potential of EOC in more detail.
Ratio's between CysC and CatH and between CysC and CatX were significantly lower in mucinous EOC 
and low-grade tumors compared to other subtypes and high-grade tumors, respectively. This finding 
might be explained by the fact that, 92.3% of our low-grade tumors were of mucinous subtype 
(data not shown), whereas almost all high-grade tumors were of serous and endometrioid subtype. 
Previous studies have reported large variations in expression of individual cathepsins between different 
tissues and even between different types of cells within the same tissue.[34] Selective expression of 
individual cathepsins in different types of tumors suggest that they may participate in specialized 
cellular functions.[35] EOC is known for its many different histological subtypes.[36] Of these subtypes, 
mucinous carcinomas are slowly developing tumors, whereas serous and endometrioid carcinomas are 
mostly high-grade, rapidly growing tumors.[37] In agreement with our results, CatH differed significantly 
between histological subtypes in lung cancer as well.[38]
CatX was discovered only recently and is thought to be involved in phagocytosis and regulation of 
the immune response rather than in degradation of the ECM.[20] Only few reports have been published 
that investigated CatX in cancer patients. While CatX was found to be highly expressed in tissue sections 
from prostatic intraepithelial neoplasms and prostate carcinomas, [39] Kos et al. did not find a difference 
in expression of the enzyme between lung carcinomas and normal long tissue [20]. Cathepsin X was 
found to be increased also in gastric carcinomas, especially after infection by Helicobacter pylori.[40] 
The present study showed detectable quantities of CatX in oCF of EOC patients, which were 10 fold 
higher than the CatX concentration reported in sera of cancer patients, which suggests a direct release 
of CatX from the tumor tissue into the oCF.[41]
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Table 3. Relationship between median (25th-75th percentile) cathepsin B, H, L, 
X and cystatin C (ng/ml) in oCF and clinicopathological characteristics
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Table 4. Univariate analysis of Cathepsin B, H, L, X and cystatin C and other potential factors for DFS of 50 patients with EOC
Cut-off value 
(median) HR (95% CI) p-value
Age 57 years (0.65-3.42) 0.345
Histology
serous 5.36 (1.20-23.89) 0.028
mucinous 1.00 (reference)
endometrioid 1 31 (0.12-14.43) 0.827
FIGO
stage I 1.00 (reference)
stage > II 85.0 (2.44-2961) 0.014
Differentiation grade
low (1) 1.00 (reference)
high (2+3) 59.9 (1.13-3162) 0.043
Residual tumor after surgery
< 1 cm 00 (reference)
> 1 cm 5.63 (2.15-14.76) <0.001
Preoperative CA 125 (serum) 126 U/ml 2.66 (1.04-6.85) 0.042
Cathepsin B  (oCF) 97 ng/ml 1.29 (0.56-2.95) 0.551
Cathepsin H (oCF) 18 ng/ml 1.17 (0.51-2.67) 0.707
Cathepsin L (oCF) 61 ng/ml 1.03 (0.45-2.33) 0.952
Cathepsin X (oCF) 20 ng/ml 1.16 (0.51-2.64) 0.722
Cystatin C (oCF) 657 ng/ml 1.38 (0.59-3.21) 0.448
CysC/CatB (oCF) 7 1.13 (0.49-2.60) 0.771
CysC/CatH (oCF) 28 1.19 (0.52-2.73) 0.680
CysC/CatL (oCF) 10 1.14 (0.50-2.59) 0.759
CysC/CatX (oCF) 30 1.95 (0.82-4.66) 0.132
5
*Parameters with a  p-value < 0,05 were selected for multivariate analysis.
Although cathepsins and CysC in oCF of EOC patients were not predictive for recurrence of EOC, 
we have shown that the interaction between CysC and cathepsins in oCF seems to be important. 
We believe that a complex cascade of proteolytic events, in which cathepsins play different roles, 
might be responsible for progression and metastasis in EOC. However, this study was explorative and to 
analyze the complex mechanism of proteolysis for EOC, further studies with larger series of patients have 
to be performed to confirm our results.
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GSTP1 -1 IN OVARIAN CYST FLUID AN D  D ISEASE O UTCO M E OF PATIENTS W ITH OVARIAN CANCER
Abstract
Detoxification enzymes, especially glutathione S-transferase Pi (GSTP1-1), have been implicated in 
resistance to platinum-based chemotherapy. We studied GSTP1-1 levels in ovarian cyst fluid (oCF), 
obtained during surgery before chemotherapy, of patients with epithelial ovarian cancer (EOC) and 
clinical outcomes were correlated. GSTP1-1 was determined by ELISA in oCF of 56 patients with EOC and 
109 noncancer controls (21 borderline and 88 benign ovarian tumors). Differences in median GSTP1-1 
between clinicopathological subgroups were studied using Mann-Whitney and Kruskal-Wallis tests. 
Differences in disease free (DFS) and overall survival (OS) between groups were analyzed by applying 
Kaplan-Meyer estimates and log-rank tests. Univariate and multivariate analysis were performed using 
Cox proportional hazard model. Significantly higher levels of GSTP1-1 were found in the oCF of malignant 
(median: 383; range: 10-32695 ng/ml) compared to benign (median: 20; range: 0-1128 ng/ml) ovarian 
tumors (p < 0.01). Significantly higher GSTP1-1 levels were found in patients with advanced FIGO stage 
(p = 0.01), high-grade tumors (p = 0.44) and/or high levels of preoperative CA 125 (p = 0.01). Of patients 
who received chemotherapy (stage > Ic; n = 30), high GSTP1-1 levels were significantly associated with 
a poor DFS and OS (log-rank: p = 0.047 and p = 0.033, respectively). FIGO stage was the only independent 
predictor for DFS. GSTP1-1 was the only independent predictor for OS.
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Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy world-wide. Approximately 70% 
of the patients are diagnosed with advanced stage of disease (International Federation of Gynecology 
and Obstetrics (FIGO) III and IV) with 5-year survival rates of only 10-20%.[1,2] Because the introduction 
of platinum-based chemotherapy into clinical practice, prognosis of patients with advanced EOC 
has markedly improved. However, this success is limited by the phenomenon of platinum-based 
chemoresistance. Platinum-resistant disease includes patients who do not respond to platinum-based 
chemotherapy at all and those who relapse within 6 months following primary chemotherapy. These 
patients have a poor prognosis, with an expected median overall survival of less than 10 months.[3] 
Early identification of platinum-resistant disease will provide the opportunity to change usual regimens, 
which may improve the prognosis of this group of patients with EOC.
The mechanism of chemoresistance has been studied extensively in recent years, and today, it is generally 
accepted that the detoxification enzymes glutathione S-transferases (GST) play an essential role in 
this process.[4] GSTs are enzymes that catalyze the phase II conjugation reaction with glutathione of 
highly reactive compounds that are formed during phase I modification of endogenous compounds 
and xenobiotics, such as anticancer agents. The human GST superfamily comprises cytosolic dimeric 
isoenzymes, which have been assigned to at least four generic classes: Alpha (A), Mu (M), Pi (P), and 
Theta (T), each class consisting of one or more isoenzymes with a wide variety of substrate specificities.[5] 
The Pi class GSTs (GSTP1-1) are believed to interact with platinum-based compounds and are frequently 
found to be over-expressed in a variety of neoplastic tissues, including ovarian cancer.[5,6] It has been 
shown that high GSTP1-1 activity results in an increased metabolism of several anti-cancer drugs, including 
platinum-based compounds, which subsequently results in a diminished cytotoxic effect on tumor 
cells.[4,6,7] For ovarian cancer, some researchers found a relationship between over-expression of GSTP1-1 
in malignant ovarian tissue and poor prognosis or bad response to chemotherapy, [8-13] whereas others 
could not detect such an association.[14-21]
Less attention has been paid to the analysis of GSTP1-1 in body fluids of patients with ovarian cancer. 
Ovarian cyst fluid (oCF) might provide a practical source of prognostic markers because it is in close 
contact with tumor tissue, it is readily available and its components are homogeneously distributed. 
The purpose of the present study was to examine the relation between important clinicopathological 
variables and their association with GSTP1-1 levels in oCF of patients with EOC.
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Materials and Methods 
Patients and cyst fluid collection
This study includes 165 patients diagnosed with primary ovarian tumors at the Radboud University 
Nijmegen Medical Centre in the period between 1988 and 2007. All these patients have undergone 
primary surgery. oCF was collected by aseptic fine needle aspiration at the Department of Pathology, 
immediately after surgical removal of the tumor. After cooled transport to the laboratory, the oCF samples 
were centrifuged at 3000 x g for ten minutes and the supernatant was stored at -35 °C in small portions 
until use. Determination of the levels of GSTP1-1 was carried out by ELISA, without prior knowledge 
of the histological or clinical outcome. Histopathological diagnosis was performed by a pathologist 
specialized in gynecologic oncology and revealed 88 benign, 21 borderline, and 56 malignant epithelial 
ovarian tumors. Informed consent was obtained from all participants.
ELISA procedures
ELISA for GSTP-1 was done in microtiter plates as described previously.[22,23] In short: plates were 
coated overnight with anti-GSTP1-1 monoclonal antibody in phosphate buffered saline (PBS) and were 
blocked with PBS-T supplemented with 1% bovine serum albumin. Between the incubations, plates were 
washed 5 times with PBS. Standards of GSTP1-1 diluted in PBS-T or diluted samples were then added 
to the wells. Plates were incubated overnight, washed, incubated with rabbit anti-GSTP1-1 antiserum 
and subsequently incubated with peroxidase-labeled swine anti-rabbit. After the final wash, plates were 
incubated with o-phenylenediamine, H2O2 in sodium citrate and Na2HPO4. The reaction was stopped by 
adding H2SO4. All standards and samples were measured in duplicate. A four-parameter weight logistic 
regression model was used to calculate standard curves and unknowns.
Clinicopathologic characteristics
From the medical and pathology reports of the patients diagnosed with EOC (n = 56), the following 
clinicopathologic characteristics were retrieved retrospectively: age at diagnosis, FIGO stage, 
histological tumor subtype, histopathologic grade, residual tumor after surgery, presence of malignant 
cells in ascites, tumor recurrence, preoperative CA 125 levels, and chemotherapeutic treatment. 
Staging was done according to the FIGO criteria.[24] Histopathological tumor type and grade were 
classified according to the World Health Organization (WHO) criteria.[25] Chemotherapeutic treatment 
was defined as complete adjuvant combination chemotherapy of six courses, always including 
a platinum-based agent and was started within three weeks after surgery. Additional information 
regarding recurrence of disease was collected for patients who received chemotherapy. Recurrence
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of disease was defined as a measurable lesion detected by computed tomography, magnetic resonance 
imaging and/or ultrasonography.
Statistical analyses
GSTP1-1 samples were measured in duplicate and in the analysis the values were averaged. For the 
purpose of statistical analysis, variables regarding patient characteristics were grouped in the following 
manner: FIGO stage, I, II versus III, IV; tumor grade, low-grade (grade 1) versus high-grade (grade 2 and 
3) [26]; histology, serous versus mucinous versus endometrioid versus other; residual disease, < 1 cm 
(definition of optimal cytoreductive surgery) versus > 1 cm (definition of suboptimal debulking); 
ascites, presence of malignant cells versus no malignant cells; preoperative CA 125, < 126 U/ml 
versus > 126 U/ml (median value). Differences in concentrations of GSTP1-1 between groups of patients 
were tested for statistical significance using the Mann-Whitney test in case of two groups and the 
Kruskal-Wallis test in case of more than two groups, respectively. Survival analysis was performed 
with the subgroup of patients with EOC that received chemotherapy after primary surgery (n = 30). 
Survival techniques were used to study the time to recurrence and to study the time to death. 
Disease free survival (DFS) was defined as the time interval from the date of the last course of 
chemotherapy to recurrence or last follow-up. Overall survival (OS) was defined as the time interval 
from the date of surgery to the date of either death or last follow-up. The oCF GSTP1-1 
value of 160 ng/ml was used for dividing patients into two groups after a statistically significant 
difference in DFS and OS was found with logistic regression analysis. The Kaplan-Meyer estimates 
were calculated of the patients with oCF GSTP1-1 values below 160 ng/ml and above 160 ng/ml, 
respectively. Subsequently, the log-rank test was used to test their difference for statistical significance. 
Univariate proportional hazards model was used to study the influence of the clinicopathological 
parameters on DFS and OS separately. Histology was not studied because of the small number of 
patients within the different subgroups (serous n = 18, mucinous n = 3, endometrioid n = 5, other n = 4). 
Tumor grade was not studied because of the small number of patients with low-grade carcinomas 
(n = 3). The hazard ratio's (HR) with the corresponding 95% confidence interval (CI) are presented. 
Multivariate proportional hazards model with selection procedures was used to find the clinicopathological 
parameters that independently contribute to a decreased time to recurrence (or death). The adjusted 
HRs with the corresponding 95% CI of the final model are presented. P-values less than 0.05 were 
considered statistical significant. All statistical analyses were performed using the software package 
SPSS 14.0 for Microsoft Windows (SPSS Inc., Chicago, IL, USA).
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Results
Patient's characteristics
Median age at diagnosis was 56 years (range: 31-89 years) for patients with EOC (n = 56), 53 years 
(range: 15-82 years) for patients with borderline tumors (n = 21), and 46 years (range: 19- 77 years) for 
patients with benign epithelial tumors (n = 88). Age differed significantly between patients with EOC and 
patients with benign ovarian tumors (p <0.01, Mann-Whitney test). No significant differences in age 
were found between patients with EOC and borderline tumors and between patients with benign and 
borderline tumors. Of the 56 patients with EOC, 22 had FIGO stage I (39%), 5 had FIGO stage II (9%), 
21 had FIGO stage III (38%), and 7 FIGO had stage IV (13%). The remaining clinicopathological data are 
listed in Table 1. For some patients, information about clinicopathological parameters was incomplete 
(Table 1). Of the subgroup of EOC patients that received complete adjuvant chemotherapeutic 
treatment (n = 30), recurrence of disease was observed in 17 patients (57%) of whom 5 (17%) showed 
recurrence within 6 months after completing chemotherapeutic treatment. DFS ranged from 1 to 84 
months, with a median of 13 months. OS ranged from 6 to 91 months, with a median of 26 months. 
Twelve patients (40%) died within the follow-up period.
Histopathological diagnosis
Figure 1 shows the boxplots of the GSTP1-1 concentrations (ng/ml) in oCF of patients by histologic 
subtype. Median (range) concentrations were 383 (10-32,695) ng/ml, 240 (2-1,193) ng/ml, and 20 
(0-1,128) ng/ml for malignant (n = 56), borderline (n = 21) and benign (n = 88) oCF samples, respectively. 
Significantly higher concentrations of GSTP1-1 were found in oCF from malignant ovarian tumors 
compared with benign tumors and in oCF from borderline tumors compared to benign tumors (both 
p <0.01, Mann-Whitney test). No significant differences in GSTP1-1 level were found between patients 
with malignant and patients with borderline ovarian tumors (p = 0.114).
GSTP1-1 and clinicopathologic characteristics
Table 1 shows the clinicopathological outcomes and median (range) concentration of GSTP1-1 (ng/ml) 
for the 56 patients with EOC. Significantly higher GSTP1-1 concentrations were found in patients with 
FIGO stage III and IV disease compared to patients with FIGO stage I and II (p = 0.01). Patients with 
high-grade carcinomas had significantly higher levels of GSTP1-1 compared to patients with low-grade 
carcinomas (p = 0.044). High CA 125 levels were correlated with high GSTP1-1 levels (p = 0.01) 
(all Mann-Whitney U test).
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Other§ 5 (9) 881
Residual tumor
unknown 3 (5)












*Mann-Whitney U test; **Kruskal-Wallis test; §clear cell, n =  4; undifferentiated, n =  1
n (% ) Cyst fluid median GSTP1-1 (range) p-value
FIGO stage 0.010*
I + II 27 (48) 162 (10-1,302)
III + IV 28 (50) 703 (10-32,695)
unknown 1 (2)
Tumor grade 0.044*
low-grade 14 (25) 89 (10-1,302)
high-grade 37 (66) 448 (10-32,695)
Disease free and overall survival
Of the 56 patients with epithelial ovarian cancer, 5 patients received neo-adjuvant chemotherapy before 
surgery and 21 patients did not receive chemotherapy at all or received less than 6 courses. These patients 
were therefore excluded and the remaining 30 patients were included for survival analysis. Surgery dates 
for this group of patients ranged between January 1996 and November 2007, and the follow-up period 
was at least 6 months after completing chemotherapeutic treatment (median: 26 months). Figure 2 shows 
the Kaplan-Meyer curves of the patients with GSTP1-1 values above 160 ng/ml and below 160 ng/ml 
of both DFS (Figure 2A) and of OS (Figure 2B). In the first group (GSTP1-1 >160 ng/ml), histological 
subtypes were serous (n = 9), mucinous (n = 1), endometrioid (n = 4), clear cell (n = 1), mixed (n = 1), 
and NOS (n = 2). Tumor grade was 1 (n = 1), 2 (n = 6), 3 (n = 8), and unknown (n = 3). In the second group
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Figure 1. The boxplots of the GSTP1-1 (ng/ml) concentration in oCF by histological subtype of patients with malignant 
(n = 56), borderline (n = 21) and benign (n = 88) ovarian tumors .
(GSTP1-1 <160 ng/ml), histological subtypes were serous (n = 9), mucinous (n = 2), and endometrioid 
(n = 1). Tumor grade was 1 (n = 2), 2 (n = 4), 3 (n = 4), and unknown (n = 2). Higher levels of GSTP1-1 
were related with both shorter DFS and shorter OS (log-rank test: p = 0.047 and p = 0.033, respectively). 
Of the group of patients with a high level of GSTP1-1, 45% (95% CI: 32-58) had recurrence of disease 
within 12 months compared to 17% (95% CI: 6-28) of the group of patients with a low level of GSTP1-1. 
After 24 months, this was 74% (95% CI: 60-88) and 47% (95% CI: 31-63), respectively. Similar results were 
found regarding the time to death. Two-year survival and 3-year survival were 82% (95% CI: 70-93) and 
41% (95% CI: 25-57) for the group of patients with a high level of GSTP1-1 and 100% and 66% (95% CI: 
45-87) for the group of patients with a low level of GSTP1-1, respectively.
Table 2 shows the hazard ratio with 95% CI, using the univariate proportional hazard model. 
For the variables "Malignant cells in ascites" and "Preoperative CA 125", in one case each, data were 
missing. GSTP1-1, FIGO stage, and presence of malignant cells in ascites were regarded as significant 
predictors of DFS. However, using the multivariate proportional hazard model with selection procedure, 
FIGO stage was the only independent predictor that had impact on DFS (HR = 9.8; 95% CI: 2.2 - 44.6; 
p < 0.01). As a result, the other factors did not contribute additionally to FIGO stage to predict the time 
to recurrence. Regarding the time to death we found that GSTP1-1, FIGO stage, and preoperative 
CA 125 level could be regarded as significant predictors of OS in univariate analysis. Now, we found, 
after the model selection procedure, that GSTP1-1 appeared to be the only independent prognostic 




Figure 2. Kaplan-Meier estimates of disease free (A) and of overall survival (B) of patients who received chemotherapy (n = 30). 
The group with low GSTP1-1 values (<160 ng/ml; solid line) and the group with high GSTP1-1 values (>160 ng/ml; broken line) 
include 12 and 18 patients, respectively. Vertical bars indicate patients with censored data.
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Table 2. HR with 95% CI of DFS and of OS by clinicopathological parameters of patients with EOC who received 6 courses 
of adjuvant platinum-based chemotherapy (n = 30), using univariate Cox Regression
DFS OS
HR (95% CI) p-value HR (95% CI) p-value
GSTP1-1
Residual disease
> 1cm 12 
Malignant cells in ascites










*Parameters with a  p-value < 0.10 were selected for multivariate analysis
Discussion
In this study, levels of GSTP1-1 were significantly higher in patients with EOC compared with patients 
with benign ovarian tumors. In patients with EOC, levels of GSTP1-1 were correlated positively to 
FIGO stage, tumor grade and preoperative CA 125 levels. For the subgroup of patients that received 
6 courses of chemotherapy, higher levels of GSTP1-1 were significantly associated with a poorer DFS. 
Although GSTP1-1 was not an independent predictor for DFS, it was the most important factor after 
FIGO stage, which was the only independent prognostic factor. Therefore, determination of GSTP1-1 
in surgically obtained ovarian cyst fluid (oCF) might be of value to predict relapse of disease and 
response to chemotherapy at the time of diagnosis. In addition, GSTP1-1 seemed to be the only 
independent predictor of OS in multivariate analysis and therefore, might be of value to serve as 
a biomarker for survival.
Up until now, the only other study investigating GSTP1-1 levels in oCF of ovarian tumors was published 
by our own research group.[23] At that time, we also found higher levels of GSTP1-1 in oCF of malignant 
tumors compared with their benign counterparts. The present study included more patient samples, 
a longer follow-up and focused on the role of oCF GSTP1-1 as a prognostic biomarker for the response 
to chemotherapy of patients with EOC. All other studies that investigated the relationship between 
GSTP1-1 and clinical outcomes and/or response to chemotherapy in patients with EOC were done
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Table 3. Published reports on outcomes of the relationship between GSTP1-1 levels and response to chemotherapy 
and survival including the methods used for tissue analysis of GSTP1-1
Reference n









Van der Zee et al. 17 High performance liquid 
chromatog raphy
No -
Green et al. 78 Immunohistochemistry Yes Yes
Hamada et al. 61 Immunohistochemistry Yes Yes
Van der Zee et al. 89 Immunohistochemistry No No
Hirazono et al. 36 Immunohistochemistry - Yes






Ghazal-Aswad et al. 39 Immunohistochemistry No -





Tanner et al. 121 Western blotting - No
Kase et al. 87 Immunoh stochemistry Yes -
Satoh et al. 67 Immunoh stochemistry - Yes
Ikeda et al. 93 Immunoh stochemistry - No
Howells et al. 77 Immunoh stochemistry No No
Saip et al. 55 Immunoh stochemistry No No
*Parameters with a  p-value < 0.10 were selected for multivariate analysis
using ovarian cancer tissue. In Table 3, we summarized published studies in which GSTP1-1 was 
determined in ovarian cancer tissue and related to the clinical outcomes of patients with EOC. 
Some researchers found a relationship between overexpression of GSTP1 1 in malignant ovarian 
tissue and poor prognosis or bad response to chemotherapy, [8-13] whereas others could not 
detect such an association.[14-21] These conflicting results might be explained by differences 
in techniques used to quantify GSTP1-1 (Table 3). It has been demonstrated that immunohistochemical 
quantification of GSTP1-1 did not always correlate with the concentrations of GSTP1-1 as measured 
in the tissue cells by other methods, such as Western blot analysis.[9,14] Wrigley et al. [14] 
concluded that the Western blotting technique was more sensitive than immunohistochemistry 
because it detected GSTP1-1 that had been missed by observer examination of stained sections. 
In addition, different scoring systems to quantify GSTP1-1 by immunohistochemistry, observer variation 
in identifying positively stained cells, different cut-off points for discriminating high from low values, 
and different types of tissue, i.e. fresh versus formalin fixed and paraffin embedded may also be 
responsible for the conflicting findings. In two studies, researchers classified their results as either 
positive or negative, which resulted in a majority of GSTP1-1 positive samples and consequently, 
no correlation of GSTP1-1 expression with response to chemotherapy or survival could be achieved.[15,20] 
In addition, immunohistochemical GSTP1-1 expression in ovarian tumor sections was found to be 
heterogeneous and not uniform [16], which means that the tumor biology will probably not be optimally
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reflected by analyzing one tissue biopsy. Therefore, the analysis of GSTP1-1 concentrations in body fluid 
samples, in which components are distributed homogeneously, might provide a valuable alternative. 
Ovarian cyst fluid has a direct relationship with the tumor tissue and compounds are homogeneously 
distributed. We believe that oCF might provide possible new prognostic biomarkers. In addition, 
measurement of GSTP1-1 by ELISA is an uncomplicated, sensitive and reliable method as compared to 
immunohistochemistry, which at best is only semiquantitative.
Our findings are consistent with our hypothesis that women with decreased levels of oCF GSTP1-1 
would have a better survival due to improved response to chemotherapy. We are aware of the fact 
that we have only studied 30 patients who received chemotherapy and we therefore suggest that 
larger studies with more uniform samples and increased power are required to replicate our findings. 
In addition, little is known about the mechanism of release of GSTP1-1 from tumor tissue into ovarian oCF. 
Since GSTP1-1 enzymes are predominantly expressed in the cytosol of living cells, it might be possible 
that an increased release into the oCF occurs in case of tumor necrosis. Necrosis is often associated with 
the differentiation grade of the tumor, the latter of which was found to be a prognostic factor for survival.[26] 
In our study, high-grade tumors contained significantly higher oCF levels of GSTP1-1 compared to 
low-grade tumors. However, we believe that tumor grade was not a confounding factor for survival in 
the group of patients that received chemotherapy because almost all patients in this subgroup had 
high-grade tumors. We therefore conclude that assessment of GSTP1-1 level in ovarian oCF, obtained 
during primary debulking surgery, could provide information about future response to chemotherapy 
and therefore might be of clinical value as a prognostic biomarker.
In summary, to the best of our knowledge this is the first study in which the relationship between 
GSTP1-1 in oCF and treatment outcomes in patients with EOC was analyzed. We focused on the group 
of patients who received chemotherapy to assess if GSTP1-1 could be a marker which can be used for 
the early identification of platinum resistant disease. We found a significant association between high 
GSTP1-1 levels in oCF and poor DFS and OS. Moreover, GSTP1-1 seemed to be the only independent 
predictor for OS in multivariate analysis. Although GSTP1-1 did not seem to be an independent predictor 
of early recurrence, after FIGO stage, it was the most important factor for prediction of DFS. In addition, 
high GSTP1-1 values were found more often in patients with chemoresistant EOC compared to patients 
with chemosensitive disease. Therefore, a combination of FIGO stage and GSTP1-1 level might be of 
value in identifying patients with chemoresistant EOC in an early phase of the disease in order to change 
therapy and improve prognosis.
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Abstract
An unassigned and prominent resonance in the region from ô 2.0-2.1 ppm has frequently been found 
in the in vivo magnetic resonance (MR) spectra of cancer patients. We demonstrated the presence 
of this resonance with in vivo MR spectroscopy in the cyst fluid of a patient with an ovarian tumor. 
Proton nuclear magnetic resonance spectroscopy on the aspirated cyst fluid of this patient confirmed 
the observation. A complex of resonances was observed between 2.0 and 2.1 ppm. It was also present 
in 11 additional ovarian cyst fluid samples randomly chosen from our biobank. The resonance complex 
was significantly more prominent in samples from mucinous tumors than in samples from other 
histological subtypes. A macromolecule (>10 kDa) was found responsible for this complex of resonances. 
A correlation spectroscopy (COSY) experiment revealed cross peaks of two different types of bound 
sialic acid suggesting that N-glycans from glycoproteins and/or glycolipids cause this resonance complex. 
In literature, plasma alpha 1-acid glycoprotein (AGP), known for its high content of N-linked glycans, 
has been suggested to contribute to the ô 2.0-2.1 spectral region. The AGP cyst fluid concentration 
did not correlate significantly with the peak height of the ô 2.0-2.1 resonance complex in our study. 
AGP may be partly responsible for the resonance complex but other N-acetylated glycoproteins and/or 
glycolipids also contribute. After deproteinization of the cyst fluid N-acetyl aspartic acid (NAA) 
was found to contribute significantly to the signal in this spectral region in three of the 12 samples. 
GC-MS independently confirmed the presence of NAA in high concentration in the three samples, 
which all derived from benign serous tumors. We conclude that both NAA and N-acetyl groups from 
glycoproteins and/or glycolipids may contribute to the ô 2.0-2.1 ppm resonance complex in ovarian 
cyst fluid. This spectral region seems to contain resonances from biomarkers that provide relevant 
clinical information on the type of ovarian tumor.
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Introduction
Ovarian cancer is the most lethal gynecological malignancy worldwide.[1] Due to the lack of specific 
clinical symptoms in an early stage of disease, patients are generally diagnosed with advanced 
stage ovarian cancer and have a 5-year overall survival of less than 20%.[2] Despite more than two 
decades of research, appropriate biomarkers for detection, diagnosis and prognosis of ovarian cancer 
are still lacking.
Ovarian tumors, benign as well as malignant, mostly present as cystic masses that contain variable amounts 
of fluid.[3] The cyst fluid has been shown to contain compounds released by the tumor tissue, [4,5] 
and therefore, might provide biomarkers for ovarian cancer. Although researchers have become 
increasingly interested in the analysis of the biochemical composition of cyst fluid, only a few studies 
have been performed investigating cyst fluid using magnetic resonance spectroscopy (MRS).[6-11] 
Boss et al. [6] were the first to investigate the overall metabolic composition of ovarian cyst fluid 
by in vitro proton nuclear magnetic resonance spectroscopy ('H-NMRS). They found detectable 
concentrations for 36 metabolites. For several metabolites they demonstrated significant differences 
in concentration between malignant and benign ovarian cysts. Studies performed with in vivo MRS 
on patients with ovarian tumors focused on lipid resonances at 1.3 ppm and 5.2 ppm, choline, lactate 
and creatine.[8,9,11] However, in a recently published in vivo MRS paper, a prominent and unknown 
resonance at 2.07 ppm was described in cystic and solid parts of 8 of the 14 ovarian tumors.[10] 
Although yet unassigned, the authors suspected this peak to be a resonance of N-acetyl-L-aspartic acid 
(NAA) or sialic acid (N-acetylneuraminic acid). For human plasma, it has been suggested that N-acetyl groups 
in alpha 1-acid glycoprotein (AGP) might contribute to a resonance complex in this spectral region.[12] 
The carbohydrate content of AGP is very high (45% of its molecular weight) and consists of 5 or 6 highly 
sialylated complex type N-linked glycans.[13]
In the present study, we investigated the presence and nature of the unassigned resonance at 2.1 ppm 
in the magnetic resonance spectra of cystic ovarian tumors. At first, in vivo MRS was performed on 
a patient with a cystic ovarian tumor. Subsequently, the cyst fluid from this patient and 11 additional 
cyst fluid samples from our biobank were investigated by in vitro 'H-NMRS and by independent 
techniques specific for NAA and AGP.
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Materials and methods
In vivo MR spectroscopy
A 57-year-old patient (patient 1) was admitted to our Department of Obstetrics and Gynecology with 
an enlarged left ovary revealed by ultrasound examination. After informed consent was obtained, 
the patient was included in our in vivo MRS study. The patient was positioned inside the magnet bore 
of a 3.0 Tesla MR system (Magnetom Tim Trio, Siemens, Erlangen, Germany). She was positioned with 
her back on the supine coil matrix and a body matrix coil was placed on top of the patient. Of both coil 
arrangements one to two three-element coil arrays were used for resonance reception during the MR 
examination. Conventional MR images revealed a 28 cm x 21 cm tumor of the left ovary. Subsequently, 
a voxel of interest (3cm x 3cm x 3cm) was selected in the inferior cystic part of the tumor (Figure 1). 
MR spectra were acquired by using a point-resolved spectroscopy (PRESS) [14,15] sequence at a short 
echotime (TE) of 30 ms and a long TE of 136 ms to obtain optimal information of as many metabolites 
as possible. Metabolite spectra were acquired with WET water suppression, [16] a repetition time of 
2 seconds and 64 averages. In addition, non-suppressed water spectra were recorded for referencing. 
Total examination time was 45 minutes.
Figure 1. Frontal (A) and sagittal (B) MR image (3.0 T) of a 57-year-old patient with an ovarian tumor. The voxel of interest (30 cc) 
was placed in the inferior cystic part of the tumor.
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Cyst fluid collection
After surgical removal, the ovarian tumor of the patient was transported to the Department of Pathology 
and collection of 40 ml fluid from the inferior part of the tumor (Figure 1) was performed by aseptic fine 
needle aspiration. Cyst fluid samples from 11 other patients (obtained from 3 malignant, 3 borderline 
and 6 benign epithelial ovarian tumors) were randomly selected from our cyst fluid biobank (Table 1). 
These samples were obtained from patients who underwent primary surgery for an adnexal mass at the 
Radboud University Nijmegen Medical Center in the period 2000 until 2008. After cooled transport to 
the laboratory, all cyst fluid samples were centrifuged at 3000 g for 10 minutes for cell separation and 
immediately stored at -70 °C in multiple small portions. Histopathological diagnosis was performed by 
a pathologist specialized in gynecology. Informed consent was obtained from all patients.
Table 1. Clinicopathological characteristics of 12 patients with ovarian tumors
Patient No. Age (years) Pathology Histological subtype
1 (case report) 56 Borderline Serous
2 55 Borderline Mucinous
3 63 Borderline Mucinous
4 66 Malignant Mucinous/Endometrioid
5 60 Malignant Serous
6 69 Malignant Serous
7 29 Benign Serous
8 56 Benign Serous
9 20 Benign Serous
10 62 Benign Mucinous
11 39 Benign Mucinous
12 55 Benign Mucinous
*Parameters with a  p-value <  0.10 were selected for multivariate analysis
Sample preparation for in vitro 1H-NMR spectroscopy
Cyst fluid samples (n = 12) were measured in three different ways: (1) in their native state (not deproteinized 
or pH standardized); (2) after deproteinization over a 10 kDa cut-off filter (Sartorius, 3000 g for 70 min; 
before use, the filter was washed twice by centrifugation with water to remove glycerol); (3) as in (2) but 
additionally pH adjusted to 2.50 ± 0.10. For analysis 50 |J D2O and 20 |J TSP were added to 700 |J sample.
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One-dimensional in vitro 1H-NMR spectroscopy
Single pulse 'H-NMR spectra (500 MHz) were obtained on a Bruker DMX-500 spectrometer as described 
by Engelke et a/.[17] Sample volume in the spectrometer was standardized at 650 |J and samples 
were placed in 5 mm NMR tubes. For evaluation of the NMR spectra AMIX software (Bruker, Germany) 
was used. Chemical shifts for the samples containing protein were referenced internally to the lactate 
resonance at ô 1.33. Chemical shifts for deproteinized samples were calibrated with respect to the position 
of the TSP resonance. Phase and baseline were corrected manually. Identification of the resonances in 
the NMR spectra was performed by using our ovarian cyst fluid model compound database.[6]
1H-1H correlation spectroscopy (COSY)
A two-dimensional 1 H-1 H COSY 500 MHz spectrum was recorded from the cyst fluid from patient 1. 
A spectral width of 6010 Hz in both dimensions, 256 and 2000 data points in F1 and F2, respectively, 
16 scans per increment and a recycle delay of 6 sec were used. Prior to Fourier transformation, both time 
domains were apodized using a sine bell function and zero filled once.[17]
Quantitative data
Quantification of the resonance complex in the region of 2.0-2.1 ppm of NMR spectra was performed 
by its peak intensity normalized to the peak intensity of the lactic acid resonance (arbitrary units). 
Lactic acid was independently measured and enzymatically determined on a COBAS FARA centrifugal 
analyzer (Hoffmann La Roche, Basel, Switzerland).[18] Differences in concentration of the compound(s) 
contributing to the ô 2.0-2.1 ppm resonance complex between tumor type groups were determined 
using Mann-Whitney and Kruskal-Wallis tests. Pearson's test was used to establish the correlation 
between AGP and the resonance complex.
N-acetyl-L-aspartic acid (NAA) was measured using a modified stable isotope dilution GC-MS method 
as essentially described by Jakobs et g/.[19]
AGP concentrations were measured using ELISA as reported previously.[20] In summary, ELISA plates 
were coated overnight with polyclonal anti-human AGP obtained from Dako (Glostrup, Denmark). 
Diluted plasma samples and a standard dilution series with human and rAGP, were added to the plate. 
Detection was carried out with a biotinylated polyclonal rabbit anti-human AGP IgG, followed by 
peroxidase-conjugated streptavidin and substrate essentially as described by De Vries et g/.[21]
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Results
In vivo MR spectroscopy
In vivo MR spectra from a voxel in the inferior cystic part of the tumor of patient 1 are shown in Figure 2A 
and 2B. Both spectra with echo times of 30 and 136 ms contained resonances of lactic acid (1.33 ppm), 
which was inverted in the MR spectrum with the longer echo time (Figure 2B). A prominent and 
unknown resonance was observed with a high peak intensity at 2.06 ppm similar to the observations 
of Stanwell et a/.[10]
Figure 1. In vivo MR spectra of the cyst fluid of our patient with echo times of 30 (A) and 136 (B) ms. An abnormal resonance 
at 2.06 ppm is indicated by an asterisk.
In vitro 1H-NMR spectroscopy
Additional information on the unknown resonance at 2.06 ppm in the in vivo MR spectrum was 
provided by in vitro 'H-NMRS performed on the aspirated cyst fluid of 12 patients before and after 
deproteinization.
(!) Native cyst fluid. For the first analysis, no sample pretreatment was performed to imitate the in vivo 
spectra. For patient 1, the native cyst fluid NMR spectrum (Figure 3A) shows many resonances, including 
the resonances from lactic acid (1.33 ppm). Furthermore, the spectrum shows a complex of several 
overlapping resonances with high intensities in the region from 2.0 to 2.1 ppm, observed as one broad 
peak at 2.06 ppm in the in vivo MR spectrum (Figure 2A and 2B). In this spectral region, CH3 protons
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from N-acetyl groups characteristically give a singlet resonance.[22] A COSY experiment on the native 
cyst fluid of patient 1 was performed (Figure 4). Cross peaks of two different types of bound sialic 
(N-acetylneuraminic) acid were observed (1.83/2.79 ppm from a 2^3 bound sialic acid and 1.75/2.70 ppm 
from a 2^6 bound sialic acid).[23] These signals may derive from glycoproteins like AGP that carry 
N-glycans. Signals from N-acetyl protons in N-acetylglucosamine residues from the same N-glycans may 
contribute to the resonance complex between 2.0 and 2.1 ppm in Figure 3A. Subsequently, we studied 
the native cyst fluid of 11 additional samples and found this resonance complex in all samples. 
In the in vitro cyst fluid spectra of patient 7-9 (Table 1) an additional high singlet resonance was observed 
at 2.03 ppm (Figure 5A) that was identified as NAA (see below). Peak intensities of the resonance 
complex between ô 2.0 and 2.1 ppm for all patients are listed in Table 2.
(2) Deproteinized cyst fluid. After deproteinization the lactic acid resonance at 1.33 ppm was still visible 
in the same intensity in the cyst fluid of patient 1. However, the resonance complex between ô 2.0 to 
2.1 ppm had fully disappeared (Figure 3B). This observation was confirmed in the other 11 cyst fluid 
samples from our biobank (data not shown). In 3 samples (patient numbers 7-9), the broad complex 
resonance disappeared but left a sharp resonance at 2.03 ppm (Figure 5B). Subsequently, the deproteinized 
cyst fluid samples were pH adjusted to pH 2.50 to compare with our model compound data base and 
assign the various metabolites (Figure 3C).[6] For patient 1, high intensities were visible for lactic acid 
(doublet 1.41 ppm), alanine (doublet 1.51 ppm), 3-hydroxybutyric acid (doublet 1.23 ppm) and acetic 
acid (singlet 2.08 ppm). Resonances deriving from NAA could not be observed. Spectra of cyst fluid 
samples from patients 7-9 showed the sharp resonance at 2.03 ppm (Figure 5B). This resonance derives 
from the N-acetyl group of NAA. Figure 5B shows the 2.03 ppm resonance and as well the 2.95 ppm 
multiplet resonance of the NAA methylene proton.[22] NAA could not be detected in the NMR spectra 
of the other 8 samples (data not shown).
NAA was measured independently by GC-MS (Table 2). In patient 1, cyst fluid NAA was 1.0 ^mol/L, 
which is below the detection limit of in vitro 'H-NMRS and in vivo MRS. In the samples of patients 7-9, 
NAA amounted to 28, 38 and 95 ^mol/L, respectively, in line with the in vitro NMR spectral observation. 
These three cyst fluid samples all derived from benign serous ovarian tumors. In the remaining samples, 
NAA was or equal to or less than 1.5 ^mol/L.
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Figure 3. In vitro 'H-NMR spectra (500 MHz) of three cyst fluid samples of our 57-year-old patient (A,B,C).
(A) Native cyst fluid (not deproteinized or pH adjusted). A broad resonance with high intensity is visible between ô 2.0-2.1 ppm.
(B) Deproteinized cyst fluid at native pH. The resonance with high intensity at 2.06 ppm has fully disappeared.
(C) Deproteinized cyst fluid adjusted to pH 2.50.
Quantitative data
The relative concentration of the compound or compounds causing the resonance complex between 
ô 2.0 to 2.1 ppm in the native in vitro NMR spectra was determined in arbitrary units by comparing 
the peak intensity of resonance complex to the independently measured concentration of lactic acid 
(Table 2). The concentration varied considerably in the 12 samples (range: 20-252). No significant 
difference in concentration was observed between patients with malignant, patients with borderline 
and patients with benign ovarian tumors (p = 0.707, Kruskal-Wallis test). Patients with mucinous tumors 
had significantly higher concentration of the compound(s) contributing to the complex (median: 217; 
range: 147-252) compared to patients with other histological subtypes (median: 133.4; range: 20-162) 
(p = 0.016, Mann-Whitney test).
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Figure 4. In vitro COSY spectrum (500 MHz) of the cyst fluid of patient 1. Cross peaks of two different types of bound sialic acid 
(N-acetylneuraminic acid) are present: 1.83/2.79 ppm from a 2^3 bound sialic acid and 1.75/2.70 ppm from a 2^6 bound sialic acid.
The AGP concentration in the 12 cyst fluid samples was measured independently by ELISA. The protein 
was present in detectable quantities in all samples (Table 2). The median AGP concentration in cyst fluid 
samples in this study was 351 ng/ml (range: 4-436 ng/ml). The AGP concentration did not correlate 
significantly with the concentration of the compound(s) contributing to the ô 2.0 to 2.1 ppm resonance 
complex (p = 0.412; R = 0.313, Pearson's test). Thus, no evidence to confirm that the presence of 
AGP alone can explain the detected resonance complex in the region between ô 2.0 to 2.1 ppm. 
on the other hand, it seems more likely that composite N-acetyl signals from the N-acetylated sugars 
N-acetylglucosamine and N-acetylneuraminic acid (sialic acid) present in N-glycans of glycoproteins 
and/or glycolipids cause this broad resonance complex.
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Discussion
In several types of cancer (including colorectal, gastric, breast, cervical, prostate and ovarian), an unassigned 
and prominent resonance in the region from ô 2.0 to 2.1 ppm has frequently been found by MRS, 
and its intensity has often been associated with tumor invasion or malignancy.[24-29] In most studies, 
this resonance was assigned to the -CH3 moiety of sialic acid or N-acetyl groups of glycoproteins, 
[24-26,29] but in other studies monounsaturated fatty acyl protons of lipids were mentioned.[27,28] 
Recently, a broad resonance at 2.1 ppm has also been found in the cyst fluid of 8 out of 14 patients 
with ovarian tumors by in vivo MRS.[10] The authors suggested that the peak most likely derived from 
NAA or from the -CH3 moiety of sialic acid, based on two-dimensional ''H-NMRS data (not shown) of 
a study on ovarian tumor tissue specimens.[29] In addition, three individual cases of a cystic ovarian 
tumor were reported in which a prominent resonance in the region from ô 2.0 to 2.1 ppm was found by 
in vivo MRS.[9,11,30] However, in these studies, the nature of the resonance was not further confirmed 
by independent techniques.
The present study revealed a prominent resonance at 2.06 ppm in the in vivo MR spectrum of a patient 
with a cystic serous ovarian tumor. The presence of the resonance in the spectrum acquired with an 
echo time of 136 ms suggested that this resonance could originate from NAA because resonances 
originating from slow-tumbling molecules such as protein complexes generally disappear rapidly with 
increasing echo time due to a short T2 relaxation time. However, the resonance in the long TE spectrum 
appeared to be broadened, which is not expected for NAA. In addition, the long T2 of the 2.06 ppm 
resonance was most probably caused by the flexibility of the carbohydrate chains which explains why 
such a macromolecule resonance survives the spin-echo delay period.
Using one-dimensional and two-dimensional in vitro 'H-NMRS on a series of 12 ovarian cyst fluid samples, 
we showed that both NAA and N-acetylated macromolecules may contribute to the 2.06 ppm in vivo 
MRS resonance. By in vitro 1H-NMRS, the unknown resonance was observed as a complex of several 
resonances in the region from ô 2.0 to 2.1 ppm. It was seen in all cyst fluid samples in our series. 
We showed that resonances from N-acetyl groups from macromolecules occurred in all cyst fluid samples. 
An additional resonance contribution of the N-acetyl group of NAA was observed in 3 out of 12 cyst 
fluid samples. NAA is a neuronal marker for brain in vivo MRS studies. Its concentration is one of 
the highest of all free amino acids in the central nervous system.[31,32] Yet the functions served by 
this metabolite in the brain remain elusive and controversial. Outside the brain the presence of NAA 
has been described in the lens of the eye, in peritoneal mast cells, and in ovarian cyst fluid.[6,33,34] 
Our study confirms and extends the presence of NAA in ovarian cyst fluid samples. Using the sensitive 
GC-MS technique it could be detected in a low concentration in all ovarian cyst fluid samples (Table 2). 
A significantly higher concentration was found in 3 of 12 samples with two independent techniques. 
These three derive from benign serous tumors. Boss et al. [6] observed a high NAA concentration in 
5 benign serous cyst fluid samples. Therefore, finding increased NAA seems a biomarker for benign 
serous cysts. We did not find high NAA in malignant cyst fluids in line with the findings of Boss et al.
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Further studies with higher numbers of samples are required to decide that a high concentration of NAA 
does not occur in malignant cysts. The function of NAA in ovarian cysts is as yet unclear. Interestingly, 
Baslow proposed a supporting role for NAA as a molecular water pump in central nervous system neurons. 
The molecular water pump can actively pump water against its gradient.[32] Our data show that the three 
cyst fluid samples with significantly increased NAA had the lowest concentration of the unassigned 
resonance complex, the lowest concentrations of the majority of metabolites, and of AGP as well, 
suggesting that these samples are more diluted than the others. This may touch on a molecular water 
pump function of NAA in the ovarian cyst.
Besides the NAA resonance at 2.03 ppm, there was a significant resonance complex in the region 
between 2.0 and 2.1 ppm in the in vitro NMR spectrum in all 12 cyst fluid samples. This resonance 
complex is caused by contributions from one or more macromolecules with N-acetylgroups. 
Two-dimensional COSY showed that the N-acetyl groups from a 2^6 bound and a 2^3 bound sialic acid 
groups in the N-glycans of glycoproteins contribute. Other N-acetylated sugars such as N-acetylglucosamine 
from the same N-glycans may also contribute to the resonance complex between ö 2.0 and 2.1 ppm. 
It cannot be excluded that N-acetylgroups from glycolipids also contribute. In human plasma, a similar 
prominent complex of resonances has been found.[12] Nicholson et al. [12] suggested that N-acetyl protons 
from AGP might significantly contribute to this resonance. AGP is a 41-43 kDa plasma protein with a high 
carbohydrate content (45%) of N-linked glycans of which 12% consists of sialic acid.[13] These authors 
suggested that other glycoproteins and CH2C=C signals from plasma lipoproteins might further 
contribute to the broad resonance complex.[12] We found that AGP was actually present in significant 
concentration in all cyst fluid samples (Table 2). Its concentration does not correlate with the peak 
height or peak area of the 2.0-2.1 ppm resonance complex or the concentration of the compounds 
contributing to it. Therefore, we conclude that this resonance must be explained in a similar way as in 
plasma with contributions from N-acetyl protons of AGP and other glycoproteins. Ovarian cyst fluid 
is known to contain high levels of glycoproteins.[35,36] It cannot be excluded that glycolipids and 
CH2C=C protons from lipoproteins also contribute to the resonance complex. An increase in size and 
branching of N-linked glycans of serum proteins has been associated with cancer, including ovarian 
cancer.[37,38] In the present study, no difference in concentration of the ô 2.0-2.1 ppm resonance 
complex was found between patients with malignant, borderline and benign ovarian tumors. 
The resonance was significantly more prominent in cyst fluid of mucinous tumors than in cyst fluid 
of other histological subtypes. Cyst fluid from mucinous tumors is known to contain high levels of 
N-acetylated glycoproteins which may explain our observation.[35,39]
In this study, in vivo and in vitro MR spectroscopic techniques were used to study an unassigned and 
prominent resonance complex between 2.0 and 2.1 ppm in ovarian cyst fluids. It was present in all 
ovarian cyst fluid samples. We demonstrated that NAA and N-acetyl groups from glycoproteins and/or 
glycolipids may both contribute to the ô 2.0-2.1 ppm resonance complex. This spectral region seems 




The authors thank Ms. Ivonne van Loosbroek (Department of Radiology, Radboud University Nijmegen 
Medical Center, Nijmegen) for performing the in vivo MRS measurements of our patient.
113
N-ACETYL RESO NANCES IN IN  VIVO AN D  IN VITRO 'H-NMR SPECTRO SCO PY OF CYSTIC OVARIAN TUM ORS
References
1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Colombo N, Van Gorp T, Parma G et al. Ovarian cancer. Crit Rev Oncol Hematol 2006;60:159-79.
3. Kurman RJ. Blaustein's pathology of the female genital tract. 5th ed. New York: Springer-Verlag;2002.
4. Bar JK, Harlozinska A, Sobanska E et al. Relation between ovarian carcinoma-associated antigens in tumor tissue 
and detached cyst fluid cells of patients with ovarian neoplasms. Tumori 1994;80:50-5.
5. Harlozinska A, Bar JK, Jothy S et al. Carcinoembryonic antigen isotypes in tissue sections and loose cyst fluid cells 
of ovarian neoplasms. Tumour Biol 1993;14:1-8.
6. Boss EA, Moolenaar SH, Massuger LF et al. High-resolution proton nuclear magnetic resonance spectroscopy of 
ovarian cyst fluid. NMR Biomed 2000;13:297-305.
7. Massuger LF, van Vierzen PB, Engelke U et al. 1 H-magnetic resonance spectroscopy: a new technique to discriminate 
benign from malignant ovarian tumors. Cancer 1998;82:1726-30.
8. Hascalik S, Celik O, Sarac K et al. Metabolic changes in pelvic lesions: findings at proton MR spectroscopic imaging. 
Gynecol Obstet Invest 2005;60:121-7.
9. Cho SW, Cho SG, Lee JH et al. In-vivo proton magnetic resonance spectroscopy in adnexal lesions.
Korean J Radiol 2002;3:105-12.
10. Stanwell P, Russell P, Carter J et al. Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at 
three Tesla. Invest Radiol 2008;43:745-51.
11. Okada T, Harada M, Matsuzaki K et al. Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy. 
J Magn Reson Imaging 2001;13:912-7.
12. Nicholson JK, Foxall PJ, Spraul M et al. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. 
Anal Chem 1995;67:793-811.
13. Hochepied T, Berger FG, Baumann H et al. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory 
and immunomodulating properties. Cytokine Growth Factor Rev 2003;14:25-34.
14. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987;508:333-48.
15. Ordidge RJ, Van de Vyver FL. Re: Separate water and fat MR images. Radiology 1985;157:551-3.
16. Ogg RJ, Kingsley PB, Taylor JS. WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H 
NMR spectroscopy. J Magn Reson B 1994;104:1-10.
17. Engelke UF, Kremer B, Kluijtmans LA et al. NMR spectroscopic studies on the late onset form of 3-methylglutaconic 
aciduria type I and other defects in leucine metabolism. NMR Biomed 2006;19:271-8.
18. De Vries J, Thijssen WA, Snels SE et al. Intraoperative values of S-100 protein, myelin basic protein, lactate, 
and albumin in the CSF and serum of neurosurgical patients. J Neurol Neurosurg Psychiatry 2001;71:671-4.
19. Jakobs C, ten Brink HJ, Langelaar SA et al. Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, 
urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan 
disease. J Inherit Metab Dis 1991;14:653-60.
20. Van Dielen FM, Van 't Veer C, Schols AM et al. Increased leptin concentrations correlate with increased concentrations 
of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 2001;25:1759-66.
21. De Vries B, Walter SJ, Wolfs TG et al. Exogenous alpha-1-acid glycoprotein protects against renal ischemia- 
reperfusion injury by inhibition of inflammation and apoptosis. Transplantation 2004;78:1116-24.
22. Engelke UF, Liebrand-Van Sambeek ML, de Jong JG et al. N-acetylated metabolites in urine: proton nuclear 
magnetic resonance spectroscopic study on patients with inborn errors of metabolism. Clin Chem 2004;50:58-66.
23. Dorland L, Haverkamp J, Viliegenthart JF et al. 360-MHz 1H nuclear-magnetic-resonance spectroscopy of sialyl- 
oligosaccharides from patients with sialidosis (mucolipidosis I and II). Eur J Biochem 1978;87:323-9.
24. Mun CW, Cho JY, ShinWJ et al. Ex vivo proton MR spectroscopy (1H-MRS) for evaluation of human gastric carcinoma. 
Magn Reson Imaging 2004;22:861-70.
114
25. Mackinnon WB, Huschtscha L, Dent K et al. Correlation of cellular differentiation in human colorectal carcinoma 
and adenoma cell lines with metabolite profiles determined by 1H magnetic resonance spectroscopy.
Int J Cancer 1994;59:248-61.
26. Schiebler ML, Miyamoto KK, White M et al. In vitro high resolution 1H-spectroscopy of the human prostate: 
benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magn Reson Med 1993;29:285-91.
27. Mountford C, Ramadan S, Stanwell P et al. Proton MRS of the breast in the clinical setting.
NMR Biomed 2009;22:54-64.
28. Mahon MM, Williams AD, Soutter WP et al. 1H magnetic resonance spectroscopy of invasive cervical cancer: 
an in vivo study with ex vivo corroboration. NMR Biomed 2004;17:1-9.
29. Mackinnon WB, Russell P, May GL et al. Characterization of human ovarian epithelial tumors (ex vivo) by proton 
magnetic resonance spectroscopy. Int J Gynecol Cancer 1995;5:211-21.
30. Hascalik S, Celik O, Sarac K et al. Clinical significance of N-acetyl-L-aspartate resonance in ovarian mucinous 
cystadenoma. Int J Gynecol Cancer 2006;16:423-6.
31. Sibtain NA, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain 
tumours. Clin Radiol 2007;62:109-19.
32. Baslow MH. N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res 2003;28:941-53.
33. Baslow MH, Yamada S. Identification of N-acetylaspartate in the lens of the vertebrate eye: a new model for 
the investigation of the function of N-acetylated amino acids in vertebrates. Exp Eye Res 1997;64:283-6.
34. Burlina AP, Ferrari V, Facci L et al. Mast cells contain large quantities of secretagogue-sensitive N-acetylaspartate. 
J Neurochem 1997;69:1314-7.
35. Yang Z, Wu JH, Kuo HW et al. Expression of sialyl Lex, sialyl Lea, Lex and Ley glycotopes in secreted human ovarian 
cyst glycoproteins. Biochimie 2009;91:423-33.
36. Yanagi K, Ohyama K, Yamakawa T et al. Biochemical characterization of glycoprotein components in human 
ovarian cyst fluids by lectins. Int J Biochem 1990;22:659-63.
37. Saldova R, Wormald MR, Dwek RA et al. Glycosylation changes on serum glycoproteins in ovarian cancer may 
contribute to disease pathogenesis. Dis Markers 2008;25:219-32.
38. Arnold JN, Saldova R, Hamid UM et al. Evaluation of the serum N-linked glycome for the diagnosis of cancer and 
chronic inflammation. Proteomics 2008;8:3284-93.
39. Wu AM, Khoo KH, Yu SY et al. Glycomic mapping of pseudomucinous human ovarian cyst glycoproteins: 
identification of Lewis and sialyl Lewis glycotopes. Proteomics 2007;7:3699-717.
115

Ovarian cyst fluid of serous ovarian tumors 
contains large quantities of the brain amino 
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Abstract
In humans, N-acetyl L-aspartate (NAA) has not been detected in other tissues than the brain. The physiological 
function of NAA is yet undefined. Recently, it has been suggested that NAA may function as a molecular 
water pump, responsible for the removal of large amounts of water from the human brain. 
Ovarian tumors typically present as large cystic masses with considerable fluid accumulation. 
Using Gas Chromatography-Mass Spectrometry, we demonstrated that NAA was present in a high 
micromolar concentration in oCF of epithelial ovarian tumors (EOTs) of serous histology, sometimes in 
the same range as found in the extracellular space of the human brain. In contrast, oCF of EOTs with 
a mucinous, endometrioid and clear cell histological subtype contained a low micromolar concentration 
of NAA. Serous EOTs have a cellular differentiation pattern which resembles the lining of the fallopian 
tube and differs from the other histological subtypes. The NAA concentration in two samples of fluid 
accumulation in the fallopian tube (hydrosalpinx) was in the same range as NAA found in oCF of serous EOTs. 
The NAA concentration in oCF of patients with serous EOTs was mostly 10 to 50 fold higher than their 
normal serum NAA concentration, whereas in patients with other EOT subtypes, serum and cyst fluid 
NAA concentration was comparable. The high concentration of NAA in cyst fluid of serous EOTs and 
low serum concentrations of NAA in these patients, suggest a local production of NAA in serous EOTs. 
Our findings provide the first identification of NAA concentrations high enough to suggest local 
production outside the human brain. Our findings contribute to the ongoing research understanding 
the physiological function of NAA in the human body.
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Introduction
N-acetyl L-aspartate (NAA) is the second most abundant free amino acid in the human brain.[1] 
Neuronal cells contain 20 x 103 ^mol/L NAA, whereas in the extracellular space of the brain, the NAA 
concentration ranges between 80 and 100 ^mol/L.[1] In spite of these high amounts of NAA, its metabolic 
and neurochemical functions remain controversial. NAA is thought to function as an important intracellular 
osmolyte and serve as a source of acetate for lipid and myelin synthesis in glia cells. Furthermore, 
NAA is considered to be an intermediate in the formation of the neuropeptide N-acetylaspartylgutamate, 
a storage vehicle for neuronal aspartate and glutamate.[1-3] Interestingly, a patient has been described 
with a biosynthesis defect of NAA. This patient had a severe neurological disorder with delayed myelination 
but was still alive at 8 years and 6 months of age.[4]
Recently, it has been proposed that the NAA system functions as a molecular water pump (MWP) 
operating between neurons and oligodendrocytes.[5] In contrast to osmolytic transport, MWPs are 
entities that actively use intercompartmental cotransport of water against a gradient.[6] Following this 
hypothesis, NAA is thought to be primarily responsible for the active removal of metabolic water from 
myelinated neurons, of which the membranes are known to have a very low water permeability.[6]
Concentrations of NAA in body fluid outside the brain are very low. In cerebrospinal fluid (CSF), plasma, 
and amniotic fluid of healthy individuals, mean ± SD (range) concentrations of NAA have been reported 
to be 1.51 ± 0.89 (0.25-2.83) ^mol/L, 0.44 ± 0.20 (0.17-0.84) ^mol/L, and 1.27 ± 0.74 (0.30-2.55) ^mol/L, 
respectively.[7] Considerable amounts of extra-neuronal NAA have been found in the lens of the eye 
and in peritoneal mast cells, although this has never been confirmed for humans.[8,9] Using magnetic 
resonance spectroscopy, NAA was shown in detectable amounts in human ovarian cyst fluid (oCF).[10,11]
Epithelial ovarian tumors (EOTs) are extremely heterogeneous entities which are mostly filled with large 
amounts of oCF.[12] The aim of the present study was to further investigate the presence of NAA in oCF 
from patients with EOTs of different histological subtypes. As the mechanism of cyst formation of EOTs 
is still unknown, this study was conducted to better understand the possible role of NAA in body water 
management.
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Patients and methods
Patients and ovarian cyst fluid
Ovarian cyst fluid was retrieved from our Radboud University Nijmegen Medical Center (RUNMC) 
biobank. This biobank contains samples of patients with an ovarian tumor who underwent primary 
surgery at the RUNMC in the period between 1998 and 2008. Samples were collected by aseptic fine needle 
aspiration at the Department of Pathology immediately after surgical removal of the ovarian tumor. 
After cooled transport to the laboratory, all samples were centrifuged at 3000 x g for 10 minutes and 
the supernatant was stored at -35°C in small portions until use. For the purpose of this study, 80 oCF 
samples were randomly selected from our biobank. Complete histopathological reports and slides of 
all patients were reviewed for correct histopathological diagnosis by one pathologist (JB), specialized 
in gynecological pathology. Eleven oCF samples were excluded because the ovarian tumor was non­
epithelial or not primary ovarian-derived. Histopathological diagnosis of the remaining 69 EOTs revealed 
36 serous, 23 mucinous, 8 endometrioid and 2 clear cell tumors (Table 1). Of these 69 EOTs, 25 were 
malignant, 8 tumors were of borderline malignancy and 36 tumors were benign. Of 7 patients with an 
EOT preoperative serum was collected as well. These samples were obtained from 3 patients with serous 
tumors (2 malignant and one borderline), 2 patients with mucinous tumors (malignant and borderline), 
a patient with an endometrioid carcinoma and a patient with a clear cell carcinoma. Of 5 patients, 
ascites samples were obtained during primary surgery. One ascites sample was obtained without 
the availability of an oCF sample. Informed consent was obtained from all participants. Ethical approval 
for the study was obtained in advance (Radboud University Nijmegen Medical Centre AMO 09/107).
Hepatic cyst fluid
Cyst fluid from 45 patients with polycystic liver disease (PCLD) was obtained between 2002 and 2008 
by percutaneous cyst aspiration or laparoscopic cyst fenestration and stored in aliquots at -20°C. 
The samples were centrifuged at 3000 x g for 10 minutes. For the purpose of this study, we randomly selected 
hepatic cyst fluid samples of 10 patients. None of these patients had a previous diagnosis of carcinoma.
Hydrosalpingeal fluid
Hydrosalpingeal fluid accumulates in the fallopian tube due to distal obstruction. This fluid was collected 
from 2 salpinges of 1 patient undergoing laparoscopic salpingectomy for presence of bilateral hydrosalpinges. 
Aspiration of the fluid was performed during surgery by fine needle aspiration before the fallopian tubes 
were excised. The samples were centrifuged at 3000 x g for 10 minutes and the supernatant was stored 
at -35°C until use.
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Table 1. Overview of biological fluid samples grouped by origin
Histopathology
Origin of biological fluid n Malignant Borderline Benign
Ovarian cyst 69 25 8 36
serous 36 9 3 24
mucinous 23 6 5 12
endometrioid 8 8 0 0
clear cell 2 2 0 0
Hepatic cyst 10 0 0 10
Ascites 5 5 0 0
Hydrosalpinx 0 0 2
Serum 5 2 0
N-acetyl-L-aspartic acid (NAA)
NAA (nmol/L) was measured using a modified stable isotope dilution Gas Chromatography-Mass 
Spectrometry (GC-MS) method essentially as described by Jakobs et a/.[7] In short, 1 nmol [D3]-NAA 
was added as internal standard to 100 l^ of oCF. This was also added to aqueous standards. The sam­
ples were acidified with 30 l^ HCL (6 mol/l) to pH < 2 and saturated with NaCl. Thereafter, the sam­
ple was extracted four times with 2 ml of an ethylacetate-2-propanol mixture (v/v 10:1). The collected 
organic fractions were dried by anhydrous Na2SO4 and subsequently evaporated to dryness at 40°C under 
a gentle stream of N2. NAA was converted to its di-isopropyl derivative by adding 500 |J isopropanol 
and 10 |J 6 mol/l HCl and subsequent heating for 1 hour at 120°C. An aliquot of 1 |J of this mixture was 
analysed by GC-MS. GC-MS analysis of 1 |J of this mixture was performed on an Agilent Technologies GC 
system 6890N with a 5973 MS detector. The gas chromatographic separation was achieved on a CPSil-88 
capillary fused silica column (25 m x 0.25 mm, df = 0.28 ^m, Chrompack Int., Middelburg, the Netherlands). 
Helium was used as carrier gas. The oven temperature was kept at 80°C for 1 min and then raised to 
240°C at a rate of 30°C/min. The interface and source temperatures were kept at 240°C. The inter-assay 
variation for this method was 8%  (n = 5) and the intra-assay variation was 2% (n = 10). All samples were 
analysed within the linear range of the standard curve (0-20 nmol/L). If concentrations were above 
the standard curve, samples were diluted with water.
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Clinicopathological characteristics of patients with an EOT
From the medical and pathological records of the patients with an EOTs, pathological diagnosis, 
histological subtype, largest tumor diameter (cm), and, in case of a malignancy, FIGO stage were scored. 
Staging was performed according to the criteria of the International Federation of Gynecology and 
Obstetrics (FIGO).[13]
Statistical analysis
Statistical analyses were carried out using SPSS 16.0.2 software (SPSS Benelux BV, Gorinchem, 
the Netherlands). Values are shown as median with 25th-75th percentile (nmol/L). Differences between 
two groups were tested by Mann-Whitney, and for more than 2 groups by Kruskal Wallis tests. 
Correlations between oCF NAA and ovarian tumor size were analyzed by Spearman's rank correlation 
testing. P-values of <0.05 were regarded as statistically significant.
Results
NAA in cyst fluid of epithelial ovarian tumors
The median (25th-75th percentile) NAA concentration in oCF of serous, mucinous, endometrioid and 
clear cell EOTs was 5.1 (2.9-17.0), 0.6 (0.5-0.8), 1.2 (0.8-4.5), and 1.3 nmol/L, respectively. NAA in serous 
EOTs was significantly higher compared to the other histological subtypes (p < 0.001, Kruskal-Wallis test). 
The NAA concentration in one third (n = 12) of the serous EOTs was more than 10.0 nmol/L. Serous 
(n = 36) and mucinous (n = 23) EOTs could almost perfectly be distinguished by a cut-off value of
1.1 nmol/L (Figure 1). All, except one, oCF samples of mucinous tumors contained less than 1.1 nmol/L 
NAA, whereas all, except two, oCF samples of serous tumors contained more than 1.1 nmol/L NAA 
(p < 0.001, Mann-Whitney test, Figure 1).
NAA in cyst fluid of epithelial ovarian tumors of serous histology
In the group of serous EOTs (n = 36), median (25th-75th percentile) NAA concentration was 4.9 (3.8-7.3), 
1.6 (0.5-14.7), and 8.2 (2.9-20.7) nmol/L for malignant (n = 9), borderline (n = 3) and benign (n = 24) 
tumors, respectively. No significant differences were found between the groups (p = 0.343, Kruskal- 
Wallis test). In addition, no significant correlation was found between the largest diameter of the serous 




















Figure 1. NAA (pmol/L) concentration of individual patients with serous (n = 36) and mucinous (n = 23) tumors. 
Values are presented by dots on a logarithmic scale. A horizontal line represents the cut-off value of 1.1 pmol/L NAA.
NAA in cyst fluid of malignant EOTs
Table 2 summarizes the data of patients with epithelial ovarian cancer (n = 25). Endometrioid carcinomas 
(n = 8) showed the largest variation in NAA concentration, ranging from 0.07 to 11.8 nmol/L (Table 2). 
Of the endometrioid carcinomas, 4 samples showed an NAA concentration below the arbitrary cut-off
1.1 nmol/L. Table 2 also lists the NAA concentration of serous (n = 9, range: 1.2- 22.8 nmol/L), mucinous 
(n = 6, range: 0.37-0.80 nmol/L) and clear cell (n = 2, range: 0.07-2.5 nmol/L) ovarian carcinomas.
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When all carcinomas, regardless of subtype, were grouped by FIGO stage, NAA concentration in oCF 
from patients with advanced stage disease (stage III and IV, n = 14, median: 4.2, 25th-75th percentile: 
1.1-7.2 nmol/L) was significantly higher than NAA concentration in oCF from patients with early 
stage disease (stage I and II, n = 11, median: 0.8, 25th-75th percentile: 0.5-1.5 nmol/L; p = 0.009, Mann­
Whitney test). No correlation was found between tumor size and NAA concentration (p = 0.612, 
Pearson's correlation test).
Table 2. NAA (pmol/L) in oCF of patients with serous (n = 9), mucinous (n = 6), endometrioid (n = 8) and clear cell (n = 2) 
ovarian cancer
Patient no. Histopathological diagnosis FIGO stage Tumor size (cm) NAA (pmol/L)
1 Serous cystadenocarcinoma IIIc 8 1.2
2 Serous cystadenocarcinoma IIIb 9 4.3
3 Serous cystadenocarcinoma IIIc 9 3.5
4 Serous cystadenocarcinoma IIIc 9 5.1
5 Serous cystadenocarcinoma IV 9 4.1
6 Serous cystadenocarcinoma IV 9 7.6
7 Serous cystadenocarcinoma IIIb 12 4.9
8 Serous cystadenocarcinoma IIIc 18 22.8
9 Serous cystadenocarcinoma IIIc 21 7.0
10 Mucinous cystadenocarcinoma IIIb 10 0.68
11 Mucinous cystadenocarcinoma IIIb 13 0.80
12 Mucinous cystadenocarcinoma Ic 17 0.37
13 Mucinous cystadenocarcinoma Ia 18 0.52
14 Mucinous cystadenocarcinoma IIIa 20 0.33
15 Mucinous cystadenocarcinoma Ic 26 0.50
16 Endometrioid cystadenocarcinoma IIb 4 0.8
17 Endometrioid cystadenocarcinoma Ic 9 1.5
18 Endometrioid cystadenocarcinoma IIb 14 0.9
19 Endometrioid cystadenocarcinoma Ia 18 5.4
20 Endometrioid cystadenocarcinoma Ia 22 0.9
21 Endometrioid cystadenocarcinoma IIb 22 1.6
22 Endometrioid cystadenocarcinoma IIIb 22 11.8
23 Endometrioid cystadenocarcinoma Ic 30 0.5
24 Clear cell cystadenocarcinoma IIIa 14 2.5
25 Clear cell cystadenocarcinom a Ia 23 0.1
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NAA concentration in ascites fluid and serum of patients with EOTs
The NAA concentration in ascites and corresponding oCF is listed in Table 3. Ascites and oCF concentrations 
of NAA were comparable for each patient. Therefore, the concentration of NAA in ascites differed 
between patients with different histological subtypes of EOTs as well.
The NAA serum concentration ranged between 0.2 and 0.8 nmol/L for all patients with ovarian tumors 
(n = 7, data not shown), independent of the histological subtype of the tumor. These values are within 
the reported reference range.[7]
Table 3. NAA (pmol/L) in ovarian cyst fluid and ascites
Patient no. Histopathology Subtype
NAA (pmol/L) 
cyst fluid NAA (pmol/L) ascites
1 Malignant Serous 4.9 5.0
2 Malignant Serous 1.2 1.0
3 Malignant Serous 24.5
4 Malignant Mucinous 0.8 0.4
5 Malignant Clear cell 0.1 0.6
NAA concentration in hepatic cyst fluid and hydrosalpingeal fluid
8
Figure 2 illustrates the boxplots of NAA concentration in oCF of ovarian tumors grouped by histological 
subtype. In hepatic cyst fluid and in hydrosalpingeal fluid, the NAA concentration was very low in cyst 
fluid from patients with PCLD (n = 10). The median (25th-75th percentile) concentration amounted to 
0.6 (0.4-0.8) nmol/L and ranged between 0.3 and 0.9 nmol/L. The NAA concentration in fluid from the 
two hydrosalpinges amounted to 12.3 and 16.6 nmol/L. These values are in the same range as the NAA 
concentration in oCF of serous EOTs.
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Discussion
This study shows that NAA is present in low micromolar concentration in all oCF samples. Serous ovarian 
tumors however, contained a significantly higher oCF concentration of NAA than mucinous, endometrioid 
and clear cell tumors. The median NAA concentration in serous EOTs was 5.1 pmol/L, whereas one third 
of all samples contained an NAA concentration above 10.0 pmol/L. The NAA concentration in serous 
EOTs was 5 to 50 fold higher than the NAA concentration previously found in CSF, serum and amniotic 
fluid of healthy individuals.[7]
Figure 2. NAA (nmol/L) in cyst fluid of patients with serous (n=36), mucinous (n=23), endometrioid (n=8) and clear cell (n=2) EOT, 
patients with hepatic cysts (n=10) and hydrosalpinges (n=2), presented on a logarithmic scale.
Some serous EOTs contained an NAA oCF concentration in the same range as found in the extracellular 
space of the human brain and all serous tumors by far exceeded the NAA concentration in human 
serum.[1] Interestingly, the oCF NAA concentration in serous EOTs did not differ between benign, 
borderline and malignant histology, indicating that NAA expression might be specific for EOTs with 
a serous cell differentiation.
NAA was present in fluid of mucinous EOTs and hepatic cysts as well but this concentration was comparable 
to the NAA concentration in human serum.[7] Serous and mucinous EOTs could almost perfectly be
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distinguished when using an NAA cut-off value of 1.1 nmol/L. Most endometrioid and clear cell carcinomas 
contained an NAA concentration which was comparable to the concentration of NAA in human serum or CFS. 
However, in some of these samples a higher NAA concentration was found. This may be explained by 
the common presence of cells of different ovarian cancer subtypes within a single tumor. In general, 
approximately 6% of the ovarian carcinomas can be classified as mixed type ovarian carcinomas 
(at least two histologically distinctive elements are present in at least 10% of the tumor surface).[14] 
However, more frequently, ovarian carcinomas are found to exist of a main subtype and a small percentage 
of cells representing a different histology.[14] Our findings indicate that the brain amino acid NAA is 
predominantly present in oCF of serous EOTs and therefore, seems to be characteristic for this specific 
histological subtype. NAA analysis in oCF might thus be used to diagnostically distinguish between 
serous EOTs and other EOT subtypes.
Although 90% of the ovarian tumors derive from the epithelial surface of the ovary, EOTs are not a single 
disease entity, but instead comprise a heterogeneous group of tumors.[15,16] These tumors are classified 
according to their pattern of histological differentiation.[17] Serous tumors bear strong resemblance 
to the normal cells lining the fallopian tube. Mucinous tumors show strong similarity to epithelium of 
the intestine and endometrioid and clear cell tumors are morphologically identical to cells of the lining 
of the endometrium.[18] Interestingly, the normal cellular lining of the ovary does not resemble any 
of these organs. The high concentration of NAA found in oCF of serous EOT, independent of their 
malignant potential, might be due to their specific cellular differentiation pattern, which resembles 
the lining of the fallopian tube and differs from the other histological subtypes. This finding is supported 
by our observation of similar high amounts of NAA found in hydrosalpingeal fluid, which is a fluid 
accumulation in the fallopian tube due to distal obstruction.[12] However, the question remains why NAA 
is found in such high amounts in oCF of serous EOT as its presence and function have been specifically 
been assigned to the human brain.
So far, the brain is the only organ where NAA synthesis has been demonstrated in humans. However, 
two animal studies have revealed extra-neuronal NAA synthesis.[8,9] In the first study, NAA has been 
demonstrated in ocular fluid, the lens and retina of fish and mammals.[9] Despite a low micromolar 
serum concentration of NAA, high amounts of NAA and all components required for synthesis of NAA 
were present in the eye of these animals. In the present study, the NAA concentration in all serum 
samples was within the normal range of 0.17-0.84 nmol/L [7] and did not vary between patients with 
different histological subtypes. The NAA concentration in oCF of serous tumors was mostly 10 to 50 fold 
higher than the normal serum NAA concentration. As serum and oCF samples were simultaneously taken, 
our data suggest a local NAA synthesis in the tumor or a pump mechanism which actively pumps NAA 
from the serum into the oCF. In other ovarian tumor subtypes, serum and cyst fluid concentration of 
NAA was comparable, which might suggest that local NAA production primarily occurs in EOTs of 
serous histology. Peripheral synthesis of NAA also has been described for peritoneal mast cells of the rat.[8] 
Release of NAA from mast cells was found to occur rapidly when degranulating agents were used.[8] 
Although this finding has not yet been confirmed in humans, release of NAA from mast cells might be
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an alternative explanation for the high NAA concentration in oCF and ascites. It has been demonstrated 
that mast cells are frequently present in stroma tissue of several cancer types, including ovarian 
carcinomas.[19,20] A growing number of studies has shown that the mast cell count correlates with 
tumor stage, tumor invasiveness and prognosis.[19] In addition, mast cells are known to be present 
in ascites of cancer patients as well.[21] However, we found that a high concentration of NAA in oCF 
and ascites was characteristic for patients with serous EOTs, independent of the malignant potential of 
the tumor. Mast cells in ovarian stromal tissue have been demonstrated in all histological subtypes 
of EOTs and numbers were found to be increased in carcinomas compared to their normal tissue 
counterparts.[20,22] Therefore, we consider a local NAA production in serous EOTs as the most likely 
explanation for the higher concentration of NAA in serous oCF samples.
Recently, Baslow proposed that the NAA cycle itself might serve as a neuronal mechanism to remove 
large amounts of water generated during action potential development.[1,5] To prevent swelling of 
neurons, this metabolic water has to be eliminated, which has been to occur energy driven and against 
a water gradient. If the NAA system would function as a so called molecular water pump, as a result of 
the enzymatic hydrolysis of NAA in the oligodendrocytes, its obligated water can be released. This would 
subsequently result in a hypoosmotic extracellular space, from which it can be removed from the brain.[5] 
Canavan Disease (CD) is a genetic disorder which causes NAA accumulation in the brain due to a deficiency 
in the NAA-degrading enzyme aspartoacylase.[2] The disease is characterized by the buildup of excessive 
fluid within the myelin lamellae, in swollen astrocytes and in extracellular fluid vacuoles.[5] Baslow suggests 
that this accumulation of NAA is responsible for the macrocephaly in CD.
EOTs, benign as well as malignant, mostly appear as large cystic masses, sometimes diagnosed with 
a diameter up to 50 cm. In mucinous tumors, cysts are thought to be formed by mucus producing 
epithelial cells. Mucus is known to contain large amounts of glycoprotein with a high carbohydrate 
content.[23] In contrast, serous EOT are usually filled with a clear and watery fluid, [12] but the mechanism 
responsible for serous cyst formation is still unknown. On the basis of our findings and taking into 
account the proposed role of NAA in body water management, [1-5] we hypothesize that high amounts 
of NAA in oCF of serous EOTs may be related to accumulation of water in the tumor and may contribute 
to cyst formation. In addition, this proposed mechanism might also be involved in the formation of 
ascites in patients with serous adenocarcinomas and in accumulation of hydrosalpingeal fluid. However, 
as yet there is no confirmatory study in the literature to prove the role of NAA in water management. 
Therefore, our findings might contribute to the understanding of the so far undefined function of NAA. 
More evidence is required for the putative role of serous epithelial cells in NAA synthesis and cyst formation.
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ALPHA 1 -ACID GLYCOPROTEIN IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN OVARIAN CANCER PATIENTS TREATED WITH CHEMOTHERAPY
Abstract
Increased synthesis of the drug-binding protein alpha 1-acid glycoprotein (AGP) during cancer can 
considerably alter the free fraction of drugs resulting in a lower efficacy of the treatment. This study 
aimed to identify the association between the AGP concentration in ovarian cyst fluid (oCF) and disease 
outcome of epithelial ovarian cancer (EOC) patients treated with chemotherapy. Additionally, the binding 
of paclitaxel to AGP and cisplatin to AGP was established. AGP was measured by ELISA in oCF of 
86 patients with ovarian tumors (53 EOC and 33 non-malignant). Clinicopathological parameters were 
retrospectively retrieved. The interaction between cisplatin-AGP and paclitaxel-AGP was determined 
by fluorescence techniques. Significantly higher levels of AGP were found in oCF of EOC patients than in 
oCF of borderline and benign patients (p < 0.001). Of patients who received chemotherapy (stage > Ic; 
n = 32), high AGP (> 600 ng/ml) was significantly associated with a poor disease free survival (DFS) 
and overall survival (OS)(log-rank p = 0.010 and p = 0.005, respectively). Using multivariate analysis, 
FIGO stage was the only independent predictor of DFS. The AGP concentration in oCF was the only 
independent predictor of OS. Paclitaxel was found to bind to AGP with high affinity (Kd = 9.3 10-6 M). 
A low-affinity binding of cisplatin to AGP was found (Kd = 1.7 10-2 M). AGP appears to be an independent 
predictor of survival for patients with EOC treated with chemotherapy. The predictive role of the oCF 
AGP for disease outcome is likely related to the high affinity binding of paclitaxel by AGP
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Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy world-wide.[1] Currently, 
20% of the EOC patients still show resistance to first-line chemotherapy.[2] Biomarkers may help 
to early predict response to chemotherapy thereby providing possibilities for tailor-made treatment 
and personalized medicine.
The acute-phase protein alpha 1-acid glycoprotein (AGP) is synthesized by the liver and its plasma 
concentration rises during pathological conditions including cancer.[3,4] Also, AGP is the next important 
drug binding protein after serum albumin.[3] Increase of AGP during cancer can considerably alter 
the free plasma fraction of chemotherapeutics with high binding affinity for AGP, contributing to 
treatment failure.[5-7] This mechanism has been described for patients with lung cancer, where the serum 
AGP concentration appeared to be an independent predictor of response to docetaxel.[6,7] For EOC, 
however, AGP has only be investigated as a non-specific biomarker for monitoring response during 
chemotherapy of EOC patients.[8-11]
Besides hepatic synthesis of AGP and its release into the serum, local extra-hepatic synthesis of AGP 
has also been described.[4] Active synthesis of AGP outside the liver has been found in human breast 
epithelial cells [12] and many pathologic tissues.[4] Therefore, the acute-phase response also may occur 
in extra-hepatic cell types at the site of the initial acute-phase reaction.[4,12,13]
EOC typically presents as a large cystic mass consisting of fluid. This ovarian cyst fluid (oCF) can be easily 
obtained and used for the measurement of compounds derived form the ovarian epithelial tumor 
wall.[14] Increased local synthesis of AGP in EOC tissue might result in a decreased free fraction of 
the chemotherapeutics at the tumor site and thus to a diminished cytotoxic effect of the chemotherapy. 
We aimed to investigate the association between the AGP concentration in oCF and disease outcome 
of EOC patients treated with chemotherapy. Additionally, the binding between AGP and two first-line 
chemotherapeutic agents for EOC, paclitaxel and cisplatin, was determined.
9
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Materials and Methods
Patients and ovarian cyst fluid (oCF) samples
In the period between January 1996 and January 2008, oCF was collected from patients who underwent 
surgery for an ovarian tumor at the Radboud University Nijmegen Medical Centre (RUNMC) and 
stored in our oCF biobank. After surgery, oCF was collected through aseptic fine needle aspiration at 
the Department of Pathology. After cooled transport to our laboratory, the oCF samples were centrifuged 
at 3000 x g for 10 minutes and the supernatant was aliquoted and stored at -35°C until use. The oCF was 
collected during primary (debulking or diagnostic) surgery and never during interval debulking surgery. 
Frozen section examination revealed 70 malignant ovarian tumors. Complete histopathological reports 
and slides of these tumors were reviewed for correct histopathological diagnosis by one pathologist (JB), 
specialized in gynecological pathology. Ten tumors were excluded because final paraffin examination 
revealed that the origin of the primary tumor was not ovarian derived. Seven were excluded because 
the ovarian malignancy was non-epithelial. Included were tumors of patients with histologically proven 
primary EOC (n = 53). As a control group, 22 and 11 oCF samples from benign and borderline ovarian 
tumors, respectively, were randomly selected from our oCF biobank. The informed consent was obtained 
verbally in presence of a witness and documented in the patient's medical record. The study was approved 
by the ethical board of the RUNMC (file number AMO 09/107).
Clinicopathological characteristics
Surgery and staging were always performed by a gynecologist specialized in oncology. From the medical 
and pathological records of the patients diagnosed with EOC (n = 53), the following clinicopathological 
characteristics were retrospectively retrieved: tumor grade, histological subtype, age at diagnosis, 
FIGO stage, residual tumor after surgery, chemotherapeutic treatment, date of tumor recurrence and 
date of death. For some patients, information on some clinicopathological parameters could not be 
retrieved (Table 1). Staging was performed according to the criteria of the International Federation of 
Gynecologists and Obstetricians (FIGO).[15] Histopathological tumor type and grade were classified 
according to the World Health Organization (WHO) criteria.[16] Chemotherapeutic treatment was defined 
as complete combination chemotherapy of 6 courses, always including a platinum-based agent, 
and was started within three weeks after surgery. Recurrence of disease was defined as a measurable 
lesion detected by computed tomography, magnetic resonance imaging and/or ultrasonography.
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ELISA for AGP
AGP concentrations were measured using an ELISA essentially as reported previously.[17] In summary, ELISA 
plates were coated overnight with polyclonal anti-human AGP obtained from Dako (Glostrup, Denmark). 
Diluted plasma samples and a standard dilution series with human and rAGP, were added to the plate. 
Detection was carried out with a biotinylated polyclonal rabbit anti-human AGP IgG, followed by peroxidase- 
conjugated streptavidin and substrate essentially as described by De Vries et a/.[18] Determination of 
the levels of AGP was carried out without knowledge of the histological or clinical outcome.
Table 1. Association of AGP in oCF (pg/ml) and clinicopathologically defined patient characteristics of all patients with EOC (n = 53)
Characteristics n  (% )
AGP (^g/ml)
Median (25th-75th percentile) p-value
Age 0.778*
< 57 years 25 (47) 650 (377-1172)
> 57 years
FIGO stage
28 (53) 615 (407-1370)
0.049*
I + II 25 (47) 438 (279-1025)
III + IV 27 (51) 684 (436-1304)
unknown 1 (2)
Tumor grade 0.027**
1 15 (28) 436 (177-673)
2 16 (30) 1172 (407-1535)
3 19 (36) 747 (483-1287)
unknown 3 (6)
Histology 0.060**
serous 23 (43) 747 (420-1304)
mucinous 14 (26) 436 (113-643)
endometrioid 9 (17) 1143 (400-1459)
other
Residual tumor
7 (14) 667 (362-1191)
0.002*
< 1cm 43 (81) 534 (338-1143)
> 1cm 9 (17) 1304 (803-1609)
unknown 1 (2)
Total 53 650 (408-1243)
*Mann-Whitney U-test; **Kruska/-Wa//is test
Materials for the drug binding study
AGP (>99% purity) was purified using Cohn ethanol fractionation and chromatography from a plasma 
pool containing more than 6,000 plasma donations (CAF-DCF R&D, Brussels, Belgium). Paclitaxel was 
obtained from Calbiochem (Merck, Nottingham, UK), cisplatin (cis-DDP) from Acros Organics (Fisher Emergo, 
Landsmeer, the Netherlands), quinaldine red (QR) (2-[2-[4-(dimethylamino)-phenyl]-1-ethyquinolium io­
dide), phosphate buffered saline (PBS) and ethanol 99.9% from Sigma-Aldrich (St. Louis, MO,USA).
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Binding of cisplatin to AGP
The binding of cisplatin to AGP was measured by quenching of the intrinsic AGP tryptophan fluorescence. 
A stock solution of cisplatin was freshly prepared in DMSO (33.3 mM) and stored at room temperature. 
Different concentrations of the drug (final concentration from 0-3.3 mM) were added to 54 ng/ml of 
AGP in PBS (pH 7.4). The mixture (300 nl) was transferred to black Microfluor 2 microplate (Thermo 
Scientific, Waltham, MA, USA). The fluorescence was measured in a multi-modale microplate reader 
Varioskan Flash (Thermo Scientific, Waltham, MA, USA). The emission fluorescence (300-400 nm) of 
the 3 tryptophan residues present in AGP was measured after excitation at 280 nm with a slit of 5 nm at 
room temperature.
The kinetics of the cisplatin binding to AGP was measured from 2-720 minutes. All experiments were 
performed in triplicate. The association constant (Ka) and binding affinity were calculated according 
to the equation: log[(F0 - F)/F ] = logKa + n log[drug]. F0 and F are the fluorescence intensity without 
and with the drug, respectively. After a log[(F0 -F)/F] versus log[drug] plot, the slope and the intercept 
(Y-axis) denoted the binding capacity (n) and the intercept on Ka, respectively.[19] Subsequently, 
the dissociation constant (Kd) was calculated using the following equation: Kd = 1/Ka.
Binding of paclitaxel to AGP
The binding of paclitaxel with AGP was determined by competition of a specific probe for AGP, 
quinaldine red (QR), [20] using a Shimadzu RF-5300 spectrofluorophotometer. A stock solution of 11.7 mM 
paclitaxel was prepared in DMSO and stored at -20°C. In a quartz cuvette with 1 cm optical pathway, 
increasing amounts of paclitaxel (final concentration from 0-30 nM) were added to a mixture of 
AGP (45 ng/ml) and QR (1 nM) in PBS (pH 7.4). The decline of the fluorescence of QR was measured 
at room temperature (excitation 495 nm, emission 480-650 nm; with excitation and emission slits of 
10 and 5 nm, respectively). All experiments were carried out in duplicate. Subsequently, the fluorescence 
at 580 nm for each concentration of paclitaxel was transformed using the following equation: 
y = 1-[(F -F )/(F„-F )]. F is the amount of fluorescence, F„ is the fluorescence without the drug;  LV m min'  v 0 min/J  m ' 0  ^
and Fmin is the lowest value of fluorescence with the drug. After fitting, the binding parameters were 
determined using the equation of one binding site: y = (n * Kd)/(Kd+[drug]). N and Kd represent 
the number of binding sites (binding capacity) and the dissociation constant, respectively.
Statistical analyses
Statistical analyses were performed using SPSS 16.0.2 software (SPSS Benelux BV, Gorinchem, the Netherlands). 
Variables regarding patient characteristics were grouped in the following manner: FIGO stage: I-II versus III-IV; 
tumor grade: 1 versus 2 versus 3; histology: serous versus mucinous versus endometrioid; residual disease:
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<1cm (definition of optimal cytoreductive surgery) versus >1cm (definition of suboptimal debulking). 
Values are shown as median with 25th-75th percentile (ng/ml). Differences in AGP concentration 
between groups of patients were tested for statistical significance using the Mann-Whitney test 
in case of two groups and the Kruskal-Wallis test in case of more than two groups. Survival 
analysis was performed with the subgroup of patients with EOC that received complete adjuvant 
chemotherapy. Survival techniques were used to study the time to recurrence and to study 
the time to death. The disease free survival (DFS) was defined as the time interval from the date of the last 
course of chemotherapy to recurrence or last follow-up. The overall survival (OS) was defined as the time 
interval from the date of surgery to the date of either death or last follow-up. The AGP oCF value of 
600 ng/ml was used for dividing patients into two groups after a statistically significant difference in DFS 
was found with logistic regression analysis. The Kaplan-Meyer estimates were calculated of the patients 
with AGP oCF values below 600 ng/ml and above 600 ng/ml, respectively. Subsequently, the log-rank 
test was used to test their difference for statistical significance. An univariate proportional hazards 
model was used to study the influence of the clinicopathological parameters on DFS and OS separately. 
Variables were divided into categories as described above. Only tumor grade was entered in the model as 
a continuous variable as 3 cases were missing and the small group of patients with grade 1. The hazard ratio's 
(HR) with the corresponding 95% confidence interval (CI) are presented. Multivariate proportional hazards 
model with selection procedures was used to find the clinicopathological parameters that independently 
contribute to a decreased time to recurrence or death. The adjusted HR with the corresponding 95% CI 
of the final model are presented. P-values <0.05 were considered statistically significant.
Results
Study population
The median age at diagnosis for patients with EOC, borderline and benign tumors was 57 (n = 53; range: 32-89), 
56 (n = 11; range: 43-82) and 52 years (n = 22; range: 20-70), respectively. Age did not differ between 
patients groups. Borderline tumors consisted of 8 serous tumors and 3 mucinous tumors. Benign tumors 
consisted of 7 serous, 11 mucinous, 1 mixed type tumors and 3 simple epithelial cysts. Of patients with 
EOC, clinicopathological characteristics are listed in Table 1. The histological subgroup "other" consisted 
of 3 clear cell tumors, 1 mixed cell tumor, 1 undifferentiated adenocarcinoma and 3 adenocarcinomas 
not otherwise specified (NOS). Of the 53 patients with EOC, 21 had FIGO stage I (40%), 4 had FIGO 
stage II (8%), 22 had FIGO stage III (42%), and 5 FIGO had stage IV (10%). Of the 53 patients with EOC, 
32 patients received complete adjuvant chemotherapeutic treatment with 6 courses of platinum-based 
combination chemotherapy and were included in survival analyses. Twenty-one patients were excluded from
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survival analyses. Of these patients, 13 did not receive chemotherapy because they were diagnosed with 
FIGO <Ib, 5 received less than 6 courses of chemotherapy, and 4 (oCF obtained during diagnostic surgery) 
received 3 courses of chemotherapy before interval debulking. Of the subgroup of EOC patients that 
received complete adjuvant chemotherapeutic treatment (n = 32), 8 patients received a combination of 
cisplatin and cyclophosphamid and 24 patients received a combination of platinum (cisplatin or carboplatin) 
and paclitaxel. No differences in DFS or OS were found between these two groups (p = 0.361 and p = 0.279, 
respectively, Kaplan-Meyer log-rank test). DFS ranged from 5-117 months (median = 13 months). 
OS ranged from 6-120 months (median = 24 months). Eighteen patients (56%) developed recurrence 
and 9 patients (28%) died within the follow-up period.
Histopathological diagnosis
Figure 1 shows the boxplots of the oCF AGP concentration of malignant, borderline and benign ovarian 
tumors. For patients with malignant, borderline and benign ovarian tumors the median (25th-75th 
percentile) concentration amounted to 650 (408-1243), 90 (40-262), and 106 (26-311) ng/ml, respectively. 
Significantly higher concentrations of AGP were found in cyst fluid from malignant ovarian tumors 
compared to borderline and benign tumors (p <0.001, Kruskal-Wallis test). The plasma or serum AGP 
concentration in healthy individuals has been reported to be in the range of 500-1000 ng/ml.[3]
AGP and clinicopathological categories
Table 1 shows the clinicopathological outcome and median (25th-75th percentile) concentration of 
AGP (ng/ml) for the 53 patients with EOC. The AGP concentration differed significantly between tumor 
grades (p = 0.027). It was significantly higher for patients with FIGO stage III and IV compared to stage 
I and II (p = 0.049), and for patients with a residual tumor after surgery > 1cm compared to patients with 
a residual tumor of < 1cm (p = 0.002).
Survival analysis
Thirty-two patients receiving complete adjuvant chemotherapeutic treatment were included for survival 
analysis (Table 2). The median follow-up period for these patients was 42 months after completing 
chemotherapeutic treatment. Figure 2 shows the Kaplan-Meier curves of DFS (Figure 2A) and OS (Figure 2B) 
for patients with an AGP concentration above (n = 15) and below (n = 17) 600 ng/ml. A high AGP 
concentration was correlated with both shorter DFS and shorter OS (log-rank test: p = 0.010 and 
p = 0.005, respectively).
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Table 2 shows the HR with 95% CI, using the univariate proportional hazard model of DFS and OS. 
For the variable "Tumor grade" 3 cases were missing, and for "Residual tumor" one case was missing. 
FIGO stage, tumor grade, residual tumor, and AGP were regarded as significant predictors of DFS. 
However, using the multivariate proportional hazard model with selection procedure, the FIGO stage 
was the only independent predictor that had impact on DFS (HR = 22.15; 95% CI: 2.77-177; p = 0.003). 
Regarding the time to death we found that FIGO stage, and AGP could be regarded as significant 
predictors of OS in univariate analysis. Now, we found, after the model selection procedure, that the AGP 
concentration appeared to be the only independent prognostic factor that had impact on OS 
(HR = 12.13; 95% CI: 1.43-102; p = 0.022).
Table 2. Univariate Cox regression analyses of DFS and OS of patients that received chemotherapy (n = 32)
> 600 pg/ml
9
#Hazard Ratio (95% Confidence Interval)
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Binding of cisplatin to AGP
It has been demonstrated that > 99% of cisplatin is irreversibly bound to albumin and that this covalent 
binding increases as a function of time.[21] Figure 3 shows the intensity of emission fluorescence of
1.2 ^M of AGP in PBS at 330 nm (excitation at 280 nm) as a function of the cisplatin concentration during 
various incubation times.
The fluorescence of AGP was markedly quenched in the presence of increasing concentrations of 
cisplatin (0-3.33 mM). The quenching effect was time-dependent and more quenching was observed 
when the incubation time of the AGP-cisplatin solution was increased (at 3 hours: Kd = 1.7 10-2 M; n = 0.62).
Binding of paclitaxel to AGP
It has been demonstrated earlier that AGP has a specific and high affinity binding for QR (Kd = 0.76.10-6 M; 
n = 0.9) and that the QR-AGP fluorescence is quenched due to displacement of QR by some basic drugs. 
[20,22,23] We found that QR, when bound to AGP, showed similar fluorescence properties as reported 
previously. Figure 4 shows the relative displacement of QR bound to AGP in the presence of increasing 
concentrations of paclitaxel (0-30 ^M). Paclitaxel strongly displaced QR from AGP (Kd = 9.3.10-6 ± 2.6. 
10-6 M; n = 1.23 ±0.08).
Discussion
This is the first study analyzing the association between AGP in oCF and the clinical outcome of EOC patients 
that received chemotherapy. AGP was present in oCF of all patients with ovarian tumors. EOC patients 
showed significantly higher oCF AGP than patients with borderline and benign ovarian tumors. 
This finding corresponds with the results of studies in serum, which demonstrated an increase of the AGP 
concentration in patients with EOC compared to serum reference values (500-1000 |jg/ml).[8,10,11,24] 
For patients with EOC that received chemotherapy, oCF AGP was significantly associated with DFS and OS. 
The independent role of oCF AGP as a biomarker of poor OS was sustained by the results of multivariate 
analysis documenting the persistence of the unfavorable significance of a high oCF AGP concentration 
after adjustment for important clinicopathological variables.
Besides hepatic synthesis of AGP, AGP synthesis also occurs in extra-hepatic cell types, notably epithelial 
cells, at the site of the initial acute-phase reaction.[4,12,13] AGP synthesis has been found in the bovine 
ovary, [25] whereas expression of other serum proteins, such as albumin, could not be detected in this 
tissue.[26] In rheumatoid synovial fluid, the glycosylation patterns of AGP differed between the serum 
and synovial fluid in the same rheumatoid patient, suggesting local production of this glycoprotein.[27]
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Although there might be passive flow of AGP between serum and oCF, we assume that AGP is, 
at least partly, produced by EOC cells in response to malignancy and subsequently released into the oCF. 
However, histochemical or genetic studies should be performed to provide direct evidence for local 
synthesis of AGP in EOC tissue.
Only a few studies investigated the effect of the drug binding properties of AGP on the response to 
chemotherapy in cancer patients, instead of using AGP as a non-specific biomarker.[6,28] In patients with 
lung cancer treated with docetaxel, Bruno et al. demonstrated that AGP correlated with the response 
to therapy.[6] It had been shown earlier that docetaxel binds strongly to AGP, thus limiting the free 
fraction of the drug.[29] Therefore, the authors stated that the effect of AGP on the pharmacokinetics 
and pharmacodynamics of docetaxel could contribute to the shorter survival observed for patients with 
lung cancer with high serum AGP[6] As AGP was found to be synthesized by breast cancer epithelial cells, 
Paterson et al. investigated the interaction between AGP and tamoxifen.[28] They showed a weak binding 
between AGP and tamoxifen and therefore, concluded that in breast cancer patients treated with 
tamoxifen, interaction of the drug and AGP is not a factor which would decrease the efficacy of the drug.
Figure 1. Boxplots of the AGP concentration in cyst fluid of patients with malignant (n = 53), borderline (n = 11) and benign 
(n = 22) ovarian tumors.
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Figure 2. Kaplan-Meier estimates of disease free (A) and of overall survival (B) of patients who received chemotherapy (n = 32). 
The group with low AGP values (< 600 pg/ml; broken line) and the group with high AGP values (> 600 pg/ml; solid line) 
include 17 and 15 patients, respectively. Vertical bars indicate patients with censored data.
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Figure 3. Maximum emission fluorescence at 330 nm of AGP in the prescence of increasing concentrations of cisplatin. 
Measurements were performed from 2 to 360 minutes.
Figure 4. Displacement of QR (1pM) bound to AGP 1pM (45 pg/ml) by increasing concentrations of paclitaxel (0-30 pM).
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After primary surgery, the current standard treatment for patients with advanced EOC involves the systemic 
administration of a paclitaxel/platinum-containing chemotherapy regimen.[30] We found a high affinity 
binding between AGP and paclitaxel, whereas the binding between AGP and cisplatin was rather weak. 
One previous study has reported the binding constant of AGP and paclitaxel (Kd = 3.45 10-6 M), [23] which 
was comparable to our findings. Another study showed that AGP has a small but statistically significant 
influence on the paclitaxel pharmacokinetics.[31] When AGP is synthesized by EOC cells, this effect may 
result in a restriction of free paclitaxel distribution in tumors with high AGP synthesis. This pharmacokinetic 
effect may reduce the cytotoxic influence of paclitaxel on the tumor cells and subsequently may 
contribute to the shorter survival observed in this study for patients with a high oCF concentration of AGP 
However, as AGP synthesis is increased in response to malignancy, the correlation between AGP and 
survival may also be related to the poor prognosis of patients with high oCF AGP. To our knowledge, 
no data have been published on the binding between cisplatin and AGP. For albumin, a minor cisplatin- 
albumin interaction has been described at low cisplatin concentrations, while at a higher drug content, 
cisplatin and albumin showed a weak binding (Kd = 1.2 10-3 M).[32] More importantly, cisplatin 
binding to albumin has shown to be essentially irreversible with less than 5% loss of protein-bound 
cisplatin after extensive dialysis.[33] Thus despite the low affinity binding, the non-covalent nature of 
the cisplatin-albumin complex may have significant impact on the distribution of cisplatin in the serum. 
The question remains whether binding between AGP and cisplatin is irreversible as well and would 
significantly diminish the cytotoxic effect on the tumor tissue when synthesis of AGP is increased.
We believe the independent predictive role of oCF AGP for survival is at least partly related to the high 
affinity protein binding effects of paclitaxel to AGP. However, further studies are needed to investigate 
this mechanism in vivo. We suggest AGP in oCF as a potential biomarker that is informative with 
respect to the time to disease progression, survival and response to paclitaxel/cisplatin chemotherapy. 
A more complete understanding of the synthesis of AGP in EOC cells as well as the pharmacokinetic and 
pharmacodynamic interactions between cisplatin and AGP warrants further study.
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Introduction
This thesis describes the research conducted to identify biomarkers in ovarian cyst fluid which could be 
of prognostic value for patients with epithelial ovarian cancer (EOC). Blood and tissue of EOC patients 
have been traditionally used as starting material for biomarker research. In this thesis, for the first time 
ovarian cyst fluid has been used as a source of biomarkers for the prediction of survival and response to 
chemotherapy. Thus far, biomarker research using ovarian cyst fluid typically had an explorative design 
and focused on the differences in the concentration of various biomarker candidates between cyst fluid 
of benign and malignant ovarian tumors. As preoperative aspiration of ovarian cyst fluid might cause 
iatrogenic spread of tumor cells, it is advised to obtain cyst fluid only after surgical removal of the ovarian 
tumor. Consequently, the clinical value of cyst fluid biomarkers is limited to the prediction of prognosis 
and/or response to chemotherapy of EOC patients. An epidemiological analysis of the pathological data 
of a large series of patients with proven EOC, revealed that 84% of the ovarian carcinomas contained one 
or more cysts (chapter 2). Ovarian cyst fluid is thus generally available and could be used for research on 
prognostic and predictive biomarkers in this fluid.
Biomarkers for chemotherapy resistance
One of the main problems that may occur during the treatment of EOC is resistance to chemotherapy. 
Although the International Federation of Gynecology and Obstetrics (FIGO) stage remains a powerful 
predictor of disease outcome, ultimate survival depends on the extent of tumor debulking and 
response to chemotherapy. While some patients with advanced stage and bulky disease have 
a complete response to chemotherapy, other patients with more limited EOC can show rapid 
progression of disease. Contemporary chemotherapy regimens, consisting of a combination of platinum 
and taxol, introduced substantial improvements in disease free survival. However, the introduction of these 
regimens ultimately did not influence the overall survival of EOC patients. Identification of biomarkers 
that can serve as reliable predictors of drug response or drug activity is an area of interest to guide 
more effective tailor-made therapy. Chemotherapy resistance has been related to multiple mechanisms. 
Biomarkers predicting chemoresistance can be classified into three broad categories: biomarkers 
involved in drug delivery, biomarkers indicating the degree of drug penetration, and biomarkers 
influencing cellular response pathways.[1]
Biomarkers involved in drug delivery
Drug delivery failure is based on the hypothesis that tumor cells are exposed to insufficient doses 
of chemotherapeutic agents. An inadequate intratumoral drug concentration can be explained by 
pharmacokinetic variables such as a low bioavailability, an extensive first-pass metabolism, a high protein
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binding and/or a low tissue binding.[1] Alpha 1-acid glycoprotein (AGP) is an important drug-binding 
and transport protein and its synthesis is induced in response to inflammation, tissue injury and cancer.[2] 
We assumed that if synthesis of AGP in adenocarcinoma cells of the ovary is enhanced, this would result 
in a higher concentration of AGP in ovarian cyst fluid (chapter 9). We indeed found a significantly higher 
concentration of AGP in cyst fluid of EOC patients compared to the concentration in cyst fluid of 
patients with benign ovarian tumors. We hypothesized that in patients with EOC, an increased cyst 
fluid concentration of AGP would result in a decreased free fraction of chemotherapeutics, resulting in 
a lower efficacy of the treatment. We first studied the in vitro interaction between cisplatin and AGP and 
paclitaxel and AGP by fluorescence techniques. The binding affinity of AGP and paclitaxel appeared to be 
high, whereas the binding affinity of AGP and cisplatin was rather weak. Interestingly, the concentration 
of AGP in ovarian cyst fluid was found to be a significant predictor of overall survival in multivariate 
analysis. We concluded that this independent predictive role of AGP was at least partly related to its 
high binding with paclitaxel. Therefore, AGP is a candidate biomarker for the prediction of paclitaxel- 
resistance in EOC. This finding should encourage further research on measuring AGP in body fluids of 
patients with EOC.
Biomarkers indicating drug penetration
Tumor hypoxia, angiogenesis and intercellular adhesion all may affect drug penetration and cell survival. 
The extracellular matrix (ECM) has been suggested to provide protection against chemotherapy- 
induced apoptosis in various types of cancers.[3] Activation of the proteolytic cascade resulting in ECM 
degradation, in general, is induced by the lysosomal cysteine proteases or cathepsins.[4] Previous studies 
have suggested that an altered ratio between proteolytic enzymes and their inhibitors might be 
responsible for the break-down of the ECM in cancer development.[5,6] In this thesis, we investigated 
whether the ratio between a number of cathepsins and their extracellular inhibitor cystatin C in ovarian 
cyst fluid was related to disease free survival of patients with EOC (chapter 5). No association between 
this ratio and disease outcome was detected, suggesting that cathepsins in ovarian cyst fluid may not 
be useful as prognostic biomarkers.
Biomarkers influencing cellular response pathways
The third group of biomarkers comprises compounds that influence cellular response pathways leading 
to cell death after exposure to cytotoxic agents.[1] Most researchers have investigated the cancer-cell 
specific pathway of drug inactivation via conjugation of glutathione, which can diminish the amount 
of free intracellular drug that is available to bind its target. This process is catalyzed by a family of 
glutathione S-transferases (GST), of which glutathione S-transferase Pi (GSTP1-1) especially is involved in 
the inactivation of alkylating agents, including platinum-based therapeutics.[7] Previous studies which 
examined GSTP1-1 expression in tumor cells suggested that increased expression of the enzyme is
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related to platinum resistance of patients with EOC.[8-11] However, GSTP1-1 expression in EOC tissue 
was found to be very heterogeneous, which limits its usefulness as a prognostic biomarker. In addition, 
the assessment of GSTP1-1 in human plasma has proven to be unreliable and controversial because it 
requires critical sampling procedures.[12] As blood cells and platelets contain large amounts of GSTP1-1, 
release of GSTP1-1 by activation or damaging of cells during or after blood sampling may lead to a falsely 
high plasma concentration. It has been shown that the GSTP1-1 concentration in cyst fluid of patients 
with EOC was significantly higher than the concentration in fluid of patients with benign tumors.[13] 
This thesis shows that a high cyst fluid concentration of GSTP1-1 was an independent predictor of a poor 
overall survival of EOC patients treated with platinum-based chemotherapy (chapter 6), indicating that 
GSTP1-1 in ovarian cyst fluid might serve as a biomarker for the prediction of platinum-resistant EOC.
Targeting chemoresistance
EOC patients who relapse within 6 months after primary chemotherapy are considered chemoresistant. 
Information on chemoresistance mechanisms can be used to stratify patients according to their 
likelihood of responding to agents. In addition, this knowledge is of help to develop new drugs that 
aim to circumvent chemoresistance. For individual patients, elimination of chemotherapeutic drugs, 
for which they are or will become resistant, from the standard regimen will avoid toxic and ineffective 
treatment. It will also minimize delay in selection of active drugs and thus may improve their survival.
Several studies have already attempted to reverse chemoresistance by interacting with the GST-pathway. 
Canfosfamide (Telcyta®) is an investigational drug that was designed to make use of elevated levels of 
GSTP1-1. Preclinical studies suggest that activation of canfosfamide occurs when GSTP1-1 splits the drug 
into two active fragments: a glutathione analog fragment and an active cytotoxic fragment. The cytotoxic 
fragment interacts with important cell components, including DNA, RNA and proteins, ultimately leading 
to cell death. In addition, the glutathione analog fragment of canfosfamide may remain bound to 
GSTP1-1, which limits the ability of GSTP1-1 to inactivate other cancer drugs. The results of several clinical 
trials indeed suggest that canfosfamide is effective when combined with other chemotherapeutic 
drugs including platinum and taxol.[14-16] Although this novel agent has not yet been adopted for 
clinical use, in the future, patients with elevated ovarian cyst fluid levels of GSTP1-1 might be selected for 
additional treatment with canfosfamide.
Chemoresistance due to an increased AGP concentration has not yet been extensively investigated. 
Small molecules or drugs with a very high binding affinity for AGP (e.g. disopyramide, thioridazide, 
bupivacaine, trazodone) may displace paclitaxel, thereby increasing the free fraction of this chemotherapeutic 
agent and thus resulting in increased pharmacological efficacy.[2] Because AGP has only one drug 
binding site, competition between different pharmaceutics may have important clinical implications.[2]
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This mechanism of competition has been investigated for patients with EOC concurrently treated with 
paclitaxel and clindamycin.[17] By adding clindamycin, which competes with paclitaxel in binding to 
AGP, the maximum concentration of paclitaxel in the plasma was enhanced. However, the changes 
in efficacy induced by giving a combination of the two drugs were minimal and the clinical relevance 
was questioned. For EOC patients with a high cyst fluid concentration of AGP, further studies with 
displacing agents might be valuable for the improvement of the cytotoxic effect of paclitaxel. A second 
possibility to circumvent paclitaxel-resistance due to an increased AGP synthesis might be first-line 
treatment with PEGylated liposomal doxorubicin (PLD)(Caelyx®) instead of paclitaxel. PLD has a much 
lower binding affinity to AGP than paclitaxel.[2] A number of studies have already shown the efficacy of 
PLD in relapsed ovarian cancer.[18-20] Recently, a phase III trial demonstrated the activity of PLD plus 
carboplatin as a first-line treatment of advanced stage EOC.[21] Patients with elevated ovarian cyst fluid 
levels of AGP might be selected for additional treatment with PLD.
Pitfalls in biomarker research for EOC
Chemoresistance is a complex multistep mechanism in which many genes, proteins and metabolites 
are involved. Therefore, a single biomarker most likely may not be able to predict the chemotherapeutic 
response of EOC patients in general. In addition, the extreme histological diversity of EOC severely limits 
the discovery of single biomarkers for response to chemotherapy. Although scientists frequently refer 
to EOC as a distinct disease entity, each histopathological subtype differs significantly in microscopic 
appearance, and in biological and genetic background as well.[22-24] Recent studies compared 
the expression of multiple candidate tissue-based biomarkers between the different histopathological 
subtypes of EOC and found profound differences.[24,25]. Also for the most common EOC biomarker, 
CA 125, the proportion of CA 125-producing cells in mucinous tumors is much lower than in the other 
histological subtypes.[26] This was confirmed in our study, as ovarian cyst fluid of mucinous tumors 
contained less CA 125 than cyst fluid of the other tumor subtypes (chapter 3). It might explain why CA 
125 in ovarian cyst fluid failed to serve as an appropriate biomarker for disease outcome. Significant 
differences in concentration of cathepsins in cyst fluid were also found among histopathological 
subtypes of ovarian tumors (chapter 4 and 5). In addition, as described in chapter 8, serous tumors 
could almost entirely be distinguished from mucinous tumors using the cyst fluid concentration of 
N-acetylaspartate (NAA). While ovarian cyst fluid and ascites of patients with serous tumors contained 
high concentrations of NAA, cyst fluid of mucinous tumors contained very low concentrations of NAA, 
which were comparable to serum reference values.
As the incidence of primary EOC is low, the studies in this thesis were performed with relatively small 
sample sizes. We were not able to extend our series as ovarian cyst fluid is not collected regularly in 
Dutch hospitals. In addition, neo-adjuvant chemotherapy is currently offered to patients who are not 
suitable for primary optimal debulking surgery. Thus far, the influence of neo-adjuvant chemotherapy
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on the concentration of biomarkers in ovarian cyst fluid has not been investigated. Therefore, the true 
prognostic value of a potential new biomarker could not be established in patients treated with 
neo-adjuvant chemotherapy and we had to exclude these patients from our studies. Another issue 
concerned the quantification of the compounds of interest in the cyst fluid. Differences in size between 
the cysts raised the question whether or not to correct for differences in total volume. The concentration 
of metabolites in urine is usually normalized on creatinine as volume correction. For ovarian cyst fluid 
however, there are no systematic studies that have addressed this question. In addition, differences in 
viscosity between the cyst fluid samples may influence the biomarker assays.
Future perspectives
It has become clear that ovarian cancer survival rates will not be improved by treating all patients 
uniformly according to standard guidelines. The ultimate goal for biomarker research is to define 
abnormalities in individual patient's cancers, permitting the choice of drug combinations that will 
optimize efficacy and minimize toxicity. In this thesis, we showed a stepwise discovery of potential 
new biomarkers using metabolomic profiling (chapter 7). By using proton nuclear magnetic resonance 
(1H-NMR) spectroscopy, NAA (chapter 8) and AGP (chapter 9) in ovarian cyst fluid were identified as 
new biomarkers. Advanced molecular profiling of ovarian cyst fluid may thus assist the identification 
of predictive biomarkers for therapy selection.
The results of this thesis have shown that that GSTP1-1 and AGP in ovarian cyst fluid may have 
the potential to predict the response to platinum- and paclitaxel-based chemotherapy, respectively. 
GSTP1-1 and AGP both were found to be independent predictors of survival, both were involved 
in different pathways of chemoresistance and both were found to interact with a different 
chemotherapeutic agent. At first, we suggest to validate the predictive value of (a combination of) 
these cyst fluid biomarkers for chemotherapy response in an independent cohort of EOC patients. 
Enlarging the sample size would improve power in statistical analyses and will enable to study 
the histological subtypes of EOC separately. Moreover, it would allow for stratification of patients. After 
successful validation, we propose to conduct an international multicenter clinical trial to investigate 
the advantage of an alternative first-line treatment for EOC patients with a high ovarian cyst fluid 
concentration of AGP and/or GSTP1-1. The alternative treatment for patients with a high cyst fluid 
concentration of GSTP1-1, might consist of a combination of paclitaxel and a platinum agent together 
with canfosfamide.[15] For patients with a high cyst fluid concentration of AGP, the alternative treatment 
might consist of a platinum agent and PLD.[21] The international character of such a trial in our view 
is mandatory in order to assure adequate accrual rates. This means that multicenter collection of cyst 
fluid remains a priority for the ongoing research on the predictive value of cyst fluid biomarkers for 
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Summary
Background
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy worldwide. Despite 
improvement in cytoreductive surgery and the introduction of platinum- and taxol-based chemotherapy, 
gains in survival rates over the last three decades are rather modest. Approximately 20% of the patients 
with primary EOC shows resistance to first-line chemotherapy. Of the EOC patients who do respond 
to first-line chemotherapy, the majority will relapse with drug-resistant disease within a few years. 
Biomarkers may help to predict drug response and survival in individual patients. Their use may lead 
to guide more effective individualized patient therapy. So far, biomarker research has been mainly 
performed using blood and tissue of EOC patients as a starting material. Up to now, these studies did 
not result in the discovery of (a) new prognostic biomarker(s) with both high sensitivity and specificity. 
The concentration of compounds in blood of patients with cancer may be influenced by drug 
treatment and/or physiological processes. Tissue biomarker research is severely limited by the extreme 
heterogeneity of EOC tissue, resulting in tumor areas with different grade and histological differentiation 
within the tumor. Ovarian cyst fluid offers an alternative source of biomarkers because of its homogeneous 
nature and proximity to the ovarian tumor. It has been demonstrated that the concentration of 
analytes in the fluid often reflects the biological processes taking place within the ovarian tumor surface. 
Ovarian cyst fluid can be easily obtained after removal of the tumor at surgery and can be used for 
the measurement of compounds with potential prognostic (predictive for patient survival) and/or 
predictive (predictive for response to therapy) value.
Chapter 1
In the introduction of this thesis, a short historical overview on the use of ovarian cyst fluid is presented, 
together with the current state of research about prognostic and predictive biomarkers in different 
biomaterials of EOC patients. A number of prognostic and predictive biomarkers which have been 
traditionally used in cancer studies are selected and presented in more detail. Thereafter, metabolic 
profiling methods for the discovery of new biomarkers are described.
Chapter 2
The first key to success in biomarker research is the collection of appropriate clinical material. Not 
all ovarian tumors are cystic and therefore, the presence of cysts in EOC is a prerequisite for research 
focused on predictive and prognostic biomarkers in ovarian cyst fluid. In chapter 2, an epidemiological 
analysis of the pathological data of 233 of patients with proven primary EOC is presented, showing
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that cysts in EOC were present in 84% of the patients. The most common histological subtypes 
(serous, mucinous, endometrioid, clear cell) contained cysts in more than 85% of the cases. These findings 
show that ovarian cyst fluid is generally available. This enables research on prognostic and predictive 
biomarkers in this fluid.
Chapter 3
CA 125 is the best known biomarker for EOC and the only biomarker that is currently used in daily practice. 
Serum CA 125 levels measured during chemotherapy correlate well with the course of the disease. 
However, the clinical value of preoperative serum CA 125 for the prediction of survival of EOC patients 
remains controversial. In chapter 3, the prognostic value of CA 125 in ovarian cyst fluid is studied for 
patients with EOC. Although high levels of CA 125 in ovarian cyst fluid were significantly associated with 
a poor survival of EOC patients, CA 125 was not of independent value and might therefore not be useful 
as a prognostic biomarker for EOC.
Chapter 4
A major step in cancer growth and dissemination involves the degradation of the extracellular matrix. 
This process is mediated by multiple degradative actions of proteolytic enzymes or proteases. 
During cancer development and progression, cathepsins (lysosomal cysteine proteases) are often 
translocated to the cell surface or secreted into surrounding fluids. We performed the first study 
to explore the concentrations of cathepsins (B and L) and their inhibitor (cystatin C) in cyst fluid of 
patients with ovarian tumors (chapter 4). Ovarian cyst fluid contained considerable amounts of 
cathepsin B, cathepsin L and cystatin C. Significant differences in concentration of cathepsins in cyst 
fluid were found among histopathological subtypes of ovarian tumors. Cathepsin B seemed to be useful 
for discriminating between malignant and benign tumors of serous histology, whereas cathepsin L 
appeared to be useful for discriminating between malignant and benign tumors of mucinous histology. 
These results contribute to findings of recent studies that detected profound differences in expression 
of multiple candidate tissue-based biomarkers between the histopathological subtypes of EOC. 
In addition, cathepsin B and cystatin C were strongly correlated in the group of patients with malignant 
serous tumors. This suggests that an increase in cathepsin B might be balanced by a corresponding 
increase in cystatin C. Therefore, the ratio between extracellularly released cathepsins and cystatin C 
seems to be of importance for the progression and metastatic potential of EOC.
161
SUM M ARY | SAMENVATTING
Chapter 5
In chapter 5, the ratio between the concentration of cathepsins (B, H, L, X) and their extracellular inhibitor 
cystatin C in ovarian cyst fluid was found to be related to disease free survival of patients with EOC. 
Ratio's between cystatin C and cathepsin B were significantly lower for patients with metastatic 
compared to localized EOC. Ratio's between cystatin C and cathepsin H and between cystatin C and 
cathepsin X differed significantly between histological subtypes and were significantly higher for 
high-grade tumors compared to low-grade tumors. Ratio's between cystatin C and cathepsins did not 
significantly predict survival for EOC patients. However, the interaction between cathepsins and cystatin C 
seems to be of importance for the development and progression of EOC.
Chapter 6
An important mechanism of chemoresistance that has been studied includes the drug inactivation via 
conjugation of glutathione, which can diminish the amount of free intracellular drug that is available to 
bind its target. This process is catalyzed by a family of glutathione S-transferases, of which glutathione 
S-transferase Pi (GSTP1-1) is especially involved in the inactivation of alkylating agents, including 
platinum-based therapeutics. In chapter 6, we showed that a high cyst fluid concentration of GSTP1-1 
was an independent predictor of a poor overall survival of EOC patients treated with platinum- 
based chemotherapy. This indicates that GSTP1-1 in ovarian cyst fluid might serve as a biomarker for 
the prediction of platinum-resistant EOC. Canfosfamide (Telcyta) is an investigational drug that was 
designed to make use of elevated levels of GSTP1-1. Although this novel agent has not yet been 
adopted for clinical use, in the future patients with elevated ovarian cyst fluid levels of GSTP1-1 might 
be selected for additional treatment with canfosfamide.
Chapter 7
In recent years, the advent of high-throughput technologies has facilitated the molecular profiling of tumors. 
Proton nuclear magnetic resonance (1H-NMR) spectroscopy of body fluids shows the majority of 
proton-containing compounds and therefore provides an overall view of metabolism. For the discovery 
of new biomarkers, such "holistic" techniques are a great advantage compared with conventional 
techniques. In chapter 7, we demonstrated the stepwise discovery of potential new biomarkers using 
metabolomic profiling. Cyst fluid samples of malignant, borderline and benign ovarian tumors were 
screened by 1H-NMR spectroscopy. The presence of high concentrations of NAA in cyst fluid samples of 
some ovarian tumors was remarkable as to this point, NAA had exclusively been attributed to neurons of 
the human brain. In addition, the presence of high concentrations of alpha 1-acid glycoprotein (AGP) in 
ovarian cyst fluid is interesting as AGP is the major binding protein for a number of chemotherapeutics. 
NAA and AGP are further investigated in chapter 8 and 9, respectively.
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Chapter 8
N-acetyl L-aspartate (NAA) has not been detected in human tissues other than brain. Recently, it has 
been suggested that NAA may function as a molecular water pump, responsible for the removal 
of large amounts of water from the human brain. As the mechanism of ovarian cyst formation is 
still unknown, in chapter 8, the possible role of NAA in body water management is investigated. 
We demonstrated that NAA is present in a high micromolar concentration in ovarian cyst fluid of ovarian 
tumors of serous histology, sometimes in the same concentration range as found in the extracellular 
space of the human brain. The NAA concentration in cyst fluid was mostly 10 to 50 fold higher than 
the normal serum NAA concentration, suggesting a local production of NAA in serous ovarian tumors. 
In contrast, ovarian cyst fluid of ovarian tumors with a mucinous, endometrioid and clear cell histological 
subtype contained low micromolar concentrations of NAA. Serous ovarian tumors have an epithelial 
differentiation pattern which resembles the lining of the fallopian tube and differs from the other 
histological subtypes. Interestingly, in fluid samples from enlarged fallopian tubes (hydrosalpinx) 
the NAA concentration was in the same range as the NAA concentration found in ovarian cyst fluid of 
serous tumors. Our findings provide the first evidence of NAA production outside the human brain and 
contribute to the ongoing research understanding the physiological function of NAA in the human body.
Chapter 9
AGP is an important drug-binding protein and acute-phase protein of which the synthesis is increased 
in response to cancer. Although most research has focused on the hepatic synthesis of AGP and its 
release into the serum, local extra-hepatic synthesis of AGP in cancer tissue has also been described. 
We hypothesized that an increased cyst fluid concentration of AGP, derived from adenocarcinoma 
cells of the ovary, would result in an increased binding of chemotherapeutics with a high binding 
affinity to AGP and consequently, in a decreased free fraction of chemotherapeutics. In chapter 9, 
the concentration of AGP in ovarian cyst fluid was found to be an independent significant predictor of 
survival of EOC patients. In addition, we demonstrated that AGP binding affinity with paclitaxel was high, 
whereas the binding affinity of AGP and cisplatin was rather weak. We concluded that the independent 
predictive role of AGP was at least partly related to its high binding affinity with paclitaxel. Therefore, 
AGP might be a candidate biomarker for the prediction of paclitaxel-resistance in EOC. This knowledge 
is of help to develop new drugs that aim to target chemoresistance. For EOC patients with a high cyst 
fluid concentration of AGP, it would be interesting to investigate whether drugs with a very high binding 
affinity for AGP may displace paclitaxel, thereby increasing the free fraction of this chemotherapeutic 
agent and thus resulting in increased pharmacological efficacy.
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Chapter 10
In the general discussion of this thesis, we primarily focus on ovarian cyst fluid biomarkers that may 
be useful for the prediction of drug response or drug activity. These biomarkers can be clinically of 
value to guide more effective, tailor-made therapy. Early identification of chemoresistance will offer 
the possibility to eliminate non-effective chemotherapeutic agents from the standard regimen. 
This will avoid toxic and ineffective treatment, and will also minimize the delay in selection of alternative drugs. 
In addition, this knowledge is of help to develop new drugs that aim to circumvent chemoresistance. 
In chapter 10, we discuss three biomarkers studied earlier in this thesis in more detail. These biomarkers 
were involved in different mechanisms of chemoresistance: AGP as a biomarker involved in drug 
delivery to the tumor, cathepsins as biomarkers indicating the degree of drug penetration, and GSTP1-1 
as a cell-specific biomarker involved in the inactivation of drugs. Suggestions for targeted-therapies are 
offered as well. We suggest that a combination of AGP and GSTP1-1 might be useful for the prediction 
of response to paclitaxel- and platinum-based chemotherapy. GSTP1-1 and AGP both were found to 
be independent predictors of survival, both were involved in different pathways of chemoresistance, 
and both were found to interact with a different chemotherapeutic agent. Further prospective studies 
with larger series of patients are warranted to validate whether a combination measurement of AGP and 
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Samenvatting
Eierstokkanker is de meest dodelijke gynaecologische maligniteit wereldwijd. Ondanks de optimalisering 
van cytoreductieve chirurgie en het invoeren van agressieve chemotherapie zijn de overlevingskansen 
voor patiënten met eierstokkanker de afgelopen drie decennia nauwelijks verbeterd. Ongeveer 20% van 
de patiënten blijkt primair niet te reageren op eerstelijns chemotherapie. Van de patiënten die in eerste 
instantie wel reageren, krijgt de meerderheid binnen enkele jaren toch nog een recidief van de tumor. 
Biomarkers die in een vroege fase van de ziekte de respons op chemotherapie kunnen voorspellen 
bij individuele patiënten zouden theoretisch kunnen bijdragen aan een effectievere therapie en dus 
aan de overleving. Tot dusver zijn biomarkers hoofdzakelijk bestudeerd in het bloed en tumorweefsel 
van patiënten met eierstokkanker. Deze studies hebben echter niet geresulteerd in de ontdekking van 
biomarkers met voldoende sensitiviteit en specificiteit om van voorspellende waarde te kunnen zijn. 
Biomarker concentraties in bloed van patiënten met eierstokkanker worden mede beïnvloed door 
systemische processen elders in het lichaam. Biomarkers in tumorweefsel zijn moeilijk te meten 
door de extreme heterogeniteit van het weefsel. Dit resulteert in gebieden met verschillende tumor 
graad en histologische differentiatie binnen één tumor. Het aanwezige cystevocht in de tumor van 
de eierstok is een alternatieve bron om potentiële biomarkers te bestuderen. Men veronderstelt dat 
de componenten in het cystevocht een directe afspiegeling vormen van de biochemische processen 
die zich in de tumor afspelen. Tegelijkertijd is de distributie van componenten in het cystevocht naar 
verwachting homogener dan in het tumorweefsel. Het ovariële cystevocht kan eenvoudig worden 
verkregen na chirurgische verwijdering van de tumor. Vervolgens kan het worden gebruikt voor 
het bestuderen van biomarkers die de overleving (prognostische biomarkers) en/of de respons op 
chemotherapie (predictieve biomarkers) van patiënten met eierstokkanker zouden kunnen voorspellen.
In hoofdstuk 1 van dit proefschrift is een kort overzicht gegeven van de toepassing van ovariëel 
cystevocht door de jaren heen. Vervolgens zijn studies vergeleken die prognostische en/of predictieve 
biomarkers hebben onderzocht in respectievelijk bloed, weefsel en cystevocht van patiënten met 
eierstokkanker. Daarna is er een overzicht gepresenteerd van een aantal veelbelovende prognostische 
en predictieve biomarkers uit eerder verschenen oncologische studies. Tot slot zijn innovatieve 
methoden beschreven die kunnen bijdragen aan de ontdekking van nieuwe biomarkers voor patiënten 
met eierstokkanker.
Voor succesvol onderzoek naar biomarkers is het verzamelen van geschikt patiënten materiaal een 
eerste vereiste. Het is bekend dat eierstokkanker meestal cysteus is, maar exacte prevalentie cijfers 
zijn niet gedocumenteerd. Hoofdstuk 2 omvat een epidemiologische analyse van de pathologische 
gegevens van een groot aantal patiënten met eierstokkanker. Hieruit blijkt dat 84% van de onderzochte 
tumoren tenminste één cysteuze component bevat. Tevens bevatten tumoren van de meest 
voorkomende histologische subtypen (sereus, mucineus, endometrioid en clear cell) in meer dan 
85% van de gevallen cysten. Deze bevindingen tonen aan dat ovariëel cystevocht bijna altijd 
beschikbaar is, wat zowel onderzoek als klinische toepasbaarheid mogelijk maakt.
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CA 125 is de meest bekende biomarker voor eierstokkanker en de enige biomarker die momenteel 
wereldwijd in de kliniek wordt toegepast voor het monitoren van de ziekte tijdens chemotherapie. 
Echter, de prognostische waarde van CA 125 gemeten in preoperatief bloed van patiënten met 
eierstokkanker voor de overleving of respons op chemotherapie is onduidelijk. In hoofdstuk 3 is 
de prognostische waarde van CA 125 in ovariëel cystevocht van patiënten met eierstokkanker 
onderzocht. Hoewel een hoge concentratie van CA 125 in ovariëel cystevocht correleert met 
een slechte overleving, blijkt CA 125 geen onafhankelijke voorspeller van de prognose. Daarom lijkt 
CA 125 in ovariëel cystevocht niet bruikbaar als een prognostische biomarker voor patiënten met 
eierstokkanker.
Een belangrijke stap in de groei en metastasering van kanker is de afbraak van de extracellulaire matrix. 
Dit proces wordt bewerkstelligd door proteases. Cathepsines zijn cysteine proteases die onder 
fysiologische omstandigheden in lysosomen van cellen zijn gelokaliseerd. Echter, tijdens de ontwikkeling 
van kanker worden cathepsines naar het celoppervlak getransporteerd en vervolgens uitgescheiden. 
In hoofdstuk 4 is onderzocht of cathepsines (B en L) en hun belangrijkste extracellulaire remmer 
(cystatine C) worden uitgescheiden in cystevocht van ovariële tumoren. Het blijkt dat ovariëel 
cystevocht hoge concentraties cathepsine B, L en cystatine C bevat. Deze waarden zijn 6 tot 10 keer 
hoger dan eerder gerapporteerde concentraties in bloed. Er worden significante verschillen in concentratie 
van cathepsines gevonden tussen de diverse histopathologische subtypen van ovariële tumoren. 
Bovendien blijken cathepsine B en cystatine C sterk met elkaar gecorreleerd te zijn bij patiënten met 
een sereus type eierstokkanker. Mogelijkerwijs wordt bij deze patiënten een stijging van de cathepsine B 
concentratie gecompenseerd door een overeenkomstige stijging van cystatine C. De ratio van 
cathepsines en cystatine C lijkt daarom interessant voor de progressie van eierstokkanker en is verder 
bestudeerd in het volgende hoofdstuk van dit proefschrift.
In hoofdstuk 5 is onderzocht of de verhouding tussen de concentratie van cathepsines (B, H, L, X) 
en hun extracellulaire remmer, cystatine C, in ovariëel cystevocht van patiënten met eierstokkanker 
geassocieerd is met de ziektevrije overleving. De ratio van cystatine C en cathepsine B blijkt significant 
lager te zijn voor patiënten met gemetastaseerde eierstokkanker dan voor patiënten met een locale 
vorm van de ziekte. Echter, de ratio van cystatine C en cathepsines (B, H, L, X) gemeten in cystevocht 
blijkt geen significante voorspeller te zijn voor de ziektevrije overleving van patiënten met 
eierstokkanker. Hoewel de interactie tussen cystatine C en (met name) cathepsine B een mogelijke 
rol speelt bij de ontwikkeling en progressie van eierstokkanker, lijken cathepsines niet bruikbaar als 
prognostische biomarkers.
Een belangrijk mechanisme van chemoresistentie omvat de inactivatie van chemotherapeutica via 
de conjugatie van glutathion. Dit proces wordt gekatalyseerd door de familie van de glutathion 
S-transferases, waarvan glutathion S-transferase Pi (GSTP1-1) in het bijzonder betrokken is bij 
de inactivering van platinum bevattende chemotherapie. In hoofdstuk 6 is aangetoond dat een hoge 
concentratie van GSTP1-1 in ovariëel cystevocht een onafhankelijke voorspeller is van een slechte
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overleving van patiënten met eierstokkanker die behandeld zijn met platinum bevattende chemotherapie. 
GSTP1-1 in ovariëel cystevocht zou dus een kandidaat biomarker kunnen zijn voor de voorspelling 
van chemoresistentie. Canfosfamide (Telcyta®) is een experimenteel geneesmiddel dat is ontworpen 
om de hoge concentratie van GSTP1-1 juist te gebruiken voor de behandeling van eierstokkanker. 
Hoewel dit nieuwe geneesmiddel nog niet op de markt is, zouden in de toekomst patiënten met verhoogde 
GSTP1-1 concentraties in ovariëel cystevocht kunnen worden geselecteerd voor een additionele 
behandeling met canfosfamide.
De afgelopen jaren hebben nieuwe diagnostische technologieën het mogelijk gemaakt om moleculaire 
en genetische profielen van tumoren in kaart te brengen. Met proton nucleaire magnetische resonantie 
OH-NMR) spectroscopie kan een compleet overzicht worden verkregen van de aanwezige meta- 
bolieten in een specifieke lichaamsvloeistof. Dergelijke "holistische" technieken zijn een groot voor­
deel bij de detectie van nieuwe biomarkers in vergelijking met de meer conventionele technieken. 
In hoofdstuk 7 is de stapsgewijze ontdekking van nieuwe biomarkers in ovariëel cystevocht met 
behulp van 1H-NMR spectroscopie beschreven. Er worden twee potentiële biomarkers voor eierstok- 
kanker gevonden in ovariëel cystevocht. N-acetylaspartaat (NAA), tot dusver uitsluitend aangetoond 
in menselijke hersenen, blijkt in hoge concentraties voor te komen in ovariëel cystevocht. Van het alfa 
1-zure glycoproteïne (AGP), een belangrijk transporteiwit voor geneesmiddelen, worden tevens hoge 
concentraties aangetoond in ovariëel cystevocht. NAA en AGP zijn verder onderzocht in de volgende 
twee hoofdstukken van dit proefschrift.
Hoewel de fysiologische rol van NAA vooralsnog niet geheel bekend is, is geponeerd dat het functio­
neert als moleculaire waterpomp, verantwoordelijk voor de actieve eliminatie van grote hoeveelheden 
water uit de menselijke hersenen. Deze waterpomp functie zou mogelijk ook een rol kunnen spelen 
bij het ontstaan van cysteuze ovariële tumoren. In hoofdstuk 8 is aangetoond dat NAA in een hoge 
concentratie aanwezig is in cystevocht van sereuze ovariële tumoren, soms in dezelfde concentratie 
als in de extracellulaire ruimte van de hersenen. Ovariële tumoren met een ander histologisch subtype 
(mucineus, endometrioid en clear cell) bevatten daarentegen verwaarloosbaar lage concentraties NAA. 
Onze bevindingen leveren het eerste bewijs dat NAA wordt aangemaakt buiten de menselijke hersenen 
en dragen bij aan de kennis over de fysiologische functie van NAA in het lichaam.
AGP is zowel een belangrijk transporteiwit voor geneesmiddelen als een acute fase eiwit. Als reactie 
op kanker wordt AGP in verhoogde mate aangemaakt in de lever. Echter, lokale extra-hepatische 
synthese van AGP op de plaats van de tumor is eerder in de literatuur beschreven. Een verhoogde 
ovariële cystevocht AGP concentratie, afkomstig van ovariële tumorcellen, zou theoretisch kunnen 
leiden tot een verhoogde binding van chemotherapeutica, met als gevolg een verminderde 
cytotoxische werking op de tumor. In hoofdstuk 9 blijkt de concentratie van AGP in ovariëel 
cystevocht een onafhankelijke voorspeller van de overleving van patiënten met eierstokkanker die 
behandeld zijn met chemotherapie. In een in vitro studie tonen we aan dat de bindingsaffiniteit van 
AGP met paclitaxel hoog is, terwijl de bindingsaffiniteit van AGP met cisplatin laag is. De voorspellende
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waarde van AGP voor de overleving van patiënten met een EOC lijkt verband te houden met de hoge 
bindingsaffiniteit van AGP met paclitaxel. AGP zou dus een potentiële biomarker kunnen zijn voor de 
voorspelling van paclitaxel resistentie. In de toekomst zou PEGylated liposomaal doxorubicine (PLD) 
(Caelyx®) in plaats van paclitaxel als eerstelijns chemotherapie kunnen worden gegeven aan patiënten 
met een hoge AGP cystevocht concentratie. PLD heeft een veel lagere bindingsaffiniteit voor AGP dan 
paclitaxel. Uit een recente fase III studie blijkt dat een combinatie van PLD en carboplatin succesvol is 
als therapie bij patiënten met een vergevorderde vorm van eierstokkanker.
Hoofdstuk 10 vormt de algemene discussie van dit proefschrift. De nadrukt ligt op biomarkers in 
ovariëel cystevocht die zouden kunnen bijdragen aan de voorspelling van de respons op chemo­
therapie bij patiënten met eierstokkanker. Bevindingen uit dit proefschrift worden geïntegreerd met 
recente ontwikkelingen om zo een kader te scheppen voor de klinische toepasbaarheid van biomarkers 
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de leuke tijd, de congressen samen en de gezellige momenten op jullie kamers. Ik heb met ieder 
van jullie een erg leuke tijd gehad. Ik denk dat de laagdrempelige manier van samenwerken tussen 
onderzoekers en stafleden bijdraagt aan de goede sfeer die ik heb mogen ervaren.
Lieve vrienden, in het bijzonder de ladies van het dispuut, ik wil jullie bedanken voor de fijne avonden, 
weekenden, vakanties en alle andere momenten samen. De oprechte interesse in elkaar, goede ge­
sprekken, onzin verhalen en nare humor maken dat ik altijd weer thuis kom bij jullie. Lieve Floor, 
dank dat we na mijn promotie lekker mogen gaan borrelen in jullie restaurant! Lieve Ak, wat een 
feest dat ik jou heb leren kennen! Onze co-schappen hebben we opgeleukt met elkaars aanwezigheid. 
Ik vind het heel bijzonder dat we nog steeds vriendinnen zijn en geweldig dat jij nu mijn paranimf bent. 
Dank voor je eeuwige interesse en vrolijkheid.
Lieve familie, dank voor jullie steun. Irene, dank voor al het werk dat je heb verricht om dit proefschrift 
mooi en leesbaar te maken. Lief broertje, wat ben ik blij met de band die wij samen hebben. 
Daar zijn geen woorden voor. Ik vind het echt bijzonder dat we zulke goede maatjes zijn. Lieve mama, 
de afgelopen jaren waren heel fijn, dank voor je gezelligheid, hulp en natuurlijk voor je uitmuntende 
oppaskwaliteiten. Lieve papa, dank voor je interesse, de prettige gesprekken en al je steun. Onze band 
is heel speciaal, ik zal je straks gaan missen. Lieve opa, je was zo trots en wilde zo graag bij mijn promotie zijn. 
Het doet me veel verdriet dat je het niet meer mee kan maken. Allerliefste oma, je bent mijn grote 
voorbeeld. Dank je wel voor al je lieve woorden, oneindige interesse en de fijne momenten samen.
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